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ABSTRACT 
Peripheral nervous system function (PNS) impairments are often unappreciated as risk 
factors for major geriatric outcomes.  This dissertation aimed to examine the mechanism of these 
consequences of poor PNS function.  The relationships of sensorimotor peripheral nerve function 
and physical activity (PA), longitudinal physical fitness assessed via endurance walking 
performance, and the associations with cardiac autonomic function were investigated.  Lower-
extremity sensorimotor impairments have been linked to poor mobility-related outcomes, while 
cardiac autonomic impairments are associated with increased risk of cardiovascular outcomes 
and death.  Ultimately, both divisions play important roles in the ability of older adults to be 
physically active and remain independent.  Diabetes-related PNS impairments may present 
challenges for maintaining PA and endurance, though this work has not been extended to age-
related PNS dysfunction. In addition, sensorimotor and autonomic function are rarely examined 
together, despite being components of the same system.  
First, worse sensorimotor peripheral nerve function in older men from the Pittsburgh site 
of the Osteoporotic Fractures in Men Study was found to be associated with lower levels of self-
reported and objectively measured daily PA.  In particular, worse amplitude, which indicates 
axonal degeneration, was associated with lower levels of objectively measured activity.  In the 
Health, Aging and Body Composition Study (Health ABC) sensorimotor peripheral nerve 
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impairments were related to lower physical fitness, evident through slower endurance walking 
and greater rate of slowing over six years of follow-up.  Those with sensory peripheral nerve 
impairments completed the long distance corridor walk approximately 15 seconds slower than 
those without impairments, and these impairments had an additional four seconds of slowing per 
year.  Finally, in Health ABC worse lower extremity sensorimotor function was associated with 
poorer cardiac autonomic function.   
  PNS impairments appear to play major roles in the disability pathway in old age and 
warrant further study. These findings suggest possible novel mechanisms for these associations, 
including lower PA, fitness and endurance, and cardiac autonomic function.    Helping older 
adults maintain their health and physical function is a major public health priority.  Interventions 
aimed at promoting PA in those with PNS impairments may be beneficial for reducing poor 
outcomes in older adults.   
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1.0  INTRODUCTION 
Declines in aerobic fitness and associated cardiorespiratory changes are hallmarks of the 
aging process [1-7]. Previous studies have suggested that aerobic fitness peaks in the early to 
mid-20s and decreases thereafter, with the steepest decline observed after the age of 45 [5,7-11]. 
Age-related declines in maximal heart rate, forced expiratory volume, and lean body tissue seem 
to explain much of the observed aerobic fitness deterioration [12-14].  Low aerobic fitness can 
lead to functional limitations and disability [15], and is associated with increased risk of all-
cause mortality [16,17].   
Though physical activity and exercise are known to increase physical fitness [18-20], 
many reasons exist as to why adopting an active lifestyle is difficult—particularly for older 
adults [21].  Behavioral scientists have played an integral role in developing lifestyle 
interventions aimed at increasing physical activity (PA) for the prevention and treatment of 
diabetes [22], obesity [22,23] and other conditions, however, the general population remains 
primarily inactive [24].  This inactivity is even more pronounced in older adults [25], who are 
often cited as the least active age group [24,26].  Exploring the impact that conditions associated 
with aging have on exercise and PA participation, and conversely, the impact that activity can 
have on these conditions remains a necessary area of investigation.  Inactivity can lead to 
reduced aerobic fitness, which can then lead to a downward spiral of further inactivity and 
reduced fitness, making even simple daily activities taxing and fatiguing [27].  Due to the 
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heterogeneity of older adults in terms of health status and functional ability, strategies to increase 
activity specific to certain prevalent conditions will be valuable for increasing PA overall in 
older adults.  
Damage to the peripheral nervous system—which encompasses the autonomic and 
sensorimotor divisions—occurs during the aging process, even in the absence of diabetes [28-
30].  Sensorimotor peripheral nerve function is worse in old age, and lower sensorimotor 
peripheral nerve function in older adults is related to worse lower extremity function [31-34], 
bone density [35], strength [36] and power [37], as well as an increased risk for falls [38-41].  
Age-related impairments in autonomic function negatively impact cardiovascular system 
function [42].   However, the relationship between exercise and physical activity participation 
with these impairments has been largely unexplored, despite the potential for exercise and PA 
participation to influence each of these outcomes.  PA could potentially be in the pathway 
between peripheral nerve function impairments and worse lower-extremity and cardiovascular 
outcomes.   Some work has been done in investigating the influence of nervous system function 
on PA and physical fitness, but this work has primarily focused on central nervous system 
function [43-47] or specific neurologic disorders, like Parkinson disease [48,49] and multiple 
sclerosis [50,51].  The association between the peripheral nervous system and PA or fitness on 
the other hand, remains a relatively unexplored area.  Figure 1 outlines the conceptual model 
linking physical activity, physical fitness, and the contribution of peripheral nervous system in 
older adults.  The purpose of this dissertation is to identify and address gaps in the literature 
pertaining to peripheral nervous system function in older adults and its association with physical 
activity and fitness.   
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Figure 1:  Conceptual Model for the Relationship between the Peripheral Nervous System, 
Physical Activity, and Physical Fitness in older Adults 
1.1 PERIPHERAL NERVOUS SYSTEM OVERVIEW 
The peripheral nervous system (PNS) includes the nerves and ganglia outside of the brain 
and spinal cord.  These nerves control automatic functions of the body and provide information 
to the central nervous system about the external environment.  The PNS is divided into two 
distinct divisions: the sensorimotor division which provides awareness of and response to 
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surroundings and the external environment to the through sensory and motor nerves, and the 
autonomic system which is largely responsible for monitoring and maintaining the internal 
environment of the body.  The autonomic nervous system controls the automatic functions of the 
body, including regulating heart rate and blood pressure, bronchial dilation and contraction, 
among other functions of the internal organs.  The autonomic nervous system is then further 
divided to the sympathetic, parasympathetic, and enteric divisions.   The sympathetic and 
parasympathetic divisions are responsible for automatic functions that help the body to either 
prepare the body to respond to a stimulus or help the body conserve energy.  Typically, actions 
of the sympathetic division are those that are related to the “fight or flight” response while the 
parasympathetic division is associated with the “rest and digest” state.  Both divisions are 
equally important and exist in a crucial balance.  The third portion, the enteric division, is also 
known as the intrinsic division and exists in the lining of the gastrointestinal system and is the 
focus of the field of neurogastroenterology.  
 Diseases Associated with Peripheral Nervous System Dysfunction  1.1.1
While the central nervous system is protected by the spine, cranium, and blood-brain-
barrier, the peripheral nervous system does not have these protections and can be vulnerable to 
chemical and mechanical injuries.  A large research focus exists regarding damage to the PNS 
caused by diabetes, although PNS impairments can arise during the aging process even in the 
absence of diabetes [29-31,42], and these impairments are often asymptomatic [30].  Other 
conditions that result in PNS damage include cancer treatment [52], Vitamin B12 deficiency 
[53,54], long-term alcohol abuse [55], multiple sclerosis [56], Parkinson’s disease, spinal cord 
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injuries, HIV [57-59] and AIDS [60], Guillain Barre Syndrome [61], heavy metal [62,63] and 
toxic chemical exposure [64], and surgery or injuries involving the nerves.   
1.1.1.1 Similarities to Peripheral Arterial Disease  
Deficits in sensorimotor nerve function often result in loss of sensation or pain in the 
extremities, though early and advanced stages of nerve function impairments may be 
asymptomatic. While peripheral nervous system dysfunction can impact the upper extremities, 
the lower extremities are the focus when considering outcomes related to mobility. Sensorimotor 
nerve dysfunction may have parallels to damage that occurs during peripheral arterial disease 
(PAD).  Although PAD impacts the lower extremities through vascular pathways rather than 
through the nervous system, both PAD [65-68] and sensorimotor nerve function impairments 
impact lower extremity function [31,34]—a cornerstone for maintaining mobility.  Much has 
been explored regarding the benefits of physical activity and PAD [69,70] and it is recognized 
that PAD may make physical activity and exercise participation difficult [71].  In particular, pain 
associated with PAD can lead to the inability to walk long distances, which is also a concern 
with sensorimotor nerve function impairments.    
Since vasculature and nerve impairments are linked conditions [72,73], the associations 
between PAD and mobility can be can be used as a model for exploring the relationship between 
peripheral nervous system function and mobility. Work by Ylitalo and colleagues in the National 
Health and Nutrition Examination Survey (NHANES) indicates that the 2.5% of the U.S. 
population age 40 and older have both sensorimotor peripheral nerve impairments (defined as 
10g monofilament insensitivity) and PAD [74].  Under half (48.8%) of those with both 
sensorimotor impairment and PAD have diabetes.  In this study, those with both conditions were 
significantly older than those with neither PAD nor peripheral nerve impairment (age 66.4 ± 2.5 
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vs. 56.2 ± 0.3 years, p<0.001).  Exercise induced lower limb ischemia is a common symptom in 
peripheral arterial disease.  Evidence exists that those with this ischemia have worse sensory 
nerve function, and the sensory nerve abnormalities may be linked to the ischemic pain felt 
during exercise [75].   Extensive work has been done in examining in the association between 
PAD and lower extremity difficulties, and this work could serve as a framework for future 
studies in lower extremity sensorimotor peripheral nerve impairments. 
 Autonomic Nervous System Function and the Cardiovascular System 1.1.2
In contrast to sensorimotor neuropathies which impact the extremities, autonomic nerve 
function impairments includes damage to the nerves that carry information from the brain and 
spinal cord to the heart, bladder, intestines, sweat glands, pupils, and blood vessels.  Autonomic 
nerve function impairments lead several conditions, including digestive system issues (vomiting, 
constipation, diarrhea, problems swallowing), urinary incontinence, unusually small pupils 
(usually occurring only in one eye), and heat intolerance, which is related to sweating and blood 
vessel contraction/dilation and sweating issues [76].  Autonomic nerve function impairments 
affect many organ systems, but damage to the autonomic nerves in the cardiovascular system is 
the form that can most greatly affect exercise and physical activity participation.  Cardiac 
autonomic neuropathy is associated with increased mortality [77], sudden cardiac death [78], and 
silent myocardial infarction [79,80].  Due to the major outcomes associated with cardiac 
autonomic nerve function impairments, they are often considered to be the most serious form of 
damage to the autonomic nervous system [81]. Like nerve impairments impacting the 
sensorimotor nerves, autonomic nerve function impairments are often undiagnosed in older 
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adults [81]. However, the impact of cardiac autonomic nerve function impairments on geriatric 
mobility outcomes is largely unknown. 
Though sensorimotor and autonomic nerve impairments are seemingly very different, 
both play crucial roles in the ability for older adults to be physically active and maintain 
functional independence.  Sensorimotor nerve dysfunction may adversely affect the ability to use 
the lower extremities, while the impairments in autonomic system function may lead to the 
inability to the cardiovascular system to respond appropriately to exercise.   
1.2 SENSORIMOTOR PERIPHAL NERVOUS SYSTEM FUNCTION IN OLDER 
ADULTS 
The sensorimotor division of the peripheral nervous system consists of sensory nerves 
which detect touch, temperature, pain, vibration, and other sensations, while motor nerves relay 
signals from the central nervous system (CNS) that allow for voluntary movement.  The sensory 
nerves relay information about the environment to the CNS for integration, which then in turn 
sends impulses via the motor nerves to lead to motion in response to the environment.   
Many methods are used for testing sensorimotor nerve function.  Ideally multiple tests 
should be used together in order to get a complete picture about both the sensory and motor 
nerves.  Sensorimotor peripheral nerve function exists on a continuum, which is important to 
consider rather than only the presence or absence of clinical neuropathy.  From work examining 
the progression of peripheral nerve function declines in diabetes, we know that intact nervous 
system function is on the highest end of the continuum, followed by asymptomatic subclinical 
impairments [82].  Then more pronounced, clinical peripheral nerve function impairments can 
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occur in the absence of symptoms, or symptoms may manifest without evidence on quantitative 
tests.  The most serious form of nerve function decline is clinical symptomatic peripheral 
neuropathy.  Compared to diabetes, the progression from intact sensorimotor peripheral nervous 
system functioning to nerve impairments and neuropathy may differ for older adults.  Currently, 
this progression has been inadequately studied in older adults.   
 Signs and Symptoms of Sensorimotor Peripheral Nerve Function Impairments 1.2.1
Common signs and symptoms of peripheral neuropathy in the lower extremities include 
prickling, stabbing, burning, or aching pain; feeling of asleep numbness; weakness or heaviness 
in muscles of the extremities; open, persistent sores; gangrene; foot drop (difficulty in lifting one 
or both feet) and sensitive skin (more common at night than during the day).  Although signs and 
symptoms are easy to assess via self-report and are specific to the disease, some of these 
symptoms are not sensitive enough to truly identify those with peripheral neuropathy, peripheral 
nerve function impairments, or subclinical disease.   
Symptoms of neuropathy are often classified as negative or positive symptoms [83],  
Negative symptoms include:  insensitivity to touch, reduced sensitivity to temperature, loss of 
vibratory sensation, or decreased ability to detect sensation from a pin-prick, and are associated 
with damage to the large, myelinated sensory fibers.  While negative symptoms may be 
uncomfortable, they are not painful.  Positive symptoms, on the other hand, include:  ongoing 
superficial pain, pain from light touch or light pressure or non-painful cold or warm stimulus, 
tingling, prickling, or burning sensation, itching, pain similar to an electric shock, “pins and 
needles” sensation, increased response from a painful stimulus, or any sensation of pain from a 
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stimulus that would not normally cause pain.  Positive symptoms are indicative of damage to the 
thinly myelinated or unmyelinated small fibers. 
Neuropathic pain differs from nociceptive pain in several ways.  Nociceptive pain serves 
as a warning for impeding tissue damage and is important for survival.  Under circumstances 
where the nervous system is functioning normally, intense stimuli activate nociceptor primary 
sensory neurons, these signals are processed in the CNS, and motor neurons illicit a response in 
order to remove the stimulus.  Neuropathic pain, on the other hand, arises from damage to the 
nerves and provides no survival benefit and can lead to diminished quality of life [84].  
Neuropathic pain can arise independently of a stimulus, or from hypersensitivity to a stimulus 
that would not normally be painful [84]. 
 Epidemiology in the General Population of Older Adults 1.2.2
Sensorimotor peripheral nerve dysfunction is commonly seen in older adults.  In 
particular, absent ankle reflexes and vibration sensation loss have at times been thought of as 
normal findings in older adults, and have been listed as such in some geriatric text books [85].  
However—as in many areas of geriatric research—peripheral nervous system function changes 
during the aging process are being more closely examined in the context of geriatric outcomes 
(falls, disability, and death).   
Prevalence estimates of peripheral neuropathy and nerve function decline vary greatly 
depending on population and definitions used.   A fundamental aspect of epidemiology is 
appropriately determining a case definition.  Unfortunately, without clear definitions of 
peripheral neuropathy or nerve dysfunction, describing patterns on the population level is 
difficult [86].  Currently, no population based studies have examined the patterns of sensory and 
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motor peripheral nerve function over time in older adults.   Even the prevalence of clinical 
peripheral neuropathy is difficult to assess because not all with symptoms follow up with a 
health care provider or have treatment [87].  Though nerve conduction testing is useful in clinical 
settings for identifying damage or impairments in the sensory and motor peripheral nerves, this 
method is invasive, time consuming, and requires specialized training in order to conduct—
ultimately making nerve conduction testing not feasible for many epidemiologic studies.    
Although symptoms are useful for characterizing severity of disease, an absence of symptoms 
does not equal an absence of disease [88].    Additionally, since early stages of the disease are 
often asymptomatic, peripheral nerve function impairments may not be detectable to the 
participant, although nerve damage may be present.  Monofilament testing or vibration detection 
testing can be incorporated into large epidemiologic studies relatively easily, though these tests 
only give information on sensory deficits, not motor.  Due to the difficulties, comparing 
prevalence estimates across studies should be done with caution.   
Older age is associated with higher incidence of peripheral neuropathy, and this was 
measured in the Italian Longitudinal Study of Aging (ILSA).  Older Italian adults age 65-84 were 
initially screened for distal symmetrical neuropathy, and then evaluated again after three years of 
follow-up [29].  A population-based sample from eight different municipalities was followed-up 
for 3 years, with 100 of the 3,066 participants developing clinical distal symmetrical neuropathy.  
The initial screening for neuropathy included two stages.  The first stage involved self-reported 
diagnosis, self-reported symptoms and a brief neurologic exam (heel gait, bilateral Achilles 
tendon reflex, touch and pain sensation).  Those who screened positive were then examined by a 
neurologist and received an extensive neurologic examination in order to determine a clinical 
neuropathy diagnosis.  For the follow-up, cases of peripheral nerve function decline were 
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identified via telephone interview which included questions about self-reported physician 
diagnosis of neuropathy in the past year.   
Age was a significant predictor of developing clinical distal symmetrical neuropathy, 
with every year of increasing age associated with a relative risk of 1.07 (95% CI: 1.01-1.14) for 
diabetic participants and 1.05 (95% CI = 1.02-1.09) for the entire study population.  Adjusted 
annual incidence of distal symmetrical neuropathy was 7.9 per 1,000 person years (95% CI = 
6.3-9.5) in the entire study population, 5.76 (95% CI: 4.3-7.3) per 1,000 person years for the 
participants without diabetes, and 32.2 (95% CI: 21.7-42.7) in diabetic participants.  Baseline 
prevalence estimates of distal symmetrical neuropathy were 6.36% in those 70-74 years of age, 
9.37 for those 75-79, and 9.32 for those age 80-84 years.   A limitation to this study is that cases 
were initially identified using a clinical diagnosis of peripheral symmetrical neuropathy, while 
the follow-up involved the self-report diagnosis of peripheral neuropathy.  Because many older 
adults with nerve function impairments may not seek treatment for symptoms or even be aware 
of their nerve function impairments, these rates may underestimate the true incidence in this 
population.     
To assess prevalence of peripheral nerve function impairments in the general U.S. 
population, Gregg and colleagues utilized 10-g monofilament touch sensation testing and self-
reported neuropathy symptom data from the NHANES 1999-2000 cycle [30].  Peripheral nerve 
function impairment was defined in this study as having one or more insensate area on the foot 
using 10g monofilament testing, though this was not a clinical diagnosis.  Self-reported 
symptoms were also collected and included the presence of numbness, loss of feeling, or painful 
or tingling sensations in the feet in the past three months.  Overall, 14.8% of the study population 
age 40+ years and 26% in the Type 2 diabetic population over 40 years old had peripheral nerve 
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function impairments.  Nearly half of the non-diabetic participants with peripheral nerve function 
impairment were asymptomatic, while 62% of diabetic participants with peripheral nerve 
function impairment were asymptomatic.  Older age was highly associated with these 
impairments.  For participants age 40-49 years, 8.1% had peripheral nerve function impairment, 
compared to 28.4% of those age 70-79 and 34.7% of those age 80 and older (p<0.05 for both).   
This study filled an important gap in the literature at the time by providing prevalence 
estimates of peripheral nerve function decline in the general U.S. population as opposed to a 
clinical population.  Additionally, the combination of monofilament testing and symptom 
reporting provided important insight into the severity of peripheral nerve function impairment in 
the U.S.  Interestingly, most participants with these impairments were asymptomatic.  Peripheral 
nerve function impairments have often been thought of as a condition only occurring with 
diabetes, but this work in NHANES indicated that this is not the case.    
In a study of 759 community dwelling older adults (age 65 and older) recruited from 
family medicine practices, the prevalence of at least one bilateral sensory deficit was 26% for 
those age 65-74, 36% in those age 75-84, and 54% in those age 85 years and older [85].  Sensory 
deficits examined in this study included light touch in the feet, vibration in the medial malleoli, 
position perception in the great toe and deep tendon ankle reflexes.    Only a portion of those 
with any sensory deficit reported symptoms of peripheral neuropathy or of impaired physical 
function: 28% reported numbness of extremities, 48% pain or discomfort, 31% restless legs, 44% 
trouble walking, and 35% reported trouble with balance, while 29% reported no symptoms.  Of 
those reporting bilateral sensory deficits, only 40% reported having any disease or condition that 
is known to cause peripheral neuropathy (diabetes, vitamin B12 deficiency, chronic hepatitis, 
renal failure, autoimmune disease, or reporting a prior diagnosis of peripheral neuropathy).  This 
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supports the thought that peripheral nerve dysfunction in the elderly is typically idiopathic, but 
using self-report diagnosis is a limitation in this study.  Many of these conditions are under 
diagnosed, and many older adults may have one or more of these conditions without being 
aware.   
 Sensorimotor Peripheral Nerve Function Assessment Methods 1.2.3
Numerous methods exist for assessing peripheral nerve function.  Methods for assessing 
motor and sensory function can vary greatly in terms of feasibility for clinical settings or 
epidemiological studies, cost, participant burden, and experience needed to administer the tests. 
1.2.3.1 Nerve Conduction Studies 
As mentioned previously, nerve conduction testing is often used in clinical settings to 
measure sensory and motor nerve function.  The usual measurements taken include latency, 
amplitude, and duration.  Latency is the time that it takes for the onset of a negative response 
after the stimulus; amplitude is defined as the distance between the baseline to negative peak or 
from the negative peak to positive peak, while the duration is the time from the onset of the 
negative or positive peak until return to baseline.  The distance between two stimulus points and 
proximal and distal latency to negative peak in milliseconds, are then used to calculate mean 
conduction velocity (m/s).   F-waves can also be studied via nerve conduction testing.  In 
contrast to sensory and motor nerve conduction studies that examine the conduction velocity 
along a limb segment, F-waves represent the action potential traveling from the simulation site to 
the spinal cord’s ventral horn, and back to the stimulation site.  F-wave conduction velocity is 
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calculated using the distance from the stimulation site to the corresponding spinal segment (this 
distance is multiplied by two since the action potential must travel back to the stimulated nerve).   
In the lower extremity, sensory nerve conduction testing is often done at the sural sensory 
nerve, while motor nerve conduction testing is done at the peroneal motor nerve or tibial motor 
nerve. Nerve conduction testing is only able be done for large, myelinated nerve fibers.  Motor 
nerve conduction methods are sensitive, specific, and have moderate to high reproducibility in 
older adults [89].   
Nerve conduction impairments often preclude clinical symptoms and may be the first 
objective indications of the disease, making them especially important for assessing subclinical 
disease [82].   However, nerve conduction studies are time consuming in clinical or 
epidemiologic settings, and the absence of a sural nerve response is common in older adults.   
Administering these tests also takes a considerable amount of education, training and experience, 
and inaccuracies in measurement technique may also lead to considerable error in the 
measurements [90,91].  F-wave analysis is particularly complicated, mostly because several 
stimuli are required in order to get an accurate measurement.  Computerized automated analyses 
are considered to be feasible and reliable alternatives to analyzing F-wave latencies [92] and 
other measures of nerve conduction.  However, established clinical cut-points of function cannot 
be used with measurements from automated methods.   
1.2.3.2 Quantitative Sensory Testing 
Quantitative sensory testing involves using a specific sensory stimulus (touch, 
temperature, pain, or vibration) to invoke a response from a specific nerve pathway.  These 
testing techniques are considered semi-objective because they rely on a patient’s response to the 
stimulus.  This response-dependent testing may be an issue in the oldest-old where cognitive 
14 
decline may influence the participant’s ability to accurately respond to the stimulus.  These tests 
can be done using a variety of stimuli, a cotton swab, light touch from a finger, or 10-g 
monofilaments.  Although using more than one monofilament, a light (1.4-g) and standard (10-g) 
monofilament, for example, allows investigators to categorize participants by having light touch 
sensitivity (1.4g) or standard insensitivity (10g),  the use of a single monofilament (typically 
10g) is common.  The monofilaments are often touched to specific locations on the foot or great 
toe, and the participant indicates if the touch is detected.  However, no standard protocol for 
monofilament testing exists, particularly in regards to number of touches or location of the foot, 
which is an issue in research and clinical settings.     
Vibration perception threshold tests are also used for sensory nerve function testing, and 
these tests can be quickly and easily administered in a research or clinical setting.  Higher 
perception threshold values indicate worse sensory nerve function.  Quantitative sensory testing 
is used for evaluating the function of small sensory nerves.    Vibration threshold testing can be 
done using an automated device or with tuning forks.  The Vibratron is a device where an 
individual rests his or her foot on a small platform that has a small post that vibrates under the 
great toe.  The voltage gradually increases and the participant indicates when he or she feels the 
vibration, and the participant is not told when the vibration will begin.  Higher vibration 
perception threshold indicates worse peripheral nerve function.  However, because the 
participant is instructed to indicate the exact moment when he or she feels the vibration, scores 
can be influenced by reaction time.      
Vibration threshold testing may be done using a tuning fork, and tuning fork tests can 
either be qualitative or quantitative in nature.  For the qualitative method, an examiner taps a 128 
Hz tuning fork on a hard surface and then touches the tuning fork to a location on the 
15 
participant’s body.  The perceived vibration of the participant is then compared to examiner.  
Although this method is easy and is done quickly in a clinical setting, it has not been well 
validated and is examiner dependent.  Questions remain about the reliability, sensitivity, and 
specificity of this method.  The quantitative method, on the other hand, involves using a Rydel-
Seiffer 64 Hz tuning fork [93].  This device has two triangles that intersect at different points 
with different vibration amplitudes from the tuning fork.  The intersection point of the triangles 
moves from 0-8 with decreasing vibration amplitude.  The participant indicates when he or she 
no longer feels the vibration, and the score is the value of where the triangles are intersecting.  A 
sum score of 4 on bilateral toe testing indicates abnormal vibration threshold.  The qualitative 
method takes no additional time compared to qualitative tuning fork method, but has been shown 
to be better associated with sensory nerve action potential amplitude in a patient population of 
middle-aged to older adults with Waldenström's macroglobulinemia and non-diseased controls 
[93]. 
 Risk Factors for Sensorimotor Peripheral Nerve Function Impairments 1.2.4
In general, peripheral nerve function dysfunction or impairments in older adults are 
idiopathic in nature with no clear cause aside from aging itself.  In older adults who are seen in 
specialty clinics, a specific cause of neuropathy is often determined [94].  However, those who 
are seen at specialty clinics often have severe symptoms or worse cases of peripheral neuropathy.  
Likely, a large proportion of older adults are not seen in a primary care setting for their 
peripheral nerve impairments, much less in a specialty setting [87].  Despite this, several risk 
factors have been identified in epidemiologic studies related to peripheral nerve impairments and 
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clinical neuropathy, both in the general population and specifically for populations with diabetes.  
These risk factors are described in detail in Table 1.   
From a demographic standpoint, older age [29,30,95], male sex [30], black race [30], and 
Hispanic ethnicity [30] are associated with a higher prevalence of peripheral nerve impairment in 
the general population.   Taller height is associated with higher prevalence of peripheral nerve 
impairment due to neuronal length [96].  Because men are often taller than women, the higher 
prevalence of peripheral nerve impairment in men compared to women is largely related to 
height differences.  Racial and ethnic differences are often attributed to the higher prevalence of 
diabetes and other cardiometabolic risk factors in some racial or ethnic minorities compared to 
whites.     
 Cardiovascular risk factors [97], obesity [74,98], coronary heart disease [99],  and 
peripheral artery disease [99] have been found to be associated with worse peripheral nerve 
function in epidemiologic studies.  In some studies, statin use has been associated with worse 
peripheral nerve function [97,100].  However, the association of statin use and peripheral nerve 
function impairments has been controversial, with some studies finding a protective effect of 
statins on the development of peripheral neuropathy [101].  Statins lower cholesterol, a 
fundamental component of the protective myelin sheath on an axon, which is one of the 
hypothesized mechanisms by which statin use is associated with worse peripheral nerve function.  
Statins are among the most commonly used medications by older adults [102], which highlights 
the importance of determining whether statins cause significant harm to the nervous system, and 
whether risks of these medications outweigh the cardiovascular benefits. 
In addition to conditions related to the cardiovascular system, knee osteoarthritis is 
another common condition in older adults that is associated with potentially worse peripheral 
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nerve function [103].  Pain arising from osteoarthritis has traditionally been considered to be 
nociceptive, however, recent evidence has suggested a contributing role of sensory nerve fiber 
damage in osteoarthritis.  In a cohort of patients with knee osteoarthritis (n=92, age 70.3±8.0 
years), knee pain was evaluated in order to determine whether the pain was neuropathic in nature 
(determined by using painDETECT, a peripheral neuropathy questionnaire) [104].  In this cohort 
5.4% were classified as having neuropathic pain in their osteoarthritic knee, with an additional 
15.2% as having probably neuropathic pain.  Presence of neuropathic pain was associated with 
later stages of osteoarthritis. 
From a nutritional standpoint, low vitamin B12 [53] and high homocysteine [54] have 
been shown to be associated with poorer peripheral nerve function in older adults.  Excessive 
alcohol use [105], which is often linked to poor nutrition and dietary habits, also can lead to 
nerve damage [106].  Currently, it is unclear whether alcohol has an independent effect on nerve 
function or whether damage occurs through nutritional pathways [106]. 
18 
Table 1:  Risk Factors for Sensorimotor Peripheral Nerve Function Impairments Identified in Epidemiologic Studies 
Risk Factor Study Population Outcome Definition Magnitude of Relationship 
Age 
Older Italians 
(Age 65-84)  
 
At baseline, peripheral neuropathy was 
clinically diagnosed.  Follow-up cases 
were ascertained via self-report 
diagnosis. 
 
Each year of older age associated with a RR of 1.07  
(95% CI =1.01-1.14) in diabetic participants for developing 
neuropathy and 1.05 (95% CI= 1.02-1.09) in the entire study 
population of older Italians [29].  
 
NHANES  
(Age 40+)  
Peripheral nerve function impairment:  
1 or more insensate area on 
monofilament testing using a 10-g 
monofilament at a total of six sites on 
the foot.     
Prevalence of peripheral neuropathy was higher in older age 
groups.  Prevalence of peripheral neuropathy was 8.1% in 
those 40-49 years, and 34.7% in those 80+ years [30].  
Women’s Health 
and Aging  Study 
participants 
(n=894, Age 65+) 
Vibration perception threshold measured 
using the Vibatron II.   
Nerve function values defined as: 
Normal = <3.43 units; 
Mild dysfunction = 3.43 to <4.87;  
Moderate dysfunction 4.87 to <6.31; 
Severe dysfunction ≥6.31 units 
Women who were age 85 and older were at a 6.5, 7.5, and 
13.3 times greater odds of mild, moderate, and severe 
dysfunction compared to women who were age 65-74 years  
[95].   
Sex 
NHANES  
(Age 40+) 
Peripheral nerve function impairment:  
1 or more insensate area on 
monofilament testing using a 10-g 
monofilament at a total of six sites.  
Men had a higher prevalence of peripheral nerve function 
impairment compared to women (18.2% vs. 12.6%, p<0.05) 
[30]. 
Race/Ethnicity 
 
 
NHANES  
(Age 40+) 
Peripheral nerve function impairment:  
1 or more insensate area on 
monofilament testing using a 10-g 
monofilament at a total of six sites.  
The prevalence of impairment varied across racial groups.  
Prevalence was 14.4% in non-Hispanic whites, 19.4% in 
Hispanic participants, and 21.9% in non-Hispanic black 
participants (p<0.05 compared to whites) [30]. 
Diabetes 
NHANES  
(Age 40+) 
Peripheral nerve function impairment:  
1 or more insensate area on 
monofilament testing using a 10-g 
monofilament at a total of six sites.  
Prevalence of peripheral nerve function impairment in 
diabetic participants was approximately twice that of the 
prevalence of the general population of U.S. adults age 40+ 
(28.5% vs. 14.8%, p<0.001) [30]. 
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Diabetes in 
Old Age 
Women’s Health 
and Aging  Study 
participants 
(n=894, Age 65+) 
Vibration perception threshold measured 
using Vibatron II.   
Nerve function values defined as: 
Normal = <3.43 units,  
Mild dysfunction = 3.43 to <4.87  
Moderate dysfunction 4.87 to <6.31, 
Severe dysfunction ≥6.31 units 
Women with diabetes were at 1.8, 2.4, and 1.6 times greater 
odds of mild, moderate, or severe dysfunction compared to 
those without diabetes [95].  (Diabetes was self-reported) 
Italians age 55 
years and older 
(n=4191)  
Those with 2 or more symptoms or 
polyneuropathy underwent clinical 
examination to confirm neuropathy. 
Probable polyneuropathy definition: 
impairment of at least 2 nerve functions 
(sensation, strength, tendon reflexes) in 
the extremities with symmetrical 
distribution 
In the study population, the prevalence of probable 
polyneuropathy was 2.2% in non-diabetic participants 
compared to 19.0% in diabetic participants [107]. 
Diabetes 
Duration 
Italians age 55 
years and older 
(n=4191)  
Those with 2 or more symptoms or 
polyneuropathy underwent clinical 
examination to confirm neuropathy. 
Probable polyneuropathy definition: 
impairment of at least 2 nerve functions 
(sensation, strength, tendon reflexes) in 
the extremities with symmetrical 
distribution 
Longer diabetes duration was significantly associated with 
probable polyneuropathy among those with diabetes 
(p<0.001).  The duration of diabetes for those without 
polyneuropathy was 10.0 years, compared to duration of 12.7 
years for those with neuropathy. (p<0.02) [107]. 
Worse 
Glycemic 
Control in 
those with 
Diabetes 
Diabetic veterans 
from an outpatient 
clinic (n=775, Age 
65-84)  
Peripheral nerve function impairment: 
insensitivity to 10-g monofilament at 
any of 9 sites on the foot. 
Each 1% increase in glycohemoglobin was associated with 
1.06 (p=0.031) greater odds of peripheral nerve impairment 
[105]. 
 
Italians age 55 
years and older 
(n=4191)  
Probable polyneuropathy definition: 
impairment of at least 2 nerve functions 
(sensation, strength, tendon reflexes) in 
the extremities with symmetrical 
distribution (clinical diagnosis). 
Among diabetic participants in this study, those with 
polyneuropathy had higher mean fasting blood glucose 
compared to those without polyneuropathy (187.1 vs. 149.0 
g/dl, p<0.001) and higher mean post parandial glucose 206.2 
vs. 165.4 g/dl, p=0.01) [107]. 
 
Table 1 Continued 
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Cardiovascular 
Risk Factors 
NHANES  
(Age 40+) 
Peripheral nerve function impairment:  
1 or more insensate area on 
monofilament testing using a 10-g 
monofilament at a total of six sites.     
Those with peripheral nerve impairment had higher 
triglycerides (187.0 vs. 158.5, p=0.05), larger waist 
circumference (105.5cm vs. 98.4cm, p<0.001) and a larger 
percentage had hypertension 66.9 vs. 55.3%, p=0.007) 
compared to those without impairment [97]. 
Coronary 
Heart Disease 
Non-diabetic, 
elderly Italians 
from ILSA 
(n=2,512, age 
74.3±5.7)  
At baseline, peripheral neuropathy was 
clinically diagnosed.  Follow-up cases 
were ascertained via self-report 
diagnosis.  Clinically diagnosed 
peripheral neuropathy was further 
classified according to etiology.  
 
A larger proportion of older adults who developed clinical 
idiopathic distal symmetric neuropathy had a history of 
coronary heart disease compared to participants who did not 
develop neuropathy over the 3 year follow up (25.5% vs 
12.0%, p=0.04) [99]. 
Obesity 
NHANES  
(Age 40+) 
Peripheral nerve function impairment:  
1 or more insensate area on 
monofilament testing using a 10-g 
monofilament at a total of six sites.  
Obese participants (BMI ≥30) were 2.20 times more likely to 
have peripheral nerve function impairment compared to non-
obese participants [74].   
Women age 42-52 
from the Michigan 
site of the Study of 
Women Across the 
Nation neuropathy 
sub-study (n=396)  
Peripheral nerve dysfunction was 
defined as ≤80% correct responses on 
10-gram monofilament testing (10 
repetitions on big toe) or ≥4 signs or 
symptoms on the Michigan Neuropathy 
Screening Instrument [108]. 
Each 5 unit increase in baseline BMI was associated with a 
1.24 greater odds of peripheral nerve dysfunction by year 12 
in the study [98]. 
Statin Use 
NHANES  
(Age 40+) 
Peripheral nerve function impairment:  
1 or more insensate area on 
monofilament testing using a 10-g 
monofilament at a total of six sites.  
Statin use was significantly associated with peripheral 
neuropathy in adjusted multivariate logistic regression:  
OR=1.3 (95% CI = 1.1-1.6) compared to those who did not 
use statins [97]. 
Low Vitamin 
B12 
Older adults in 
Health ABC 
(n=2279, age 72-
83)  
Peroneal motor nerve conduction 
amplitude and velocity and 1.4 and 10-g 
monofilament testing were used to 
measure peripheral nerve function. 
Vitamin B12 deficiency (serum B12 < 260pmol/L) was 
associated with a 1.50 greater odds off insensitivity to the 
light monofilament compared to those with normal Vitamin 
B12.  Vitamin B12 deficiency was also associated with worse 
nerve conduction velocity compared to those with normal 
Vitamin B12, 42.3 vs. 43.5 m/sec, respectively, p=0.01 [53].   
Table 1 Continued 
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High 
Homocysteine 
Italian older adults 
in the InCHIANTI 
Study 
(n=678, age 60+) 
Motor nerve conduction testing, 10-g 
monofilament testing. 
High homocysteine was associated with worse compound 
motor action potential.  Those with initially normal but 
transitioned to high homocysteine had 5.4 greater odds of not 
feeling the monofilament compared to those with normal 
homocysteine [54].   
Height 
NHANES 
(n=5,229, age 
40+) 
Peripheral nerve function impairment:  
1 or more insensate area on 
monofilament testing using a 10-g 
monofilament at a total of six sites.     
Those taller than 175.5 centimeters were at a 2.3 greater 
adjusted odds of peripheral neuropathy compared to those 
175.5 centimeters or shorter [96].   
Excessive 
Alcohol Use 
Diabetic veterans 
(n=775, age 65-
84)  
Peripheral nerve function impairment:  
1 or more insensate area on 
monofilament testing using a 10-g 
monofilament at a total of six sites.     
A CAGE Alcohol score of 4 (highest possible score) was 
associated with an increased odds of 6.96 (0.008) of 
peripheral neuropathy compared to a CAGE score of 0 
(lowest possible score) [105]. 
Peripheral 
Artery Disease 
Non-diabetic, 
elderly Italians 
from ILSA 
(n=2,512, age 
74.3±5.7)  
Peripheral neuropathy was clinically 
diagnosed at baseline.  Follow-up cases 
were ascertained via self-report 
diagnosis.  Clinically diagnosed 
peripheral neuropathy was further 
classified according to etiology.  
 
Peripheral artery disease was an independent predictor of  
clinical idiopathic distal symmetric neuropathy (HR = 2.45, 
95% CI: 1.01-5.91) [99]. 
Renal Failure 
Participants 
(n=135) 
undergoing 
hemodialysis 
  Participants underwent clinical nerve 
function using twenty 
neurophysiological parameters.   
The prevalence of having an abnormal value on any of the 
neurophysiological tests was 84.4%, with 63% of the study 
population having two or more abnormal values [109].   
Knee 
Osteoarthritis 
Adults (age 53-81) 
with knee 
osteoarthritis 
(n=92) being seen 
at an outpatient 
clinic for knee 
pain.  
 
 
The PainDETECT questionnaire 
(possible scores 0-38) was used to assess 
the possibility of peripheral neuropathic 
pain.  Participants were categorized as 
likely having neuropathic pain (score 
≥19), possibly having neuropathic pain 
(score 13-18) and as unlikely to having 
neuropathic pain (score ≤12) 
In this cohort, 5.4% of participants were classified as likely 
having neuropathic pain, and 15.2% as possibly having 
neuropathic pain.  Pain score was positively correlated with 
Kellgren-Lawrence grade, indicating that neuropathic pain 
may be associated with later stages of knee osteoarthritis 
[104].    
Table 1 Continued 
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1.2.4.1 Peripheral Neuropathy in Diabetes 
Although peripheral nerve impairments arise during aging, most of the research regarding 
nerve impairments has been focused on nerve dysfunction that occurs with the progression of 
diabetes.  Diabetic peripheral neuropathy (DPN) has been defined by the Toronto Diabetic 
Neuropathy Expert Group as “a symmetrical, length-dependent sensorimotor poly neuropathy 
attributable to metabolic and microvessel alterations as a result of chronic hyperglycemic 
exposure (diabetes) and cardiovascular risk covariates” [82].  Hyperglycemia is a major factor in 
the development of neuropathy in diabetes.[110] DPN is the one of the most frequent 
complication related to diabetes and poor diabetic control, with some estimates of upwards of 
50% of peripheral neuropathy in older diabetic populations [88].  Neuropathic pain in diabetes 
has been defined as “pain arising as a direct consequences of abnormalities in the peripheral 
sensorimotor system” [111] and symmetrical decreased or loss of distal sensation is also 
common in DPN [82].  Advanced DPN is often preventable, with podiatric care, patient 
education, glycemic control, and cardiovascular risk factor reduction being the main targets for 
prevention [88]. 
Candrilli and colleagues utilized combined NHANES data from the 1999-2000 and 2001-
2002 cycles, to describe the prevalence and burden of peripheral nerve function decline 
symptoms among adults with self-reported diabetes age 40 and older [112]. Using self-reported 
symptoms of peripheral neuropathy, the estimated prevalence of symptoms of peripheral 
neuropathy among this sample was 32.7% [112]. Symptoms of peripheral neuropathy were most 
prevalent in the 60-69 year age group among diabetic adults (34.4%), and this may have been 
due to a survival or participation effect.  Symptoms were more prevalent in women compared to 
men (34.4% vs. 31.0%) and in non-Hispanic blacks (38.4%) compared to other race/ethnicity 
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groups (p<0.05 for all).  Symptoms of peripheral neuropathy among diabetic adults were 
associated with an increased odds of being unable to work due to physical limitations (OR=3.32, 
95% CI=1.60-6.52), and having four or more health care visits in the past year (OR=2.25, 95% 
CI=1.32-3.83) compared to those without symptoms.   Although the ability to work may be less 
relevant to those past retirement age, physical limitations can threaten older adults’ 
independence, which is a major concern in this age group.   
Metabolic disorders are also associated with peripheral nerve dysfunction.  In particular, 
diabetes is a major risk factor for peripheral nerve dysfunction in older adults [30,29,95],  with 
longer diabetes duration [29] and worse glycemic control [105,107]  being associated with worse 
peripheral nerve function in those with diabetes.   Renal failure and poor kidney function can 
also adversely affect peripheral nervous system function.  Uremic polyneuropathy is commonly 
seen in patients with chronic renal failure, and may potentially stabilize or improve with chronic 
dialysis treatment or renal transplantation [113].  Uremic neurotoxin accumulation is the primary 
mechanism of nerve damage in renal failure.   
Though work in diabetes gives insights about damage that occurs to the peripheral 
nervous system with age, many gaps remain in the literature about the age-related nerve 
impairments that occur during independently of diabetes.  The combined increase of the aging 
population and rise in diabetes prevalence may lead to much higher rates of peripheral nerve 
function decline in the coming years.  From a public health perspective, urgency exists to 
understand these nerve function impairments and develop strategies to minimize them in the 
population. 
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1.2.4.2 Disease-Related Peripheral Neuropathy 
Without question, diabetes is the single largest cause of disease-related peripheral 
neuropathy, however, other factors are known causes of peripheral neuropathy.   These causes 
fall under a few main categories, including physical injury, systemic disease, toxic exposures, 
infectious and autoimmune disorders, and inherited conditions [106].  Specific diseases, 
conditions and the explanations of their effects on peripheral nerve function are listed in Table 2.  
The specific diseases and conditions that may be most relevant for older adults include kidney 
disorders, vascular diseases, repetitive injuries, cancer treatments and Shingles.   
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Table 2:  Causes of Clinical Peripheral Neuropathy 
General Cause Specific Cause Explanation 
Physical Injury 
Traumatic Injury 
Traumatic injury can lead to nerves being severed, crushed, 
compressed, or stretched.  In severe cases, these forces can 
partially or fully detach the nerve from the spinal cord.  
Repetitive Stress on 
Joints 
Repetitive stress on joints can lead to entrapment neuropathy.  
The repetitive flexing of joints can damage and inflame 
ligaments, tendons, and muscles, thus narrowing nerve 
passageways.    
Systemic 
Disease 
Diabetes Chronic hyperglycemia damages nerve tissue and is a common cause of peripheral neuropathy [82].   
Kidney Disorders 
Kidneys are responsible for eliminating toxic substances in 
the blood.  If not functioning properly, toxic substances that 
damage nerve tissue can accumulate.   
Vascular Diseases Vascular damage with blood flow can deprive nerve tissue of oxygen and lead to damage.   
Vitamin Deficiencies 
Certain vitamins, namely E, B1, B6, B12, thiamine and 
niacin play essential roles in promoting nerve function.  
Deficiencies of these vitamins can then in turn lead to nerve 
tissue damage.   
Chronic Inflammation 
Inflammation of the tissue surrounding nerves can spread to 
the nerve itself.  Additionally, chronic inflammation with 
swelling can lead to nerve entrapment.   
Alcoholism 
Alcoholism is often associated with poor nutrition and 
nutritional deficiencies, with thiamine deficiency being 
common in alcoholism.   Additionally, alcohol itself may 
directly damage the nerves, but this is not yet clear in the 
literature.   
Toxic 
Exposures 
Anticancer Drugs 
Some chemotherapy drugs are neurotoxins, and damage to 
nerves is dependent on the cumulative dose of the drugs.  
Recovery from chemotherapy induced neuropathy can take a 
long period of time in order for nerve regeneration to occur 
[52].   
Heavy Metals 
Arsenic, lead, mercury, cadmium are neurotoxins and can 
lead to neuropathy.  In some cases, the neuropathy reverses 
when the exposure is taken away, but damage may also be 
permanent [62].  
Industrial Chemicals 
Many solvents and volatile substances are neurotoxins, and 
exposure is typically seen in industrial workers.[114] These 
substances may also have synergistic effects when exposure 
and alcohol abuse occur together [64].   
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 Biomechanical Impact of Sensorimotor Peripheral Nerve Impairments 1.2.5
Although much of the work investigating the biomechanical effects of peripheral nerve 
function decline has been done in diabetic populations, considerable evidence exists that 
peripheral nerve function impairments result in altered gait mechanics [115-120], and the 
adoption of inefficient and less stable gait patterns.  These gait alterations include shorter and 
wider steps, and spent more time in the double support and stance phases, and utilize a “hip 
strategy” while walking by pulling the legs forward using hip flexor muscles, rather than an 
“ankle strategy” of pushing the legs forward using plantar-flexor muscles [116].  Many of these 
Infectious and 
Autoimmune 
Disorders 
Shingles,  Epstein-Barr 
Virus, 
Cytomegalovirus, and 
Herpes Simplex Virus 
This group of viruses target nerve tissue and often lead to 
damage to the sensory nerves.    
HIV 
Neuropathic symptoms are common in HIV, and different 
forms of neuropathy may develop during different stages of 
HIV. 
Charcot-Marie-Tooth 
Disease 
Charcot-Marie-Tooth is a condition where the genes 
responsible for making neurons or the myelin sheath flawed. 
Genetic Mutations 
Other genetic mutations may lead to heredity neuropathies.  
Inherited neuropathies that present in childhood are typically 
severe, while those that present in early adulthood are less 
severe.   
Guillain-Barré 
This syndrome results in inflammatory neuropathies due to 
the immune system attacking the nervous system.   
Inherited 
Conditions 
Charcot-Marie-Tooth 
disease 
This disease is the most common cause of genetic-related 
peripheral neuropathy and is characterized by mutations in 
the genes responsible for the structure or function of the axon 
or myelin sheath [106].   
General inherited 
conditions 
Other genetic mutations can lead to peripheral nerve 
dysfunction.  Typically more severe mutations result in 
severe dysfunction that presents in childhood while less 
severe mutations may not present with any impairment and 
are typically evident in adulthood, if at all.   
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Table 2 Continued
gait abnormalities may result from the reduced range of motion at the ankle, reduced motor 
control, loss of sensation, and thickening of soft   tissues [115,117,118,121].  Because of the 
associations of gait alterations and injuries and falls [117,122-124], these biomechanical factors 
are likely in the pathway between peripheral nerve function impairments and reduced physical 
function.    
 Sensorimotor Peripheral Nerve Function and Walking Endurance 1.2.6
Studies examining sensorimotor peripheral nerve function and gait have typically utilized 
short walking courses, and little work has been done examining sensorimotor peripheral nerve 
function on longer courses.  Walking endurance—the ability to walk for a sustained time or 
distance—is important for remaining active in the community.  Özdirenç and colleagues 
compared walking endurance from a 6-minute walk test between diabetic adults (age 59.3±7.8 
years) and healthy non-diabetic adults and found that the diabetic adults had significantly worse 
walking endurance [125]. Though the differences between diabetic and non-diabetic adults may 
be in part due to peripheral nerve function, this study did not include any measure of peripheral 
nerve function, which prevented the investigators from fully exploring the potentially reasons for 
the differences in endurance walking.  In addition, although the 6-minute walk test is considered 
a valid measure of physical fitness, it has been shown that older adults are more likely to work 
closer to their maximal effort on the Long Distance Corridor Walk (LDCW)—an endurance 
walking test that was developed in the Health ABC Study [126].  In general, walking in daily 
activities is performed over a specific distance rather than for a specific time, making walking 
tests like the LDCW potentially more relevant for daily living in terms of endurance walking. 
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In the InCHIANTI study, faster motor nerve conduction velocity (indicating better 
peripheral nerve function) was associated with faster completion of a 400m endurance walking 
test. Though nerve conduction velocity testing allows for the examination of a range of motor 
nerve function, this single measure only gives a partial picture.  Ideally, studies should include 
more than one measure, including the presence of symptoms, sensory nerve tests, and touch 
sensation examinations [82].   
1.3 AUTONOMIC PERIPHERAL NERVOUS SYSTEM FUNCTION IN OLDER 
ADULTS 
Autonomic nerve function impairments can affect various involuntary processes in the 
body, but these impairments are often overlooked in clinical settings.  Compared to sensorimotor 
peripheral nerve impairments and neuropathy, autonomic peripheral nerve impairments are less 
understood and studied.  However, like sensorimotor peripheral nerve function dysfunction, 
when autonomic nerve function dysfunction acknowledged, it is often in the context of diabetes, 
although changes occur in the autonomic nervous system with aging [42].   
 Cardiovascular Autonomic Neuropathy 1.3.1
Cardiovascular autonomic neuropathy (CAN) is a condition that arises due to damage to 
the autonomic nerve fibers that innervate the heart and blood vessels, which leads to the inability 
cardiovascular system to properly regulate heart rate, blood pressure, and vascular dynamics.  
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Autonomic balance is necessary for cardiovascular system regulation, the ability of the 
cardiovascular system to respond to stimuli, and the maintenance of homeostasis.   
Autonomic balance involves the complex interaction between the parasympathetic and 
sympathetic nervous system and other physiologic mechanisms that keep heart rate and blood 
pressure functioning normally [80].  CAN results in a higher risk for cardiac arrhythmias, silent 
myocardial infarction and sudden cardiac death [80].  Signs and symptoms of CAN include 
resting tachycardia, orthostatic hypotension, and silent myocardial ischemia [127] resulting from 
cardiac injury from increased mitochondrial oxidative stress and calcium dependent apoptosis 
[128].  Exercise intolerance is also common in CAN due to the inability of the cardiovascular 
system to respond appropriately to stimuli.  Exercise intolerance is the lack of ability to exercise 
for a duration or intensity that would be expected for an individual’s age and condition, and may 
result in severe fatigue from exercise, unusual breathlessness, and muscle weakness or pain.   
 Cardiac Autonomic Function Assessment Methods 1.3.2
Several methods exist for assessing cardiac autonomic function.  These methods vary 
widely in their clinical utility, feasibility, and cost.   
1.3.2.1 Heart Rate Variability 
Heart rate variability is the most commonly used method for assessing CAN, and 
decreased heart rate variability is the earliest clinical indicator of CAN [128].  Heart rate 
variability is defined as “the variation over time of the period between consecutive heartbeats” 
[129] and reflects abnormalities in parasympathetic and sympathetic function.  Imbalances 
between the sympathetic and parasympathetic nervous system lead to changes in heart rate, with 
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low sympathetic and/or high parasympathetic activity leading to cardio-deceleration, while high 
sympathetic and/or low parasympathetic activity leading to cardio acceleration [129].    Reduced 
heart rate variability may be indicative of poor cardiovascular health, and is predictive of adverse 
cardiovascular outcomes, such as hypertension, coronary artery disease, chronic heart failure, 
and myocardial infarction [130].   
In the collection of heart rate variability, a participant wears a standard Holter monitor, 
which includes an electrocardiogram (ECG).  Collection periods vary, with durations short 
durations of  5-7 minutes to free-living data collection of 24 hours being common in the 
literature [82].  The ECG readings are analyzed using specialized software, with various 
techniques available for characterizing the data.  A number of complex indices related to cardiac 
electrophysiology and autonomic function can be obtained through HRV measurements, 
depending on the analysis technique used.  These methods include time-domain, geometric, 
frequency-domain, non-linear methods, and long term correlation, although the time-domain and 
frequency-domain methods are the most common.  The time-domain method is based upon the 
intervals from beat to beat, while the frequency-domain method utilizes bands of frequency, and 
then the beats within each band are summed.   Common time-domain indices include the 
standard deviation of all normal to normal intervals (SDNN), the root mean square of successive 
differences between normal to normal intervals (rMSSD), and the standard deviation of normal 
to normal intervals in a given short-term time frame (SDNN-index). Generally, higher values are 
considered to reflect healthier HRV, though exceptions exist.   
High frequency signals are indicative of parasympathetic activity (0.15-0.40 Hz) while 
low frequency signals indicate sympathetic activity (0.04-0.14 Hz) [129]. In general, recordings 
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of shorter duration (i.e. 5-7 minutes) should be analyzed using the time-domain analysis, where 
longer recordings (i.e. 24 hours) should be analyzed with the frequency-domain analysis method.   
Though higher heart rate variability measures are considered to reflect better cardiac 
functioning, in some instances this is not the case.   For example, in a study of older adults from 
the Cardiovascular Health Study, abnormal heart rate patterns were found to be associated with 
elevated time and frequency domain heart rate variability indices [131].  In particular, higher 
rMSSD values usually reflect higher parasympathetic input, though in older adults higher values 
can also reflect the presence of erratic heart rhythms.  Non-linear heart rate variability measures, 
however, can detect abnormal heart rate variability indices resulting from underlying cardiac 
control or function abnormalities.  Poincare ratios are often used for the characterizing the degree 
of erratic rhythms.  However, non-linear heart rate variability analysis is often much more time 
consuming than time or frequency domain analysis.  Many older adults may have abnormal heart 
rate patterns, which add to the complexity of utilizing these measures in older adults. 
1.3.2.2 Bedside Autonomic Function Batteries 
Although heart rate variability is largely considered the gold standard for assessing 
cardiac autonomic function, other tests involving blood pressure or heart rate measurement can 
be easily utilized in the clinical setting [132].  First, orthostatic hypotension is a common 
indicator of CAN.  As a patient transitions from sitting to standing, blood pressure drops 
significantly  with common cut points being >20mmHg for systolic or >10mmHG drop for 
diastolic blood pressure [132].  Often times this can lead to dizziness, lightheadedness, or 
syncope, but orthostatic hypotension is commonly asymptomatic.  Other measures include:  
measuring blood pressure during the Valsalva maneuver; heart rate during deep breathing; blood 
pressure response to a hand grip test, where a patient holds 30% of their maximal hand grip on a 
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dynamometer for 3-4 minutes; and the 30:15 ratio, where heart rate is measured 30 seconds prior 
to and 60 seconds after going from supine to standing.  In the 30:15 ratio, heart rate should be 
highest at 15 seconds after standing, while 30 seconds after standing the heart rate should be 
close to the supine heart rate [132].   
1.3.2.3 Resting Heart Rate 
Resting heart rate (HR) alone is an easy performed measure used to estimate cardiac 
autonomic function [132].  Though resting HR can be influenced by several factors, resting HR 
is indicative of vagus nerve function and parasympathetic function.  Elevated resting heart rate 
has been shown to be associated with an increased risk of cardiovascular morbidity and mortality 
[133-135].  Elevated resting heart rate has been shown to be associated with an increased risk of 
cardiovascular morbidity and mortality in numerous studies, even after adjusting for common 
cardiovascular risk factors.  Change in resting heart rate has also been shown to predict ischemic 
heart disease deaths [136].  In a large prospective cohort study of 13,499 men and 15,826 women 
without cardiovascular disease in Norway, resting heart rate was measured at baseline and then 
10 years later, with mortality follow up continuing for approximately 13 years after the second 
measure.  After a mean follow-up of 12 ± 2 years, there were 3038 deaths, with 388 of the deaths 
being caused by ischemic heart disease.  A change in resting heart rate of greater than 25 beats 
from the first to the second measure was associated with a 1.80 (95% CI 1.10-3.10) increased 
risk of death compared to those with a resting heart rate change of ± 5 beats.   
 Elevated resting heart rate is associated with poor outcomes, though the 
association between resting heart rate and disease is not necessarily linear.  In a meta-analysis 
including data from three population-based cohorts of middle aged and older adults (including 
the Health Aging and Body Composition Study, Cardiovascular Health Study [137], and Kuopio 
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Ischemic Heart Disease Study), a non-linear association was found between resting heart rate and 
risk of heart failure [138].  Risk for heart failure was higher for those with higher heart rate, but 
those with very low heart rate (< 60 beats per minute) also had a higher risk of heart failure.   
Although resting heart rate can give some insight on cardiovascular autonomic function, 
it may also be influenced by other factors, including acute illness, emotional stress, caffeine 
intake, and certain medications, among others.  In particular, beta blockers, calcium channel 
blockers, and tricyclic antidepressants [139] can influence heart rate.  In addition, very low heart 
rate in young, healthy populations is often indicative of very high fitness levels rather than 
autonomic imbalance.  Because of this, interpreting heart rate as a measure of pure autonomic 
function should be done with caution. 
1.3.2.4 Heart Rate during Exercise Testing 
Heart rate should be variable and responsive to various situations (i.e. accelerate during 
exercise, and then return to normal post-exercise).  Thus, measuring heart rate during exercise 
testing is also be useful for identifying cardiovascular autonomic function impairments [140].  
Typically, to evaluate heart rate response, resting heart rate is subtracted from peak heart rate 
from an exercise test.   Though heart rate response is often calculated from maximal graded 
treadmill tests, these measures can also be examined from submaximal exercise tests.  To 
evaluate heart rate recovery, the difference between peak heart rate and heart rate after a 
specified rest period after testing (typically one or two minutes post-test).    A delay in heart rate 
returning to normal after exercise has been associated with increased risk of mortality in those 
with CAN and diabetes [141], though heart rate changes during exercise are also associated with 
increased risk of cardiovascular outcomes and sudden death in healthy individuals [142].   
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In healthy, working men between the ages of 42 and 53 years, an increase of heart rate 
less than 89 beats per minute during a peak exercise test was associated with an increased risk of 
sudden death (relative risk = 6.18, 95% CI: 2.31-16.11) during 23 years of follow-up.  
Additionally, a decrease in heart rate post exercise of less than 25 beats per minute (difference 
between peak heart rate and heart rate measured 1-minute post-test) was associated with an 
increased risk of sudden death (Relative Risk= 2.20, 95% CI: 1.02-4.74).  Likely, the best 
measures of autonomic function to consider for epidemiologic studies are resting heart rate and 
heart rate response and heart rate recovery during a submaximal exercise test because of their 
relative ease to collect and analyze without extensive equipment. 
 Risk Factors for Cardiac Autonomic Neuropathy  1.3.3
Presently, few studies have examined cardiac autonomic function in the general 
population of non-diabetic older adults.  Much of the work in this area has been focused on 
populations with diabetes, although risk factors for decreasing heart rate variability have been 
identified through epidemiologic studies.  In particular, older age, male sex, diabetes (fasting 
glucose ≥126 mg/dL), and the presence of other cardiovascular risk factors are associated worse 
measures of heart rate variability [42,143].  
Stein and colleagues were among the first to analyze heart rate variability in a large 
epidemiologic study of older adults.  In the Cardiovascular Health Study, older adults (n=585, 
age >65 years) had two 24-hour Holter recordings, 5 years apart to examine the change in heart 
rate variability.  When examining the changes, it was found that autonomic cardiac function 
decreased the most between the ages of 65-75, with function leveling out at 75 and beyond, 
although overall changes were small.  These changes were independent of cardiovascular risk 
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[42].  However, because participants had to have two visits in order for change to be analyzed, 
likely the healthiest older participants were able to return for a second visit.  In essence, 
participants who were not unable to return for the visit may also have experienced larger changes 
in autonomic function, biasing the results towards the null.   
When examining differences in heart rate variability by cardiovascular disease risk, those 
at higher risk for cardiovascular disease at baseline had worse heart rate variability measures 
after adjusting for covariates compared to those at lower risk.  (Low risk for cardiovascular 
disease was defined as having SBP ≤140 mmHg, DBP ≤90 mmHg, no beta blockers or anti-
hypertensive medications, BMI ≤ 30, no history of MI, stroke, known coronary heart disease or 
congestive heart failure, fasting glucose <110 mg/dl, and no hypoglycemic medication use.)  
Higher risk participants had lower heart rate overall, and the authors hypothesized that this was 
likely due to lower physical activity in the higher risk group.  Because physical activity was not 
measured in conjunction with HRV, no confirmation was provided for this hypothesis and it 
remains to be tested. 
In the Atherosclerosis Risk in Communities (ARIC) study [143], Schroeder and others 
examined the effect of diabetes on 9-year change in heart rate variability using 2- and 6-minute 
beat-to-beat heart rate recordings.  Participants in this study were younger (45-64 years) than 
those in CHS, and the study sample was also larger (n=6,245 individuals with 9 year follow up 
data, and n=9,940 with baseline data).  Diabetic participants (defined as those with fasting 
glucose ≥7.0mmol/L, non-fasting glucose ≥11.1mmol/L, self-reported physician diagnosis, or 
use of pharmacologic hypoglycemic treatment) had lower heart rate variability at baseline (R-R 
interval 852.69, 95% CI: 844.45-860.94, for diabetic participants vs. 916.99, 95% CI: 913.54-
920.43, for participants with normal fasting glucose, p<0.05).  (Normal fasting glucose defined 
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as <5.6mmol/L.)   In those with diabetes, the adjusted mean annual change in R-R intervals was 
3.88 milliseconds/year (95% CI: 2.72-5.04), compared to 6.74 (95% CI: 6.33-7.16) in 
participants with normal fasting glucose (p<0.05).  Though these epidemiologic studies were 
useful for identifying changes in autonomic function, more work is needed in order to determine 
how changes in autonomic function over time are related to geriatric outcomes.   
 Autonomic Nervous System Function in Diabetes 1.3.4
Diabetes has a major impact on the autonomic nervous system.  Changes in cardiac 
autonomic function can be detected though exercise-based CAN assessments and these 
abnormalities are even present in middle-aged diabetic individuals who have no evidence of 
autonomic neuropathy otherwise [144].  In a study of 18 middle age diabetic participants (age 55 
± 2 years) and 20 healthy controls (age 51 ± 1 years) participants underwent two 16-minute 
submaximal bicycle exercise tests followed by a 45 minute recovery autonomic nervous system 
function was measured during exercise and recovery.  During the second exercise test, atropine 
was administered at peak exercise in order for the final two minutes of exercise and the recovery 
period to occur under parasympathetic blockade.  Participants underwent standard CAN testing 
(heart rate response to deep breathing, standing, and Valsalva maneuver, and blood pressure 
response to standing and during sustained hand grip) to determine whether exercise based testing 
could uncover cardiac autonomic dysfunction in those with normal standard CAN assessments.  
In the early recovery period after submaximal exercise, diabetic participants had a delay in heart 
rate recovery compared to the controls (heart rate recovery one minute post exercise: 18.5 ± 1.9 
bpm for diabetic participants compared to 27.6 ± 1.5 bpm for controls, p<0.001).  Diabetic 
participants also had a suppressed parasympathetic effect on the RR interval during recovery 
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compared to controls (RR interval during recovery: 154 ± 16 milliseconds for diabetic 
participants vs. 211 ± 15 milliseconds for controls p = 0.004).   
The diabetic participants in this study had well-controlled type 2 diabetes and had good 
scores on the standard CAN assessments.  The fact that diabetic participants have autonomic 
abnormalities on exercise-based assessments but not high scores on typical CAN measures 
highlights the importance of measuring subclinical autonomic function.    However, a limitation 
of this study is that the techniques used to capture reduced autonomic function (two separate 
submaximal exercise tests, one with parasympathetic blockade) are not feasible to use in 
population studies and may be inappropriate for older adults with chronic conditions (particularly 
cardiovascular disease risk factors) that may make this testing unsafe.  Early detection of 
dysfunctions using techniques that are feasible for older adult populations will be important for 
future work in this area.   
Currently, it is unclear whether tight glucose control has a long-term impact on protecting 
against the development of autonomic neuropathy in diabetes [80].  In the Veteran’s Affairs 
Diabetes Trial, no microvascular benefits of intensive glucose therapy over standard therapy for 
veterans with type 2 diabetes, and there was a slight trend of an increase in incidence of 
autonomic neuropathy existed in the intensive therapy group [145].  However, the participants in 
this study were a relatively homogeneous group in that they were all veterans, predominantly 
men (97%) had a relatively long duration of diabetes (mean 11.5 years since diagnosis), and 
many (40%) already had a cardiovascular event. Long term studies with representative 
populations of older adults or those with diabetes would be needed to help address this question.   
The results of this study were in contrast to studies of Type 1 diabetes where better glucose 
control was related to a lower incidence of CAN in the Diabetes Control and Complications Trial 
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and Follow-up Study from baseline to study year 13/14 [146].   These contradictory results are 
possibly due to the “metabolic memory” effect of hyperglycemia, and that historical glucose 
levels may be most important factor in predicting CAN [147]. 
1.4 PHYSICAL ACTIVITY AND PERIPHERAL NERVOUS SYSTEM FUNCTION  
The benefits of physical activity on metabolic and cardiovascular risk factors are well 
established and supported by leading professional organizations [26,148-150].  Physical activity 
may also be beneficial for peripheral nervous system function for older adults.  Muscle 
contraction has an insulin-like effect on the body by increasing the cell membrane ability to 
absorb glucose from the blood [151], therefore  physical activity may be an important part of 
reducing the damaging effects of hyperglycemia have on the peripheral nervous system.  
Additionally, physical activity can improve vascular and endothelial function in the lower 
extremities [152-154], and higher levels of physical activity participation are associated with 
lower levels of inflammatory markers [155,156], both of which could potentially influence 
peripheral nerve function.   
 Evidence of Physical Activity Improving Sensorimotor Peripheral Nerve Function 1.4.1
Worse peripheral nerve function may be associated with lower levels of physical activity, 
and in turn, low levels of physical activity could potentially lead to worse peripheral nerve 
function.  Despite the potential for these bidirectional effects, little has been done to explore the 
relationship between physical activity and sensorimotor peripheral nerve function.  The 
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relationship between sensorimotor peripheral nerve function and physical activity has not been 
examined in epidemiologic studies of older non-diabetic participants.  Additionally, only small 
studies have been performed in humans examining the effects of PA or exercise training on 
peripheral nerve function, and these studies have been primarily conducted in populations of 
middle-aged diabetic populations rather than populations of older adults.     
One study examining peripheral neuropathy and walking in older adults indicated that 
older adults with peripheral neuropathy take fewer steps per day compared to older adults 
without peripheral neuropathy [157].  However, from prior epidemiologic studies it is known 
that worse sensorimotor peripheral nerve function is associated with worse lower extremity 
physical functioning even without progressing to the point of clinical peripheral neuropathy [31], 
making it important to study a full range of peripheral nerve function.   In addition, although 
pedometers can be useful for promoting activity in an intervention setting, pedometers only 
count ambulatory activity and may not accurately reflect an individual’s total daily activity.   
In an analysis of diabetic participants in NHANES, no direct relationship was found 
between peripheral neuropathy and the number of minutes spent in moderate to vigorous 
physical activity (MVPA) per day [158].   Nevertheless, those with better diabetic control (as 
measured by HbA1c) and higher levels of activity were less likely to have peripheral neuropathy 
compared to what would be expected from the individual effects of PA and diabetes control.    In 
this study, the mean number of minutes of MVPA was only 11.7 minutes, which could be an 
explanation for the lack of association between PA and peripheral neuropathy.   Though the use 
of accelerometer in NHANES may help provide a more accurate representation of participants’ 
total daily activity, only MVPA was considered.  Examining objectively measured physical 
activity at a wide range of intensities (including light intensity activity) may beneficial for 
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clarifying the relationship between peripheral nerve function and PA in older adults—
particularly since older adults spend very little time in MVPA [25,159].  
In regards to intervention studies examining change in peripheral nerve function with 
physical activity, Kluding and colleagues conducted a pre-test post-test design study with middle 
aged participants (n=19, age 58.4 ± 5.98 years) with diabetes (duration 12.4 ± 12.2 years) to 
determine the effects of an exercise intervention on neuropathic symptoms and nerve function 
[160].  The exercise program lasted for 10 weeks and included 2 days per week of aerobic 
exercise and 2 days of resistance training.  After the training program, participants reported less 
pain compared to baseline on the Michigan Neuropathy Screening Instrument symptom 
questionnaire (5.2 points vs. 4 points, p=0.01).  No differences existed after training in nerve 
conduction or on quantitative sensory tests.  A major limitation to this study is that no control 
group was studied and the sample size was very small.  Additionally the training program may 
not have been long enough to elicit positive changes in quantitative tests of motor and sensory 
nerve function.  Despite the limitations, this study does provide important insight into the relief 
of neuropathy pain that could result from an exercise program.  However, a controlled trial is 
needed before making definitive conclusions about these improvements.   
A clinical trial in Italy examined the effects of a long-term exercise training program in 
the prevention of the development of peripheral neuropathy in type 1 and type 2 diabetic 
participants (n=78) without signs or symptoms of neuropathy [161].    The intervention group 
(n=31, age 49 ± 15.5 years) participated in a 4 hour per week treadmill-based brisk walking 
program for a total of 4 years.  Control participants did not receive any intervention.  After the 4 
year trial, 8 control participants (17.0%) but zero intervention participants developed motor 
neuropathy (p<0.05), and 14 (29.8%) control and 2 (6.4%) intervention participants developed 
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sensory neuropathy.  Although this is a promising result, the authors did not define sensory or 
motor neuropathy, limiting the interpretability of the results.  However, continuous measures of 
nerve function were included, and peroneal motor nerve conduction improved in the intervention 
group (1.8 ± 2.7 m/s), while a slight decrease in motor nerve conduction (-0.6 ± 3.3 m/s) was 
observed in the control group (p<0.001 for between group differences).  Similarly, there was a 
slight increase in sural sensory nerve conduction velocity for the intervention group (0.4 ± 3.3 
m/s) while there was a decrease in sensory nerve conduction velocity for the control group (-2.7 
± 2.8, p<0.001 for difference between groups).  
Importantly, this study was much longer than the typical exercise trial (four years total), 
and required a large commitment from the intervention participants (four one-hour supervised 
exercise sessions per week).  The authors reported that all participants in both arms completed 
the study, and the attendance rate for the intervention was greater than 90%--adherence that is 
rarely seen in any kind of clinical trial.  The participants in this trial were likely very highly 
motivated and concerned about their health in order to achieve this sort of attendance—and 
differed from the general population with diabetes, limiting the generalizability of this study.   In 
addition, the participants in this study had only mild hyperglycemia, and are not representative of 
those with more serious disease.   
Alternative modes of aerobic exercise aside from walking have been proposed as 
potentially beneficial for those with peripheral neuropathy.  These recommendations have been 
acknowledged in diabetes literature, and the American College of Sports Medicine and American 
Diabetes Association have recommended that those with peripheral neuropathy engage in non-
weight bearing activity [162].  These recommendations may be relevant to older adults with 
peripheral nerve impairments.  In particular, non-weight bearing activity may be a safer 
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alternative to walking for older adults with sensory impairments or symptoms of numbness or 
pain in the lower extremities.    
In a small (n=29) randomized clinical trial, a walking program was compared to a non-
weight-bearing (NWB) exercise program for improving walking capacity (6-minute walking 
distance) and daily step counts (measured via pedometer) in adults with diabetic peripheral 
neuropathy (mean age 64.5 ± 12.5 years) [163].  The walking intervention consisted of 1-hour 
group sessions, 3 times a week, for 12 weeks where participants were instructed to walk to 
achieve specific step counts, based upon their baseline activity.  Step counts were increased 
every two weeks.  Sessions also included balance exercises and body weight resistance exercises.  
Participants were also instructed to walk outside of the center-based sessions.  The NWB group 
also participated in 1-hour group sessions, 3 times a week for 12 weeks, but used performed all 
exercises while either lying or sitting.  Participants used elastic bands for resistance exercises, 
and used either a stationary upright or recumbent cycle ergometer for their aerobic exercise.   
After the 12-week intervention, the walking group experienced greater increases in 
walking endurance compared to baseline (27 more meters during the 6-minute walking test for 
the walking group compared to two fewer meters for the NWB group compared to baseline, 
p=0.014).  Also, the walking group increased their daily step count by an average of 685 steps 
from baseline, compared to the NWB group who on average walked 493 steps fewer compared 
to baseline (p=0.026 comparing group differences).  Although the walking group improved 
walking endurance and in daily step counts, the NWB group had greater improvements in 
HbA1c, (-0.4% compared to baseline) compared to the walking group (-0.2% compared to 
baseline, p=0.037 comparing group differences).  The improvements in glucose control could 
potentially help peripheral nerve function.  Additionally, during exercise, those in the NWB 
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group had fewer lower extremity musculoskeletal pain complaints compared to the walking 
group.    
It is not particularly surprising that a group in a walking intervention will walk more than 
a group in an intervention that promotes other modes of exercise.  Comparing activity of the two 
intervention groups using other tools (i.e. an accelerometer or questionnaire) may have given a 
more accurate comparison of activity between the two groups.  This was a small study not 
powered to detect differences in secondary outcomes, and also did not measure peripheral nerve 
function, which are limitations to this study.  However, this study provides evidence that 
exercise, whether through walking or NWB activity can be beneficial for those with diabetic 
peripheral neuropathy, although the benefits may be different for the different exercise modes.  
Exploring whether walking or NWB exercise is more beneficial for pain and peripheral nerve 
function outcomes in older adults would be an important next step considering the results of this 
study. 
1.4.1.1 Physical Activity and Sensorimotor Peripheral Nerve Function:  Animal Models 
Animal models have been utilized in exploring nerve impairments and the physiologic 
changes that occur after exercise training.  Animal work has suggested that aerobic exercise 
training is beneficial in reducing myelin loss in the sciatic nerves of type 1 diabetic rats (diabetes 
induced with streptozotocin) with neuropathy after 56 days of aerobic training [164].  In the rats 
that developed neuropathy, the exercise training was successful in improving motor nerve 
function compared to the rats with neuropathy that did not undergo the training program.  
Additionally, treadmill training in wild-type C57BL6 mice with injured peripheral nerves 
enhanced motor axon regeneration after two weeks of training [165].  These adult mice had 
surgical induced peripheral nerve injury, where the sciatic nerve was severed and then repaired.  
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Similar results were found in a study of adult Sprague-Dawley rats that had their sciatic nerve 
severed and repaired, comparing passive (bicycle) and active (treadmill) exercise in nerve 
regeneration after transaction and repair at the sciatic nerve [166].  After two months of training, 
both modes of training led to slight improvements in muscle reinnervation, and there was an 
increase in the number of regenerated axons in the distal nerve compared to the control animals.    
These animal studies provide evidence that exercise is beneficial for nerve and motor axon 
regeneration in a laboratory setting—important precursor work for examining relationships 
between regeneration of human nerves via exercise training.   
Some evidence exists from animal studies that weight bearing aerobic exercise can 
potentially increase Schwann cell apoptosis in distal peripheral nerves [167].  This work was 
done in diabetic rats, in which rats were randomly assigned to one of three groups: an aquatic 
exercise group, a treadmill exercise group, and control.  After 12 weeks of exercise, sural and 
sciatic nerves were assessed, and it was determined that the treadmill based exercise lead to the 
increased Schwann cell apoptosis in the sural nerves.  However, no evidence exists in humans 
that different aerobic exercise modes differentially affect mechanical loading on peripheral 
nerves, although this may be an area worthy of investigation in determining ideal modes of 
exercise for those with peripheral nerve dysfunction. 
 Evidence of Physical Activity Improving Cardiac Autonomic Function 1.4.2
Physical activity and aerobic exercise are beneficial for overall cardiovascular health, and 
may help improve heart rate variability by improving vagal tone and decreasing sympathetic 
activity in the heart [130].  During aerobic activity, the heart rate accelerates in response to 
increased sympathetic activity and reduced vagal modulation of heart rate.  After long term 
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aerobic training, the balance between sympathetic and parasympathetic activity shifts towards a 
parasympathetic predominance due to increased vagal modulation of the heart rate and in 
response to reduced sympathetic activity [168].  The primary autonomic nervous system 
adaptation with exercise training is a decrease in resting heart rate and lower heart rate at 
submaximal exercise [128].  Exercise training also improves heart rate variability due to 
increased compliance of large arteries, which leads to a higher load on barorecepter nerves, 
which can improve parasympathetic tone [128].  Aerobic exercise may improve vagal tone and 
decrease sympathetic activity [130], and also increase cortical blood flow, which improves 
sympathetic, parasympathetic, and central cholinergic activity [169].   
Compared to evidence for exercise improving sensorimotor function, more evidence 
exists to support the benefit of PA and fitness to the cardiac autonomic nervous system.  In 
general, a variety of exercise programs have been shown to improve heart rate variability—
particularly in patient populations with diabetes, chronic heart failure, prior myocardial 
infarction, or those that undergo coronary artery bypass grafting [130].  These prior studies 
generally involved small sample sizes (n<50) with exercise programs ranging in duration from 2 
to 52 weeks.   
In one study focusing on older adults, an intensive, 14-week interval cycling training 
program was found to increase heart rate variability in a small sample of older men (n=11, age 
73.5 ± 4.2 years) [170].  However, these older men were former trained cyclists free of any 
known cardiac abnormalities, and are not representative of the population of older adults.  
Although the intensity of this program may not be suitable for all older adults, this study 
supports cycling as an exercise to improve autonomic nerve function.  Because cycling is a non-
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weight bearing activity, this form of exercise could be beneficial for older adults who have 
difficulty walking.     
The Diabetes Prevention Program (DPP) was a landmark phase III randomized clinical 
trial which compared a lifestyle intervention (PA + diet), Metformin treatment, and control for 
the development of diabetes in pre-diabetic adults (age 50.4 ± 10.6 years).  Heart rate variability 
was measured at baseline and annually throughout the four year trial using a ten second 12-lead 
ECG segment [171]. Mean heart rate, standard deviation of all normal-to-normal R-R intervals 
(SDNN), and the root mean square of successive differences between all normal-to-normal R-R 
intervals (rMSSD) were generated for examining cardiac autonomic function.  These measures 
did not vary between treatment groups at baseline; however, the lifestyle intervention group saw 
the greatest improvements in these measures over the mean follow up of 3.2 years (p<0.05 for 
all).  Heart rate decreased by 4.74 beats per minute (95% CI: -5.21 to -4.27) for the lifestyle 
group, compared to a decline 1.88 beats per minute for the Metformin group (95% CI: -2.39 to -
1.37), and a decline of 2.12 beats per minute (95% CI: -2.57 to -1.67) in the control group. For 
SDNN, the lifestyle group experienced an increase of 1.32 (95% CI: 0.32 to 2.34) ms, while 
there was no significant change for the Metformin group, and the control group experienced a 
decline in this measure of 1.21 ms (95% CI: -2.03 to -0.39).  The lifestyle group also saw 
improvements in rMSSD over the follow-up period (change of 2.98 ms, 95% CI: 1.71-4.25) 
while there were no significant changes for either the Metformin or control groups.  Although 
physical activity was a main component to the lifestyle intervention in the DPP, weight loss 
through dietary modifications was also an important part of the study.  Physical activity could 
very well have played a major role in the heart rate variability improvements seen by the lifestyle 
intervention group, but weight loss and dietary changes may have also contributed.   
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This study was important in that it focused on heart rate variability in a population free of 
disease at baseline, and the fact that the PA program focused on moderate-intensity activities that 
could easily be adopted by older adults.  Additionally, the large, multicenter design of this study 
improved generalizability. Though the lifestyle intervention was most effective in the prevention 
of diabetes in participants age 60-85 [172], the results for this study were not stratified by age, so 
we cannot conclude whether the improvements in heart rate variability in the lifestyle group were 
different across age groups.       
In the Look AHEAD study, overweight adults with type 2 diabetes (n= 5145 participants 
from 16 study centers, age 45-75 years) were randomized to participate either in an intensive 
lifestyle intervention (weight loss via physical activity and dietary changes) or diabetes support 
and education (general recommendations about healthful eating and physical activity in type 2 
diabetes) [173].  The primary purpose of the Look AHEAD trial was to assess whether the 
intensive lifestyle intervention was successful in reducing cardiovascular morbidity and mortality 
long-term.   
Several measures of cardiovascular function were collected in this study, and in a paper 
by Ribisl and colleagues, change in heart rate recovery from baseline to 1-Year follow-up were 
assessed [174].  At baseline, participants underwent a graded exercise treadmill test in order to 
assess maximal cardiorespiratory fitness.  Fitness testing was repeated at the 1-Year follow-up, 
though this test was submaximal.  Because of the potential for certain medications, namely beta-
blockers, to influence heart rate response during exercise, participants taking these medications 
were analyzed separately.  Heart rate recovery was used in this study as a measure of autonomic 
function.   
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At baseline, no differences existed between the intensive lifestyle group vs. the diabetes 
education group in any measure of heart rate (resting heart rate, peak exercise heart rate, heart 
rate range, heart rate at 2-minutes post-test, and heart rate recovery), stratified by beta blocker 
use.  After one year of follow-up, the intensive lifestyle intervention group not taking beta- 
blockers had significantly lower resting heart rate, higher heart rate range, lower heart rate at 2-
minutes post-test, and better heart rate recovery compared to those not taking beta blockers in the 
diabetes support and education group.  These relationships were also observed between the 
intensive lifestyle intervention group and diabetes support and education group in those taking 
beta-blocker, though the associations were not as strong.  Though the effects of weight loss, 
dietary changes, and physical activity cannot be teased apart in this study in terms of which had 
the largest effect on autonomic improvement, this study provides evidence that cardiac 
autonomic function can be improved via an intensive lifestyle intervention for those with type 2 
diabetes.  Physical activity interventions appear to be promising for improving cardiac 
autonomic function, though more work is needed to determine the effect for older adults.   
1.5 PHYSICAL ACTIVITY AND OLDER ADULTS 
Throughout history—with the exception of the past few decades—humans had little 
choice but to live active lifestyles in order to survive.  Although modern life is astronomically 
different from that of our Stone Age ancestors, in a biologic and metabolic sense we are still 
programmed for their way of life.    From an evolutionary standpoint, optimization of aerobic 
metabolic pathways was advantageous in order to conserve energy and prepare for food 
shortages [175].  Today, food shortages are uncommon in most developed nations and 
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overconsumption of calories is a cause for concern.   Physical inactivity  leads to decreased 
skeletal muscle insulin sensitivity and increased abdominal fat storage, both of which play roles 
in promoting metabolic dysfunction [175].  Some exercise physiologists assert that rather than 
studying the effects of physical activity, we are actually studying “the effect of reintroducing 
exercise into an unhealthy sedentary population that is genetically programmed to expect 
physical activity” [176].  Physical activity across the lifespan is associated with lower levels of 
fat mass in women in early old age, and in higher appendicular lean mass in both older men and 
women [177].    
 Physical Activity Definitions and Recommendations 1.5.1
Physical activity has been defined as “any bodily movement produced by skeletal 
muscles that results in energy expenditure” [178], while  exercise  “is a subset of physical 
activity that is planned, structured, and repetitive and has as a final or an intermediate objective 
the improvement or maintenance of physical fitness” [178].  The 2008 Physical Activity 
Guidelines for Americans recommends that older adults follow the guideline of performing at 
least 150 minutes per week of moderate intensity activities, 75 minutes of vigorous intensity 
activities, or a combination of both, which is consistent with the guidelines for healthy adults 
[179].  Activities should be performed in bouts of at least 10 minutes, and for optimal health 
benefits, it is recommended to gradually work up to accumulating 300 minutes per week of 
moderate activities or 150 minutes per week of vigorous activities.  Ideally, this activity should 
be spread throughout the week.  In addition, strength training exercises should be performed at 
least two days per week at a moderate to high intensity, while working all major muscle groups.   
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Although these guidelines may be appropriate for older adults without major disease, it 
has been acknowledged that older adults who are very unfit or have chronic conditions may not 
be able to achieve these recommendations. Instead, these older adults should be as active as their 
conditions allow, and any amount of physical activity is better than none.  For older adults, the 
recommendations include performing balance exercises, particularly if they are at risk for falling, 
although the guidelines do not describe those who may be at fall risk.  Balance exercise 
examples may include backwards walking, standing on one foot, toe stands, and heel or toe 
walking.  These exercises should be progressive, working towards more difficult skills once 
beginning balance exercises are mastered.  Three days of balance exercises are recommended 
from a balance program designed to reduce the risk of falls in older adults.  Flexibility exercises 
are also important for older adults in order to maintain the range of motion necessary for 
activities of daily living and physical activities.  Flexibility exercises should not take the place of 
aerobic or strength training activities, and are not known to confer any specific health benefit.  
Due to the lack of clear evidence of the ideal frequency or duration of flexibility exercises for 
older adults, no specific flexibility training guidelines exist.  All of the above recommendations 
are consisted with the guidelines set in the ACSM position stand for exercise and older adults 
[26].   
Health and functional status can play major roles in the ability for older adults to adopt a 
physically active lifestyle [180].  Physical activity could potentially play a role in improving 
health, but those with health issues may need additional guidance and support from fitness and 
health care professionals on becoming active.  In fact, pain and poor health are the two most 
common reasons older adults cite as their reason for not being physically active [181].  Also, 
acute illnesses, which are common in older adults, can quickly lead to loss of muscle tissue and 
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strength and can delay recovery and the return to prior functional status [182].  Each consecutive 
illness can lead to inactivity, strength and aerobic capacity declines, and make it harder to return 
to prior functional capacity.  Continuation of this cycle can be extremely detrimental and put 
older adults at much higher risk for disability [182].   
 Physical Activity Epidemiology in Older Adults 1.5.2
Despite the numerous health benefits associated with physical activity, older adults are 
the most physically inactive age group in the U.S. [24], with only roughly 10% of adults age 70+ 
reaching national physical activity guidelines [183]. Over the past 50 years, physical activity has 
been declining in the population, and these declines can be attributed to changes in occupations, 
land use, and transportation, and increase in sedentary behaviors like television watching and 
computer use [184].  NHANES data from 2005-2006 have indicated that the mean minutes of 
moderate activities declines with age, with 20-29 year old individuals achieving an average of 
approximately 58 minutes per week, in contrast to those who are age 70 and older, who achieve 
only approximately 20 minutes of moderate activity per week [183]. Physical activity was 
measured via hip-worn accelerometry.  Though the average number of minutes of moderate 
activity declines with age, on average, even younger adults do not reach the minimal 
recommendations of 150 minutes per week.   
Prior studies incorporating objective measures of physical activity have shown that most 
of the activity energy expenditure in older adults comes from sedentary or light activity, like 
housework or sitting activities [25].  Because light and sedentary activities are difficult to recall 
using subjective measures, objective tools (like accelerometers and other physical activity 
monitors) are needed to capture the full range of activity. Also, recent work has shown that 
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separate health risks from sedentary behaviors exist, independent of physical activity [185,186]. 
Objective physical activity measures can allow investigators to examine both sedentary activities 
and physical activities; however, this is a more recent area of focus, and many studies still focus 
on moderate or vigorous physical activity, which may not be common in populations of older 
adults.  
 Methodological Issues in Measuring Physical Activity in Older Adults 1.5.3
Accurately assessing physical activity is challenging in all populations, though there are 
some methodological issues unique to assessing activity in older populations.  Table 3 describes 
common tools used to measure physical activity, and the strengths and limitations of these tools.  
Unfortunately, no single tool is perfect, and strengths and limitations must be considered when 
designing a study.  
When choosing a tool for measuring physical activity, several factors must be considered.  
First, cost is often a barrier, particularly for large scale epidemiologic studies.  Although the cost 
of many physical activity monitors has dropped substantially as technology has improved, the 
cost of purchasing hundreds of monitors and the needed software for data processing can be 
prohibitively expensive.   Second, an appropriate assessment tool should be appropriate for 
measuring the types of activities the population actually does.  Common domains of activity 
include occupational activity, transportation, household and care taking, and sports and leisure 
[187].   In the context of older adults, a questionnaire focusing on occupational activities, sports 
participation, or activities that older adults are unlikely to do would be inappropriate and likely 
lead to an underestimation of physical activity.  Questionnaires specifically developed for and 
validated in older adult populations, such as the Physical Activity Scale for the Elderly (PASE) 
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[188] or CHAMPS [189] would be important to consider.  Because light intensity activities make 
up a large proportion of energy expenditure by older adults, and these light activities can be 
difficult to recall, physical activity monitors can help to capture the full spectrum of activity 
intensity.  In general, subjective methods are appropriate for assessing moderate and higher 
intensity activities, while objective measures are more accurate in assessing a range of physical 
activities [187]. Similarly, the tool of choice should accurately measure the exposure (type of 
activity) of interest.  For example, if light activity is of interest, an objective measure may better 
capture the exposure rather than a questionnaire.  However, a limitation of accelerometry and 
other activity monitors is that although they can give information about physical activity 
participation on a full spectrum of intensity, they do not give information about specific 
activities.  For example, resistance training and weight-bearing activity are important for bone 
density [190], though in general, many activity monitors cannot currently distinguish these from 
other activities.  Though limitations exist with monitors, this is a quickly growing field and the 
conjunction of physical activity researchers with computer scientists has driven the development 
of novel analysis techniques and algorithms which can aid in the recognition of specific activities 
and patterns.              
Intensity is an important aspect of classifying types of physical activity, though intensity 
is a relative term.   Activity that one individual may consider “moderate” for one individual may 
be “very intense” for another individual who has very low aerobic capacity or functional ability.    
Physical activity monitors can help classify intensity though objective definitions, however, 
many definitions of intensity were developed from work in young, healthy populations. 
Comparing activity between younger and older adults even using objective measures should be 
done with caution.  Though older age is associated with lower levels of physical activity, making 
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absolute comparisons between older and younger adults may be inappropriate using cut-points.  
Some groups have begun utilizing alternative measures from acceleromtery data rather than 
counts using cut-points to determine intensity.  These measures include minute-by-minute 
activity counts to examine patterns of activity throughout the day; cumulative activity counts to 
determine total activity for a day [191].  The field of computer science has also begun to intersect 
with physical activity epidemiology, and techniques using raw acceleromtery to identify specific 
activities have also been developed [192,193]. However, currently these techniques require 
considerable training in computer science and biostatistics to use, though these developments 
will ultimately help shape physical activity assessment in the future and hopefully help to 
improve current measurement methods.  
Unfortunately, physical activity is not just a public health issue in the United States, but 
the issue is prevalent in other westernized nations, and is increasingly becoming a problem in 
developing nations as well [194].  Worldwide, older age is associated with lower levels of 
physical inactivity, which could lead to a major global public health burden in conjunction with 
the aging population becoming the fastest growing demographic [195].  Direct comparisons of 
physical activity levels between countries are difficult due to inconsistent methods used to 
measure activity, and the lack of reliable data from many low income countries [196]. 
Expectations about the aging process can influence whether older adults remain or become 
physically active or participate in other healthy behaviors [197,198].  Norms and expectations 
regarding aging can vary widely between cultures [199], adding to the complexity of promoting 
physical activity on a global scale.   
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Table 3:  Common Tools Used to Measure Physical Activity 
Measurement Tool Description Advantages 
 
Disadvantages 
Physical Activity 
Scale for the Elderly 
(PASE)  
The PASE assesses physical 
activity from the past seven 
days.  Participants indicate how 
often and for how long they 
participated in activities in each 
intensity category.  Participants 
also indicate whether they 
participated in household, 
gardening, occupational, or care 
giving activities [200] 
The questionnaire refers to the 
past seven days, a period where 
recall should not be difficult.  The 
questionnaire can be administered 
in less than 15 minutes, and it is 
easy to score, making it feasible 
to incorporate into large studies.  
Activity from the past seven days may not be 
representative of an individual’s usual activity 
habits, which may be more relevant to health 
outcomes.  In a validation study, the 
correlation between PASE score and doubly 
labeled water was 0.28 [201].  
Modified Minnesota 
Questionnaire  
used in the Health 
Aging and Body 
Composition Study 
(Health ABC)   
 
Measures leisure activity, 
housework, care giving, 
walking, and stair climbing.  
Participants first indicate 
whether they have done each 
specific activity at least 10 
times in the past year.  If yes, 
participants are then questioned 
about the number of times per 
week and the duration [202].  
Time spent in the activity is 
multiplied by its metabolic 
equivalent [203] to obtain 
weekly energy expenditure.   
This questionnaire is easy and 
quick to administer.  Although 
modified from its original form in 
order to be appropriate for Health 
ABC, energy expenditure from 
this questionnaire is associated 
with functional outcomes 
important in studies of older 
adults [204]. 
Because this is a modified questionnaire, 
validation data does not exist specifically for 
this questionnaire.  Energy expenditure values 
resulting from scoring the total energy 
expenditure from the original Minnesota 
Leisure Time Questionnaire (MLTQ)  is 
weakly correlated with total energy 
expenditure measured by doubly labeled water 
(r=0.23) .  MLTQ energy expenditure (from 
the original or modified version) may not 
accurately represent true energy expenditure.  
Rather, energy expenditure values should be 
used to rank or group participants.  
Additionally, participants may have difficulty 
recalling whether they participated in an  
56 
activity at least 10 times in the past year.  
Detailed questions are only asked about 
activity in the past seven days, which may not 
be representative of usual activity habits.   
CHAMPS  
Participants indicate the number 
of days per week and number of 
hours per session of various 
physical activities that older 
adults commonly do.  The time 
frame used in this questionnaire 
is a “typical week in the past 
four weeks” [189]. 
Participants are instructed to think 
about a typical week in the past 
four weeks, which may better 
represent usual activities.  In 
addition to questions about 
physical activities, this 
questionnaire also contains 
questions about other activities 
that older adults may do (i.e. play 
cards, visit with friends, etc), to 
minimize socially desirable 
responding.  The questionnaire 
can be administered quickly in 
about 10-15 minutes.   
Participants may have difficulty quantifying 
activity from a “usual week” of the past month.   
Physical Activity 
Diary 
Participants record all of their 
physical activities for a 
specified duration (i.e. seven 
days).  Typically the specific 
activity, duration, and intensity 
are recorded.   
Participants can indicate all 
activities rather than choosing 
from a specific list of activities.  
In theory, since participants are 
recording the activities as they do 
them, there should be fewer recall 
issues. 
This method requires considerable participant 
burden.  Participants may stop recording their 
activity if they feel the diary is burdensome.  
Additionally, calculating and processing data 
from a physical activity diary is difficult and 
time consuming for study staff.  
 
 
Table 3 Continued 
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Accelerometer 
Accelerometers have the 
capability to capture movement 
and quantify that movement for 
the assessment of activity 
intensity, duration, and 
frequency.   
Accelerometers objectively 
measure physical activity and are 
able to capture the full range of 
physical activity: sedentary, light, 
moderate, and vigorous.   
Specialized software is needed to process 
accelerometry counts.  Several cut-points have 
been identified for distinguishing the intensity 
of various activities.  However, many cut-
points have been established using younger 
adults and may not be appropriate for older 
adult populations [205].  Additionally, 
accelerometers may underestimate step counts 
for individuals who walk very slowly [206]. 
ActivPAL 
Inclinometer  
This physical activity monitor is 
attached to the right upper thigh 
and records body posture.  This 
monitor can identify lying, 
sitting, and standing positions, 
as well as transitions and steps.   
This monitor provides accurate 
and valid estimations of time 
spent lying, sitting, and standing 
upright, which is useful for 
studies examining sedentary time.   
Step counting may be less accurate for older 
adults with impaired physical function and 
slow gait speed [207].  This monitor is to be 
used for identifying time spent in various 
postures, and should not be used in a study 
where the aim is to measure physical activity.   
Pedometer  
Pedometers are small devices 
used for counting steps and are 
typically worn on the waist 
band.   
Pedometers are inexpensive and 
can be easily incorporated into an 
epidemiologic study or clinical 
trial.  Recording step counts is 
relatively easy and has a low 
participant burden.   
Pedometers may underestimate step counts for 
those with very slow gait speed [206].  
Accuracy of pedometers can vary widely 
between various piezoelectric and spring 
levered devices [208].  Positioning on the body 
is very important.  If the device is not 
positioned properly, it may not be able to 
detect steps.  Additionally, since pedometers 
only count steps, any activity that does not 
involve walking or running (i.e. biking, 
swimming, and weight lifting) would not be 
counted.   
Table 3 Continued 
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Body Media 
SenseWear Armband 
This physical activity monitor is 
worn on the upper arm and uses 
body temperature, heat flux, 
galvanic skin response, and a 
tri-axial accelerometer to 
calculate energy expenditure 
and track physical activity and 
sleep [209]. 
This activity monitor has been 
validated to provide estimates of 
energy expenditure in  older 
adults [210].   
There have been some reports of minor 
discomfort while wearing the device  [211].  
Those with low shoulder mobility may have 
difficulty putting the monitor on and taking it 
off.    
Doubly Labeled 
Water 
This method involves the 
ingestion of a measured amount 
of water labeled with isotopes 
of oxygen and hydrogen that 
can be traced as they break 
down and leave the body, and 
this rate is used to calculate 
energy expenditure using 
calorimetric equations [212].  
This method is considered to be 
the gold standard for assessing 
free-living energy expenditure.  
Energy expenditure can be 
assessed over periods of several 
days or several weeks, and this 
method has relatively low 
participant burden.   
Although this method gives information about 
energy expenditure, the types of activities a 
participant engages in cannot be assessed.  
Also, the required isotopes and equipment 
needed for doubly labeled water analysis is 
cost prohibitive for large epidemiologic 
studies.   
Table 3 Continued 
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1.5.3.1 Sensorimotor Peripheral Nerve Function Impairments and Exercise Prescription 
On a national scale, brisk walking is encouraged as a primary mode of aerobic exercise.   
Although walking is important for the maintenance of independence, situations exist where 
walking is not the most appropriate mode of exercise.   For example, many symptoms that 
develop in the lower extremities during peripheral nerve function decline, including numbness in 
the feet can make weight bearing exercises like walking—difficult and painful.  In the ACSM 
and American Diabetes Association (ADA) joint position statement on exercise and type 2 
diabetes, this difficulty has been acknowledged, and non-weight bearing activities (e.g. 
swimming or biking) are recommended for those who have symptoms in the feet and lower 
extremities.  If a walking exercise program is deemed appropriate for a patient, foot care is 
highlighted as a vital component of the program in order to prevent open sores or ulcers [162].  
Translating this recommendation to older adults without diabetes but with peripheral nerve 
function impairments is important since these symptoms can occur in the absence of diabetes.   
1.5.3.2 Cardiac Autonomic Function Impairments and Exercise Prescription 
Cardiovascular autonomic neuropathy and nerve function decline brings its own set of 
challenges when prescribing exercise for older adults.  Pre-participation screening by a physician 
is an important step before beginning an exercise program for individuals with cardiovascular 
risk factors, metabolic disease, or for older adults aiming to exercise at a high intensity [148].  
Due to the risk of adverse cardiac events with CAN, a physician should evaluate those with CAN 
before beginning an exercise program.  Screening should be performed in order to detect 
cardiovascular abnormalities [162]. 
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  Because those with autonomic neuropathy often have resting tachycardia but reduced 
maximal heart rate, the estimated maximal heart rate calculation of 220 minus age may not be 
suitable for assessing exercise intensity [213].  Alternatively, having participants indicate their 
rating of perceived exertion (RPE) is appropriate, providing that the scale has been fully 
explained.  Because cardiac autonomic nerve function impairments are associated with low 
exercise tolerance, physical activity programs should start with short bouts, with gradual 
increases in duration and intensity.   It may take a considerable amount of time before a 
participant with low exercise tolerance can work up to achieving the recommended dose of 
physical activity consistent with national guidelines.   
1.6 SPECIFIC AIMS 
 Sensorimotor Peripheral Nerve Function and Physical Activity 1.6.1
A major gap in knowledge exists for the descriptive relationship between physical 
activity and peripheral nerve function in older adults.  The work by Loprinzi [158] and 
colleagues examining objectively measured physical activity and peripheral neuropathy in 
diabetic participants from NHANES disregarded the importance of light activities and only 
focused on MVPA, though it is known that levels of MVPA may be low in the general 
population, particularly in the general population of older adults.  This study also only focused 
on those with diabetes, and peripheral nerve function was not measured, rather peripheral 
neuropathy was used as the outcome.  In MrOS, peripheral nerve function measures were 
collected at Visit 3, along with objectively measured physical activity.  Although this study only 
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includes older men, the large sample size, variety of sensorimotor peripheral nerve function 
measures, and objectively measured physical activity data make this study an excellent 
opportunity for determining the descriptive relationship between physical activity and peripheral 
nerve function. 
Specific Aim 1: To determine whether better peripheral nerve function is associated with 
higher levels of physical activity participation and fewer minutes of sedentary time in older men. 
Hypothesis: Men with better sensorimotor peripheral nerve function will participate in 
more minutes of physical activity (light, moderate, and vigorous activity) and fewer minutes of 
sedentary behaviors per day compared to older men with worse sensorimotor peripheral nerve 
function. 
 Sensorimotor Peripheral Nerve Function and Endurance Walking Performance 1.6.2
Second, we do not know how sensorimotor peripheral nerve function impacts endurance 
walking.  In the Health, Aging, and Body Composition (Health ABC) study sensorimotor 
peripheral nerve function measures were collected the 2000/01 clinic visit.  Additionally, the 
long distance corridor walk (LDCW)—a validated measure of walking endurance in older adults 
[214] was administered at the 2000/01 clinic visit, and every other year thereafter through the 
10th year of the study (2006/07 clinic visit).  Currently the relationship between walking 
endurance and sensorimotor peripheral nerve function has not been explored in a longitudinal 
matter, making this a novel analysis.  
Specific Aim 2:  To determine whether worse sensorimotor peripheral nerve function 
associated with worse performance over time on an endurance walking test, the long distance 
corridor walk (LDCW). 
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Hypothesis:  Participants with worse sensorimotor peripheral nerve function will be more 
likely to be ineligible or unable to complete the LDCW, will have slower initial completion 
times, and experience greater slowing over time compared to those with better sensorimotor 
peripheral nerve function. 
 Sensorimotor Peripheral Nerve Function and Indicators of Cardiac Autonomic 1.6.3
Function 
Finally, sensorimotor peripheral nerve function and cardiovascular autonomic function 
are often studied separately, though function in both divisions is worse in older age.  
Cardiovascular autonomic function can be assessed using heart rate and blood pressure measures 
from fitness tests, like the Long Distance Corridor Walk in Health ABC. Because of the common 
risk factors associated with sensorimotor and autonomic peripheral nerve impairments 
(particularly cardiovascular risk factors), it is plausible that those with worse sensorimotor 
peripheral nerve function also have worse cardiac autonomic peripheral nerve function. Using 
sensorimotor peripheral nerve function measures and information on heart rate measured during 
the LDCW from Health ABC 2000/01 clinic visit (resting heart rate, heart rate response to the 
LDCW, and heart rate recovery after the LDCW), we can assess the associations between these 
two divisions. 
Specific Aim 3:  To determine whether sensorimotor peripheral nerve function is 
associated with cardiac autonomic function in older adults.   
Hypothesis: Older adults with better sensorimotor peripheral nerve function will also 
have better cardiac autonomic function. 
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2.0  SENSORIMOTOR PERIPHERAL NERVE FUNCTION AND PHYSICAL 
ACTIVITY IN OLDER MEN 
ABSTRACT 
Sensorimotor peripheral nerve (PN) impairments are common in older adults and 
negatively impact mobility.  The purpose of this study was to determine whether worse PN 
function is associated with lower levels of PA in older men.  In 2007-09, participants at the 
Pittsburgh, PA, site of the Osteoporotic Fractures in Men Study (age 78.9 ± 4.7 years) underwent 
nerve conduction testing of the peroneal motor and sural sensory nerves to assess amplitude, 
latency, and f-wave latency.  Sensory PN function was also assessed using 1.4g and 10g 
monofilaments.  Symptoms of peripheral neuropathy were collected via self-report.  Self-report 
PA was assessed using the Physical Activity Scale for the Elderly (PASE).     PA was assessed 
objectively using a multisensor armband to determine minutes per day spent in sedentary (<1.6 
METS, excluding sleep), light (1.6 to <3.0 METS), moderate (3.0 to <6.0 METS) and vigorous 
(6.0+ METS) activity.  Continuous measures of PN function were split into worse function 
(lowest tertile) and better function (highest two tertiles) to approximate clinical thresholds of PN 
function.   We compared adjusted mean PASE scores between PN function groups using 
ANOVA.   Multivariate linear regression modeled the association between PN function and 
minutes per day of each level of activity.   
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Participants (n=341) spent a median of 832.4, 63.8, 69.2, and 8.80 minutes per day in 
sedentary, light, moderate, and vigorous activities, respectively.  Higher mean PASE scores 
(adjusted for age, BMI, self-reported health, diabetes, peripheral arterial disease, and arterial 
stiffening) were found for those with better distal motor compared to those with worse distal 
motor latency (PASE score 160.6 vs 138.3, p<0.01). Participants reporting any neuropathic 
symptoms had lower mean PASE scores compared to those with no symptoms (131.9 vs. 155.8, 
p<0.05).  In unadjusted models,  men with better motor amplitude participated in 17.9%, 19.4 
and 41.5% more minutes of light, moderate and vigorous activity per day, and 3.9% fewer 
minutes in sedentary time compared to those with  worse motor amplitude (p<0.05 for all).  
Participants with better sensory amplitude participated in 19.6%, 24.1, and 41.4% more minutes 
of light, moderate, and vigorous activity compared to those with worse sensory amplitude, 
though sedentary time did not differ.  Adjusting for age, BMI, self-reported health, diabetes, 
peripheral arterial disease, and arterial stiffening attenuated many relationships with light, 
moderate, and sedentary time to non-significance, though those with better amplitude 
participated in more vigorous activity then men with worse amplitude.  No relationships were 
found with other nerve function measures.  Worse sensory and motor PN function is associated 
with less PA in older men, indicating a potential pathway for disability that warrants further 
investigation.     
2.1 INTRODUCTION 
Sensorimotor peripheral nerve (PN) dysfunction negatively impacts mobility in older 
adults—a cornerstone for maintaining independence.  Worse sensorimotor PN function in older 
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adults is associated with poorer lower extremity function [31-34,66], strength [36,215], and 
power [37], as well as an increased risk for falls [38-41] and mobility disability [216]. Deficits in 
sensorimotor nerve function may result in pain or loss of sensation in the extremities, which 
could greatly influence the ability to be physically active.   
Currently, few studies have examined the association between clinical peripheral 
neuropathy and physical activity (PA), and existing studies have focused on adults with diabetes 
[157,158] rather than community-dwelling older adults. Though diabetes is a common 
contributor to PN impairments, PN dysfunction occurs with aging even in the absence of 
diabetes [29].  Worse PN function is associated with worse lower extremity outcomes in older 
adults even without diagnosed clinical peripheral neuropathy [31], highlighting the importance of 
examining a full range of PN function.   
A major gap in the literature exists regarding the descriptive relationship between PN 
function and PA in older adults.  Examining objectively measured physical activity across a wide 
range of intensities (including light activity) may be beneficial for clarifying the relationship 
between PN function and PA in older adults—particularly since older adults spend very little 
time in moderate or vigorous PA [25,159].  Despite the potential for lower extremity function to 
influence the ability to be physically active, the relationship between PN function and PA 
participation has not been explored in community dwelling older adults.  Whether worse PN 
function is related to lower levels of PA is unclear, though PA could potentially be in the 
pathway from PN impairments to mobility disability.  The aim of this study was to determine 
whether better PN function is associated with higher levels of participation in PA in older men. 
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2.2 METHODS 
 Participants 2.2.1
Participants at the Monongahela Valley, PA (near Pittsburgh, PA), site of the 
Osteoporotic Fractures in Men Study (MrOS) underwent peripheral nerve function assessments 
at the 2007/09 clinic visit.   Briefly, MrOS is a multicenter longitudinal cohort study of healthy 
aging focusing on the risk factors for fractures in older men (n=5,994; mean age 73.7 ± 5.9 years 
at baseline) [217].   Ambulatory men age 65 and older were recruited and completed the baseline 
visit between March 2000 and April 2002 from six U.S. clinical sites [218].  Eligibility criteria 
for the main study at the baseline visit included the ability to walk without assistance from 
another person or walking aid, ability to provide self-reported data, capacity to understand and 
provide informed consent, absence of bilateral hip replacement, absence of any severe disease or 
condition that would results in imminent death, and anticipated residence near a clinical site for 
the duration of the study period. In total, 426 men had PN function and PASE questionnaire data 
the 2007/09 clinic visit, and objective physical activity data was available for 341 participants 
(Figure 2).   The study protocol was approved by the University of Pittsburgh Institutional 
Review Board, and all participants provided written informed consent before testing.   
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 Figure 2:  Participant Flow Diagram from the MrOS Pittsburgh Site 
 Peripheral Nerve Function Examination 2.2.2
Nerve conduction testing was performed bilaterally on the deep peroneal motor nerve and 
the sural sensory nerve using an automated nerve conduction study device (NC-stat)—a valid 
and reliable method for assessing nerve function in older adults [92].  Before testing, 
participants’ feet were warmed to 30°C if they were <30°C.   Peroneal motor nerve parameters 
included: motor amplitude of the compound muscle action potential in millivolts (CMAP); distal 
motor latency in milliseconds; and mean F-wave latency in milliseconds.  Sural sensory nerve 
measures included sural nerve action potential (SNAP) and sensory amplitude in microvolts and 
distal sensory latency in milliseconds.  Continuous measures of nerve function were split into 
poor function (lowest tertile) and higher function (middle and highest tertiles) to approximate 
clinically relevant cut points indicating poor nerve function.    
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Sensory PN function was also assessed through monofilament testing using light (1.4-g) 
and standard (10-g) monofilament touches at the dorsum of the left great toe.  Light and standard 
monofilament sensitivity were defined as feeling at least 3 out of 4 touches, while insensitivity 
was defined as the inability to detect three touches.  The standard monofilament was only used if 
the participant had light monofilament insensitivity.  Sensory testing was performed on the non-
dominant side while motor testing was performed on both sides except in the case of technical 
difficulty.   
Symptoms of peripheral neuropathy within the past 12 months were assessed via self-
report from a modified Michigan Neuropathic Screening Instrument [108] and included (1) 
numbness or tingling, (2) sudden stabbing, burning, or aches, or (3) an open persistent sore or 
gangrene on either foot or leg in the past 12 months. 
  Physical Activity Assessment 2.2.3
Self-report physical activity was assessed using the Physical Activity Scale for the 
Elderly (PASE) [200].  Briefly, the PASE includes questions about the intensity, frequency, and 
duration of various physical activities over the past seven days.  Activities include walking, 
strenuous (ex. jogging, swimming, singles tennis), moderate (ex. golf without a cart, doubles 
tennis) and light activities (ex. golf with a cart, shuffleboard), muscle strengthening exercises, 
lawn work and gardening, occupational activities that include walking or standing, caring for 
another person, home repairs, and housework.  The frequency and duration of participation in the 
various categories are multiplied by activity weights based on intensity and summed in order to 
give a total PASE score.  The PASE score is a unitless, relative measure, with higher scores 
indicating higher levels of physical activity.  The PASE has been previously validated against 
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energy expenditure measured via doubly labeled water [188,201] and objectively measured PA 
[219,220], and PASE score has been correlated with physiologic and performance characteristics 
in older adults [221].  The PASE has high test-retest reliability [200,222] and longitudinal 
changes in PA over approximately five years have been previously described in the MrOS study 
population [223]. 
Objective physical activity was measured using the SenseWear Armband (SWA; Body 
Media, Inc., Pittsburgh, PA).  Participants were instructed to wear the monitor at all times for 7-
days, removing the monitor only for brief periods for bathing or water activities.  The SWA 
includes heat flux, galvanic skin response, skin temperature, and near body temperature sensors, 
as well as a two-axis accelerometer.  Data were sampled in 1-minute epochs and used to estimate 
energy expenditure in kilocalories per day [224].  Data collected by the sensors along with age, 
height, weight, handedness, and smoking status were used in propriety algorithms (Innerview 
Professional 5.1 software) to estimate energy expenditure, metabolic equivalents (METS), and 
sleep time.  Energy expenditure measured by SWA has been validated using doubly labeled 
water in older adults [210]. Average minutes per day spent in each level of PA were calculated 
using MET cut-points, with categories being defined as follows:  light/lifestyle activity = 1.6 to 
<3.0 METS, moderate activity 3.0-<6.0 METS, vigorous activity 6.0+ METS, and sedentary 
time < 1.6 METS (excluding sleep time).  Total time spent in each of these categories during the 
wearing period was averaged over all days in order to limit variability and reflect usual activity 
patterns.  As described previously by Cawthon and colleagues [225], if a participant wore the 
monitor < 90% of the time during any 24-hour period, that period was not used in calculating 
energy expenditure.  Only participants with at least five 24-hour periods were included in 
analyses.      
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 Covariates 2.2.4
We considered several factors potentially related to PA or PN function as covariates.  
Height and weight were measured using a stadiometer and calibrated balance beam scale, 
respectively, and were used to calculate body mass index (BMI).   Lean and fat mass were 
measured using dual-energy x-ray absorptiometry (Hologic 4500A).  Diabetes was defined by 
fasting glucose measure of ≥126mg/dL [226] at the baseline MrOS clinic visit or self-reported 
physician diagnosis at the 2007/09 clinic visit.  Peripheral arterial disease was defined as ankle-
brachial index (ABI) of <0.9, while arterial stiffening was defined as an ABI of >1.3 [227].  The 
Teng Modified Mini-Mental State Exam (3MSE) was used to assess cognition [228] and the 
Geriatric Depression Scale (GDS) measured depressive symptoms [229].  History of cigarette 
smoking (never, current, former), current alcohol consumption (drinks/week), and health status 
(excellent, good, fair, poor, very poor) were assessed though self-report. Chronic health 
conditions included self-report hypertension, congestive heart failure, cerebrovascular disease, 
and cardiovascular disease.  
 Statistical Analyses 2.2.5
Descriptive statistics were expressed using mean ± standard deviation for continuous 
variables or median and interquartile range where appropriate, and frequencies for categorical 
variables.  Participants were grouped based upon tertile of daily average METS from the 
SenseWear Armband, and tests of trend were used to assess differences in participant 
characteristics between the three ordered groups.  PN function measures and minutes spent in the 
four levels of activity were also compared between MET groups.  ANOVA models compared the 
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adjusted mean PASE score between PN function groups.  Because many measures of PN 
function were correlated (correlation coefficients ranging from 0.17 for sensory amplitude and 
latency and 0.34 between motor and sensory amplitude, p<0.05 each), each measure of PN 
function was modeled separately.  Multivariate linear regression was used to model the 
association between PN function and objectively measured PA, which allowed an examination of 
the effect of PN function on participation in each level of activity (sedentary, light, moderate, 
and vigorous) in one model.  This method makes use of the correlations between the components 
of the multi-dimensional outcome to better identify differences between the groups.  Minutes 
spent in each level of activity were right skewed to no activity, thus natural logged versions of 
these variables were used for analysis.  Results were back transformed in order to report minutes 
spent in each level of activity.   
All models (ANOVA models for PASE; multivariate regression models for SWA 
outcomes) were built progressively, with covariates with p<0.10 being considered for a 
multivariable model, though diabetes was forced into the final model regardless of significance.  
Factors that could influence PA or PN function were considered as covariates until a final, 
parsimonious model with only factors reaching p<0.05 was determined for each PN function 
predictor and PA level outcome.   All data analyses were performed using STATA version 12.1 
(StataCorp, College Station, TX). 
2.3 RESULTS 
Participants (n= 341, age 78.7 ± 4.7 years, BMI 28.1 ± 4.0 kg/m2) in this cohort of older 
men spent a median of 832.4, 63.8, 69.2, and 8.80 minutes per day in sedentary, light, moderate, 
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and vigorous activities, respectively. Those with lower mean daily MET levels were older, 
consumed fewer drinks per week, had higher BMI, higher fat and lean mass, were more likely to 
have diabetes, and reported more depressive symptoms compared to those in the higher mean 
daily MET tertile (Table 4; p<0.05 for trend for all).  Differences across other chronic conditions 
and diseases were not significant.  Participants with lower daily average MET levels had lower 
motor amplitude, were more likely to have 1.4 or 10-g monofilament insensitivity, and had a 
higher burden of neuropathic symptoms—particularly numbness (Table 4).  As expected, those 
with lower daily MET levels had lower scores on the PASE, spent fewer minutes per day in 
light, moderate, and vigorous activities, and spent more minutes per day being sedentary 
compared to those with higher daily MET levels (Table 5; p<0.001 for all).     
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Table 4:  Participant Characteristics by Tertile of Average Daily METS 
 Tertile 1 (n=114 ) 
Average Daily METS:  
0.79 – 1.11 
Tertile 2 (n= 114) 
Average Daily METS:  
1.11 -- 1.29  
Tertile 3 (n= 113) 
Average Daily METS:  
1.30 – 2.11 
P for Trend 
Age, Mean ± SD  80.0 ± 5.2 78.6 ± 4.6 77.6 ± 4.1 <0.001 
Health Habits 
     Drinks per week 2.4 ± 1.2 2.5 ± 1.2 2.9 ± 1.2   0.013 
     Current Smoker, N (%) 4 (3.5) 3 (2.6) 2 (1.8)   0.963 
     Former Smoker 64 (56.1) 73 (64.0) 67 (59.3) 
Body Composition 
     Height, cm 171.8 ± 6.1 173.1 ± 6.1 171.9 ± 6.4   0.754 
     BMI, kg/m2 30.3 ± 4.0 27.9 ± 3.3 26.1 ± 3.4 <0.001 
     Fat Mass, kg 27.5 ± 7.0 22.7 ± 5.8 19.0 ± 6.1 <0.001 
     Lean Mass, kg 58.3 ± 7.5 57.0 ± 6.5 54.5 ± 7.0 <0.001 
Chronic Health Conditions 
     Diabetes, N (%) 35 (33.3) 20 (18.9) 17 (16.2)   0.003 
     Hypertension 72 (63.2) 59 (51.8) 60 (53.1)    0.127 
     Heart Attack 22 (19.3) 9 (7.9) 13 (11.5)   0.079 
     Stroke 7 (6.1) 3 (2.6) 7 (6.2)   0.988 
     Congestive Heart Failure 8 (7.0) 3 (2.6) 3 (2.7)   0.098 
     Peripheral Arterial Disease 14 (13.6) 13 (12.0) 8 (7.6)   0.210 
     Arterial Stiffening 18 17.5) 26 (24.1) 31 (29.3) 
Cognition and Mental Health 
        3MSE Score 92.8±5.3 94.3 ± 4.7 92.6 ± 6.3   0.554 
GDS Score 2.0 ± 2.0 1.5 ± 1.6 1.5 ± 1.6   0.034 
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 Table 5:  Peripheral Nerve Function and Physical Activity by Tertile of Average Daily METS 
 
 
 
 Tertile 1 (n=114 ) 
Average Daily METS:  
0.79 – 1.11 
Tertile 2 (n= 114) 
Average Daily METS:  
1.11 -- 1.29  
Tertile 3 (n= 113) 
Average Daily METS:  
1.30 – 2.11 
P for 
Trend 
Motor Nerve Function 
Motor Amplitude (CMAP), mV 1.9 ± 1.4 2.2 ± 1.6 2.6 ± 1.6 <0.001 
Distal Motor Latency, ms 4.6 ± 0.9 4.6 ± 0.7 4.5 ± 0.8   0.757 
Mean F-Wave Latency, ms 61.2 ± 4.5 61.6 ± 5.5 61.0 ± 5.5   0.924 
Sensory Nerve Function 
Sensory Amplitude (SNAP), mV 2.2± 2.6 3.4 ± 3.0  4.0 ± 3.1 <0.001 
Distal Sensory Latency, ms 3.2 ± 0.2 3.2 ± 0.2 3.2± 0.3   0.311 
1.4-g Monofilament Insensitivity 25 (26.6) 31 (35.6) 17 (18.5)   0.012 
10-g Monofilament Insensitivity 21 (22.3) 5 (5.8) 12 (13.0) 
Neuropathic Symptoms 
Numbness 36 (38.7) 25 (28.7) 19 (20.7)   0.007 
Stabbing Pain 15 (16.0) 11 (12.6) 11 (12.0)   0.425 
Open Sore 1 (1.1) 2 (2.3) 0 (0.0)   0.492 
Any symptoms 43 (45.7) 30 (34.5) 25 (27.2)   0.008 
One Symptom 33 (35.5) 23 (26.4) 20 (21.7)   0.012 
Two Symptoms 9 (9.7) 6 (6.9) 5 (5.4) 
Three Symptoms 0 (0.00) 1 (1.2) 0 (0.0) 
PASE Score 118.6 ± 65.8 152.9± 57.3 172.6 ± 70.5 <0.001 
Daily Minutes of Activity from SenseWear Armband, Median (Interquartile Range) 
Sedentary, <1.6 METS 894.8 (830.4-953.8) 846.4 (806.0-908.4) 742.4 (693.7-808.0) <0.001 
Light, 1.6 to <3.0 METS  38.5 (28.4-54.4) 63.7 (50.0-81.8) 89.4 (74.6-111.4) <0.001 
Moderate, 3.0-<6.0 METS 37.5 (21.8-52.8) 71.1 (51.0-88.8) 134.0 (102.0-163.8) <0.001 
Vigorous, ≥6.0 METS 4.7 (2.0-8.5) 8.6 (5.6-13.0) 17.8 (10.0-28.2) <0.001 
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Figure 3 displays the differences in adjusted mean PASE score (adjusting for age, BMI, 
self-reported health, diabetes, peripheral arterial disease, and arterial stiffening) by PN function.  
Those with better distal motor latency had significantly higher total PASE scores compared to 
those with worse distal motor latency (160.6 ± 9.7 vs 138.3 ± 13.5, p=0.009).  Those without 
symptoms of peripheral neuropathy had higher PASE scores compared to those reporting one or 
two or more symptoms (155.8 ± 10.3 vs 131.9 ± 13.3, p=0.007).  Specifically, those without 
numbness had higher PASE scores compared to those with numbness (153.5 ± 10.4 vs 132.4 ± 
15.1, p=0.025). Motor amplitude, f-wave latency, sensory amplitude, distal sensory latency, 
monofilament detection, stabbing pain, and presence of open sores were not associated with 
PASE score.  
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 Means adjusted for age, BMI, self-reported health, diabetes, peripheral arterial disease, arterial and stiffening.  
 
Continuous measures of nerve function were split into tertiles and those with worse function (lowest tertile of amplitude, highest 
tertile of latency) were compared to those with better function (combined highest and middle tertile of amplitude, combined lowest 
and middle tertile of latency). 
 
*P<0.05 for difference between groups. 
 
Figure 3: Adjusted Means of Total Physical Activity Scale for the Elderly (PASE) Score by Peripheral Nerve Function 
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In unadjusted multivariate regression models examining minutes spent in objectively 
measured activity, men with better CMAP participated in 17.9%, 19.4 and 41.5% more minutes 
of light, moderate and vigorous activity per day, and 3.9% fewer minutes in sedentary time (data 
not shown) compared to those with  worse CMAP (p<0.05 for all).  Participants with better 
sensory amplitude participated in 19.6%, 24.1, and 41.4% more minutes of light, moderate, and 
vigorous activity compared to those with worse sensory amplitude, though sedentary time did not 
differ.  Adjusting for age, BMI, self-reported health, diabetes, peripheral arterial disease, and 
arterial stiffening attenuated the relationships with light, moderate, and sedentary time to non-
significance.  Those with better motor amplitude participated in 27.2% more minutes of vigorous 
activity compared to those with worse motor amplitude (p=0.015), while those with better 
sensory amplitude participated in 24.2% more vigorous activity compared to those with worse 
sensory amplitude (p=0.046) (Figure 4).  Distal motor latency, f-wave latency, distal sensory 
latency, monofilament detection, and symptoms of peripheral neuropathy were not associated 
with objectively assessed physical activity. 
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 Means adjusted for age, BMI, self-reported health, diabetes, peripheral arterial disease, and arterial stiffening.  Activity Definitions; 
Light: 1.6 to <3.0 METS; Moderate: 3.0 to < 6.0 METS; Vigorous: ≥6 METS.  *p<0.05 for difference between worse and better 
function groups.  
Figure 4:  Mean Minutes Spent in Light, Moderate, and Vigorous Activity per Day by Motor and Sensory Amplitude 
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2.4 DISCUSSION 
In this cohort of community dwelling older men, better PN function was associated with 
higher levels of PA.  However, not all nerve function measures were associated with PA.  We 
observed relationships of PN function with PA both using both objective and self-report 
measures of PA.  Sensory and motor amplitude were associated with objective PA, while distal 
motor latency and presence of neuropathic symptoms were associated with self-report PA.  We 
are uncertain as to why these relationships varied, though were consistent in indicating motor 
nerve function relationships with PA.    Importantly, motor nerve function is rarely measured in 
studies of PA and older adults, though future studies should consider doing so.  This study adds 
to the growing body of literature that PN function should be evaluated as a factor in the 
disablement pathway for older adults. 
Presently, very little work has been done in investigating the relationship between PN 
function and PA, and this work has focused on diabetic populations rather than older adults. In 
diabetic participants in the in 2003-2004 cycle of for the National Health and Nutrition 
Examination Survey (NHANES), no direct association was found between minutes per day of 
moderate to vigorous PA and peripheral neuropathy.  However, though those with better diabetic 
control (as measured by HbA1c) and higher PA were less likely to have peripheral neuropathy 
compared to what would be expected from the individual effects of PA and diabetes control 
[158].  On average, this population participated in very few minutes of objectively measured PA 
(measured using hip-worn accelerometers) per day (mean = 11.7 minutes, 95% CI = 9.1-14.4 
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minutes), which may have limited the ability to examine the relationship between PA and 
peripheral neuropathy in this population.  
 Peripheral neuropathy has been acknowledged in the diabetes literature as potentially 
making PA difficult.   Due to the relationship between worse sensory PN function and worse 
lower extremity outcomes [31-34,36-41,66,215,216],  these considerations may be relevant for 
older adults with PN impairments.  The American College of Sports Medicine and American 
Diabetes Association recommended in a joint position statement that those with peripheral 
neuropathy can safely participate in weight-bearing exercises as long as they do not have any 
open sores [162].  Additionally, it was recommended that foot care (examining for potential 
sores, selecting appropriate footwear) be an important component of any PA program for those 
with diabetic peripheral neuropathy.  However, these recommendations have not been tested for 
older adults, and clearly more work is needed in this area.   
In our study, motor and sensory amplitude were associated with objective PA, though 
other measures of nerve function were not.  Nerve conduction testing may be a more sensitive 
measure to pick up earlier or subclinical impairments compared to monofilament testing or 
symptoms.   Interestingly, we observed relationships with objective PA and both sensory and 
motor amplitudes but not latencies.  This is consistent with prior work in this cohort by Ward and 
colleagues who examined the association between PN function and lower extremity muscle 
power [230].  Amplitude and latency are indicators of different types of PN damage, with worse 
amplitude being indicative of axonal degeneration, while latency, a component of conduction 
velocity, is a sign of demyelination [231]. These aspects of PN function do not necessarily 
decline simultaneously, and the protective myelin sheath may remain intact for remaining motor 
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units [232].  The effect of reduced axonal degeneration may have a greater impact on PA than 
latency, though this should be examined further.   
In the InCHIANTI study—a population based cohort study of older adults in Italy—
higher CMAP measured at the peroneal motor nerve was found to be associated with higher calf-
muscle density in older adults [232].  PN impairments, particularly axonal degeneration along 
with the associated worse muscle quality and function could make activity more difficult, and 
PA is also known to influence body composition and muscle function.  Determining the timing 
of these neuromuscular changes with PA patterns is worthy of future study in order to develop 
interventions to reduce the burden of lower extremity outcomes.   
A major strength of this study is the inclusion of comprehensive PN function measures, 
which allowed us to examine a range of PN function and also examine potential specific 
pathways of PN function.  Also, assessing objective PA in addition to self-report PA allowed us 
to better characterize the activity patterns of these older men than through using a self-report 
measure alone.  This was particularly helpful for assessing participation in light intensity 
activities and sedentary time.  The majority of energy expenditure for older adults comes from 
sedentary and light activities [25,159], which makes it especially important to measure the lower 
end of intensity in order to capture the full extent of activity in this population.  Light activity 
and sedentary time are difficult to recall, and PA questionnaires may not be adequate for 
assessing these intensities [233].  
Limitations to this work should be considered.  Although the use of an automated 
neurodiagnostic instrument allowed nerve conduction testing to be done in a non-invasive, 
efficient manner, clinical cut-points established using traditional methods cannot be applied to 
measurements from automated instruments.  Instead, we approximated clinical thresholds by 
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comparing those in the worst tertile to those in the middle and best tertiles.   Future work is also 
needed in order to determine whether these results are applicable to other populations, including 
those with disabilities, women and non-white older adults.    
In our analyses examining objective activity, we used MET cut-points to define intensity 
levels of physical activity.  Though these categories allowed us to examine a range of activity 
intensities, cut-points can have limitations when applied to populations of older adults.  Physical 
activity guidelines include recommendations for specific intensity levels, but relative intensity is 
important for prescribing physical activity for older adults [26].  Because many studies originally 
validating cut-points from accelerometer output were conducted in younger, healthy populations, 
alternate activity count cut-points and novel analysis methods have been suggested for assessing 
physical activity for older adults using accelerometers [191,234-236].   Many of these 
suggestions were made for traditional accelerometers, not necessarily for multi-sensor devices 
which process data using proprietary algorithms.   
We considered the cross-sectional relationship between PN function and PA, though a 
bidirectional relationship between PN function and PA is possible. PN impairments—
particularly sensory impairments—may make activity more difficult, while PA may be beneficial 
for improving PN function.  Small studies of participants with diabetes have indicated that 
exercise training may help reduce symptoms in those with peripheral neuropathy [237], a long-
term exercise intervention (4 years) can help reduce the incidence of peripheral neuropathy 
[161], and short term interventions may produce beneficial changes in gait performance in those 
with diabetic peripheral neuropathy.  Improving functional outcomes via PA is important for 
helping those with PN impairments to maintain independence.   
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In conclusion, some measures of better PN function were associated with more PA per 
day in older men.  Lower levels of physical activity may potentially be in the pathway between 
worse PN function and lower extremity disability.  This potential pathway warrants further 
investigation in diverse populations of older men and women, and also in longitudinal work.   
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3.0  SENSORIMOTOR PERIPHERAL NERVE FUNCTION AND THE 
LONGITUDINAL RELATIONSHIP WITH ENDURANCE WALKING IN THE 
HEALTH, AGING AND BODY COMPOSITION STUDY 
ABSTRACT 
Sensorimotor peripheral nerve deficits affect gait and may reduce walking endurance in 
older adults.  The purpose of this study was to determine whether lower extremity sensorimotor 
peripheral nerve deficits are associated with reduced walking endurance in older adults.  
Community dwelling older adults enrolled in Health, Aging and Body Composition study who 
participated in the 2000/01 annual clinical examination (n=2393; age 76.5 ± 2.9 years; 48.2% 
male; 38.2% black) and subset with longitudinal data (n=1,178) underwent sensorimotor 
peripheral nerve function testing.  Nerve conduction amplitude and velocity were measured at 
the peroneal motor nerve.  Sensory nerve function was measured using vibration detection 
threshold and monofilament testing at the big toe.  Symptoms of lower-extremity peripheral 
neuropathy included numbness or tingling and sudden stabbing, burning, pain, or aches in the 
feet or legs.   The long distance corridor walk (LDCW) was administered in 2000/01 and every 
two years afterwards for 6 years to assess endurance walking performance over time.  In separate 
fully adjusted linear mixed models poor vibration threshold (>130 microns) 10g and 1.4g 
monofilament insensitivity were each associated with slower LDCW completion time (16.0, 
14.1, and 6.7, seconds slower, respectively, p<0.05 for each).  Poor motor amplitude (<1mV), 
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poor vibration perception threshold, and 10-g monofilament insensitivity were related to a 
greater slowing/year (4.7, 4.3, and 4.3 additional seconds/year, respectively, p<0.05), though 
poor motor amplitude was not associated with initial completion time.  Poorer sensorimotor 
peripheral nerve function is related to slower endurance walking and greater rate of slowing over 
time.  Interventions for those with poor sensorimotor peripheral nerve functioning should be 
considered in order for adults to maintain walking endurance.    
3.1 INTRODUCTION 
Sensorimotor  peripheral nerve function deficits are common in older adults; with 
estimates from the National Health and Nutrition Examination Survey (NHANES) indicating 
that 28.5% of older adults aged 70-79 and 34.8% of those 80+ have reduced touch sensation on 
the foot as measured by a simple screening tool [30].    In the Health, Aging and Body 
Composition (Health ABC) study, recent work has shown that 55% of older adults (N=1,680; 
age 76.5 ± 2.9 years) without mobility disability at the 2000/01 examination had evidence of 
lower extremity peripheral nerve impairments [216].  Poor peripheral nerve function in older 
adults is associated with worse lower extremity function [31-34], quadriceps and ankle 
dorsiflexion strength [36,215] quadriceps muscle power [37], as well as an increased risk for 
falls [38-41] and lower extremity limitation [216].  Worse lower extremity sensation and motor 
control resulting from sensorimotor peripheral nerve dysfunction can lead to altered gait 
mechanics and the adoption of inefficient and less stable gait patterns [115-120].   In addition, 
symptoms related to peripheral nerve function impairments—including pain or numbness in the 
lower extremities—may make weight bearing activities, such as walking, difficult.     
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Although poorer sensorimotor peripheral nerve function is associated with slower usual 
gait speed on short walking courses  
[31,34,66], the impact of peripheral nerve function on endurance walking in community 
dwelling older adults is limited in current literature.  Walking endurance—the ability to walk 
quickly for a sustained time or distance—is important for maintaining independence and 
remaining active in the community.  Though aerobic fitness plays a major role in walking 
endurance, other disease-related factors—such as peripheral nerve function—may influence 
walking endurance and the maintenance of walking endurance over time, particularly given the 
associations with lower extremity function.   
Poor peripheral nerve function in older adults occurs even in the absence of diabetes [29], 
though diabetes is a major contributor.  However, work has been limited in exploring the 
association of peripheral nerve dysfunction and walking endurance in either population.  
Evidence exists that walking endurance is worse in diabetic adults compared to non-diabetic 
healthy adults [125],  Peripheral nerve function may contribute to these differences, though it 
was not measured in previous studies.  Walking endurance is worse in the presence of a greater 
burden of lower extremity complications resulting from diabetic peripheral neuropathy, 
including ulcers and amputations [238], however, these are extreme examples of peripheral 
neuropathy damage.    In the InCHIANTI study, motor nerve conduction velocity was cross-
sectionally associated with slower completion of a fast-paced 400m walking test for older adults 
[66].   These studies were limited in their peripheral nerve function assessments by using only 
peripheral neuropathy diagnoses or one measure of motor nerve function.  Ideally, both motor 
and sensory nerve assessments should be included in addition to the collection of symptoms in 
order to examine the full range of peripheral nerve function from subclinical to symptomatic [82] 
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and also investigate the contribution of sensory versus motor function.   Furthermore, no 
longitudinal studies have examined if peripheral nerve function contributes to decline in 
endurance walking over time in old age.   
 The aims of this study were to 1) examine whether sensorimotor peripheral nerve 
function is related to walking endurance in older adults, and 2) determine whether sensorimotor 
peripheral nerve function is associated with the rate of change in walking endurance over six 
years of follow-up in the Health ABC study.   
3.2 METHODS 
 Participants 3.2.1
Participants were from  Health ABC, a longitudinal cohort study of community-dwelling 
older adults (n=3075; age 70-79; 48.4% male; 41.6% black at baseline) from Pittsburgh, PA and 
Memphis, TN aimed at investigating factors related to the development of functional limitation 
and disability [126].  Participants were recruited through mailings to a random sample of white 
Medicare beneficiaries and to all age-eligible black community residents.  To be eligible for the 
study, participants had to self-report no difficulty in walking ¼ mile, climbing 10 steps, or 
performing any basic activity of daily living; be free of any life-threatening cancers; and plan to 
remain in the study area for at least three years.  Participants completed the baseline visit 
between April 1997 and June 1998 and provided written informed consent.  All protocols 
associated with the Health ABC study were approved by institutional review boards at the 
University of Pittsburgh and University of Tennessee Health Science Center.   
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A total of 2,404 participants had a clinic visit in 2000/01.  Of these, 2393 had complete 
data for nerve function and long distance corridor walk measures.  Figure 1 describes the number 
of participants who completed this visit and had complete nerve function and long distance 
corridor walk measures.       
 
 
 
 
 
  
Figure 5:  Participant Flow Diagram for the Health ABC Cohort 
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 Endurance Walking Assessment 3.2.2
The  long distance corridor walk (LDCW) was administered in 2000/2001 and at follow-
up visits in 2002/03, 2004/05 and 2006/07 to assess walking endurance [214].  Exclusion criteria 
included: systolic blood pressure >200 mmHg, resting pulse of  ≥120 beats per minute, presence 
of an electrocardiogram abnormality, or cardiac surgery, worsening of chest pain or shortness of 
breath in the prior three months. The test was conducted in a dedicated corridor with two traffic 
cones spaced 20 meters apart.  Participants walked 10 laps around the cones for a total of 400 
meters.  The distance walked in the two minute warm-up was measured and completion time for 
the 400m walk was recorded in seconds.  This test included a two minute warm-up walk where 
the participant was instructed to “cover as much ground as possible” followed immediately by 
the LDCW performed “as quickly as possible at a pace that can be maintained for 400 meters” 
[239].  Heart rate was recorded for each lap and blood pressure was measured at the end of the 
test. The test was stopped if heart rate surpassed 135 beats per minute, or for lightheadedness, 
dizziness, chest pain, shortness of breath or leg pain.   
 Peripheral Nerve Function Examination 3.2.3
Lower extremity sensory and motor nerve function was assessed in 2001/2002 visit by a 
trained examiner.  Motor nerve function was measured objectively using peroneal motor nerve 
conduction amplitude in millivolts and peroneal motor nerve conduction velocity in meters per 
second, as previously described [89].  Stimulation occurred at the popliteal fossa and ankle using 
the NeuroMax 8 (XLTEK, Oakville, Ontario, Canada).  Sensory nerve function was measured 
using vibration detection threshold and monofilament testing.  Vibration detection threshold (in 
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microns) was measured at the bottom of the great toe with a VSA-3000 Vibratory Sensory 
Analyzer (Medoc, Durham, NC).  Monofilament insensitivity was defined as the inability to 
detect three out of four touches at the dorsum of the large toe with a standard 10-g monofilament 
and light touch 1.4-g monofilament (North Coast Medical, Morgan Hill, CA).  Feet were warmed 
to 30°C before all tests.  All measures were performed on the right side unless contraindicated 
due to knee replacement, amputation, trauma, ulcer, or recent surgery, in which case the left side 
was tested unless also contraindicated. 
Symptoms of peripheral neuropathy were collected via self-report in a modified 
Michigan Neuropathy Screening Instrument questionnaire [108] and included (1) numbness,  
"asleep feeling,"  prickly feeling or tingling (2) sudden stabbing, burning, or  deep aches, or (3) 
an open persistent sore or gangrene on either foot or leg in the past 12 months. 
Clinically meaningful cut points were used to define motor nerve impairment, with motor 
amplitude <1 mV and motor nerve conduction velocity <40 m/sec being used to define poor 
function [240].  For vibration threshold, >130 microns was used to define impairment.  These 
cut-points were previously established by Ward and colleagues and are related to quadriceps 
strength changes over time [215] and incident mobility limitation [216].  
 Additional Covariates 3.2.4
Clinical site, baseline age, sex, and race were included as demographic characteristics.  
Several factors potentially related to poor nerve function or walking endurance were also 
considered as covariates.  These measures were from the 2000/01 clinic visit unless otherwise 
noted.   
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Smoking history (never, former, current) was reported by questionnaire at 1999/2000. 
Health status (excellent, very good, good, fair, or poor), current alcohol use (drinks per week), 
physical activity (kilocalories expended per week in walking and stair climbing) [203]  were 
assessed via questionnaire.  Body composition (fat mass and bone-free lean mass) was measured 
using dual-energy X-ray absorptiometry (DXA; 4500A, Hologic, Inc., Bedford, MA).  Body 
mass index (BMI) was calculated in weight in kilograms per squared height in meters using a 
standard physician’s balance scale and stadiometer, respectively.   
Diabetes was defined using self-reported physician’s diagnosis, hypoglycemic 
medication use, or by fasting glucose ≥126 mg/dL (8 hour fast), and impaired fasting glucose 
was defined as fasting glucose level of 100-125 mg/dL after an 8 hour fast [226]. Arterial 
stiffening and peripheral arterial disease were assessed using ankle brachial index [227], with 
values <0.9 being used to indicate peripheral arterial disease and >1.3 for arterial stiffening.  
Hypertension was defined by self-report, medication use, or measured systolic blood pressure 
≥140mmHg or diastolic blood pressure ≥90mmHg.  Poor vitamin B12 status was defined as 
<260 pmol/L [53] and insufficient renal function was defined as Cystatin-C >1mg/dL [241]. The 
Center for Epidemiologic Studies Depression Scale (CES-D) score assessed depressive 
symptoms [242].    
Cognitive function was measured using the Digit Symbol Substitution Test [243] at 
baseline and the Modified Mini-Mental State Examination [244] in 1999/2000.  Prevalent 
coronary heart disease (bypass/coronary artery bypass graft, carotid endarterectomy, myocardial 
infarction, angina, or congestive heart failure), cerebrovascular disease (transient ischemic attack 
or stroke), lung disease (asthma, chronic obstructive pulmonary disease, or emphysema), and 
osteoarthritis in the knee or hip were assessed at baseline.   
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 Statistical Methods 3.2.5
Participants were grouped based upon initial 2000/01 eligibility and completion.  Groups 
included: being ineligible for the LDCW, starting but not completing the full 400m, completing 
the full LDCW in >7 minutes, and completing the LDCW in ≤7 minutes.  Prior work from the 
aerobic fitness validation study of the LDCW has indicated that those who require  >7 minutes 
(420 seconds) to complete the LDCW likely have significant functional limitations [214]. 
Descriptive statistics were expressed using proportions for categorical variables and mean ± 
standard deviation for continuous variables.  Tests of trend were used to assess differences in 
characteristics between the four ordered groups.  We also examined the peripheral nerve function 
measures between the four initial LDCW eligibility and completion groups.  Linear mixed-
effects models were used to assess the association between peripheral nerve function and change 
in LDCW completion time over six years of follow-up.  Mixed models were used in order to 
maximize the available data, though only participants who completed the LDCW in 2000/01 and 
at least one follow-up could be included in the models (n=1178, Figure 5).  We used two-sample 
t-tests for continuous variables and chi-square tests for categorical variables to compare those 
who were included in the model or not.   
Some peripheral nerve function measures were moderately correlated; therefore each 
peripheral nerve function measure was modeled separately.  The date of each Health ABC visit 
was used in the models as the time parameter.  Interaction terms between each predictor and time 
indicate rate of change in LDCW completion time over the course of the study contributed by 
that predictor.   We used time-varying covariates for factors that were updated throughout the 
study (physical activity, weight, body composition). Models were built progressively using 
forward stepwise techniques, initially retaining factors reaching a significance of p<0.10.  We 
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started with unadjusted models including peripheral nerve function and the interaction term 
between time and peripheral nerve function.  Age, sex, race, site, height, and weight and 
interaction terms for each of the covariates with time were then added for a minimally adjusted 
model.  We further adjusted for baseline health status, lifestyle habits (smoking, alcohol 
consumption, and physical activity), prevalent diseases and conditions, and mental health and 
cognitive function variables as well as the time interactions for each of these covariates.  For our 
final, parsimonious model, we retained only factors reaching a significance of p<0.05 in the 
multivariate model.  Because of the strong relationship between diabetes and peripheral nerve 
function, diabetes was retained in the final model regardless of significance.  No factors other 
than these appreciably attenuated the effect of peripheral nerve predictors.  For sensitivity 
analyses we added an interaction term between diabetes and peripheral nerve function, and we 
also reran the linear mixed models excluding participants with diabetes.   We did not impose any 
structure on the covariance matrix of the random effects, and all models included a random 
intercept and a random slope for the visit parameter. All data analyses were performed using 
STATA version 12.1 (StataCorp, College Station, TX).  
3.3 RESULTS 
Of the participants with complete data on 2000/01 visit LDCW eligibility and at least one 
measure of nerve function (n=2393; age 76.5 ± 2.9 years; 48.2% male; 38.2% black), 345 
participants (14.4%) were ineligible for the LDCW, 407 participants (17.0%) started the walk but 
were unable to complete the full 10 laps, 113 participants (4.7%) completed the LDCW in >7 
minutes, and 1528 participants (52.0%) completed the LDCW in ≤7 minutes.  A significant trend 
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existed for those who completed the LDCW to be slightly younger, have a lower BMI, be less 
likely to be female or black, and generally be in better health and have fewer chronic conditions 
than those who were ineligible or unable to complete the full LDCW (Table 6).  Specifically, 
there were approximately 3.5 times more participants who were ineligible for the LDCW 
reported fair or poor health compared to those who completed the LDCW in ≤7 minutes.  
Though trends were significant across groups, similarities existed between those who were 
ineligible, did not complete the full LDCW, and completed in >7 minutes.   
 
  
95 
Table 6:  Participant Characteristics by Long Distance Corridor Walk (LDCW) Eligibility 
and Completion in the Health, Aging, and Body Composition Study 2000/01 Clinic Visit 
 
Participant Characteristics Ineligible  
for LDCW 
n=345 
Did Not  
Finish 
LDCW 
n=407 
Completed 
LDCW    
in >7 
Minutes 
n=113 
Completed 
LDCW in 
≤7 minutes 
n=1528 
P for 
Trend 
Pittsburgh Site % (n) 55.7 (192) 53.6 (218) 43.4 (49) 49.7 (760)   0.03 
Age, Mean ± SD 77.2 ± 2.9 76.8 ± 2.9 76.8 ± 3.0 76.3 ± 2.8 <0.001 
Female Sex 57.1 (197) 62.7 (255) 62.8 (71) 46.9 (716) <0.001 
Black Race 55.7 (192) 46.2 (188) 54.0 (61) 31.0 (473) <0.001 
Health Fair or Poor 29.2 (100) 22.7 (92) 22.3 (25) 8.3 (127) <0.001 
Body Composition  
BMI 28.9 ± 5.4 28.6 ± 5.3 28.6 ± 5.8 26.4 ± 4.1 <0.001 
Bone-Free Lean Mass (kg) 48.6 ± 9.3 48.6 ± 9.7 47.4 ± 9.5 49.3 ± 10.7   0.24 
Fat Mass (kg) 28.5 ± 10.1 28.6 ± 9.5 28.8 ± 10.4 24.9 ± 7.7 <0.001 
Lifestyle Habits  
Current Smoker 10.2 (34) 10.4 (42) 11.6 (13) 7.5 (113) <0.001 
Drink >1 Drink/Week 25.2 (84) 23.6 (95) 21.4 (24) 33.6 (509) <0.001 
Physical Activity* (kcal/kg/week) 3.1 ± 6.7 3.6 ± 6.0 3.0 ± 7.4 7.3 ± 20.1 <0.001 
Prevalent Diseases and Conditions  
Diabetes 29.9 (103) 28.8 (117) 30.1 (34) 26.3 (263) <0.001 Impaired Fasting Glucose 15.7 (54)  18.0 (73) 13.3 (15)  15.8 (242) 
Hypertension 77.9 (261) 67.5 (272) 68.8 (77) 54.5 (822) <0.001 
Coronary Heart Disease 21.5 (73) 26.3 (105) 15.2 (17) 14.7 (222) <0.001 
Cerebrovascular Disease 11.5 (38) 9.9 (39) 7.3 (8) 4.8 (72) <0.001 
Lung Disease 24.6 (85) 26.3 (105) 17.7 (20) 15.0 (229) <0.001 
Osteoarthritis (Knee or Hip) 17.1 (59) 14.0 (57) 14.2 (16) 9.0 (138) <0.001 
Peripheral Arterial Disease 28.8 (90) 24.5 (94) 19.4 (21) 11.2 (167) <0.001 
Arterial Stiffening 4.5 (14) 4.4 (17) 8.3 (9) 5.2 (79) <0.001 
Insufficient Renal Function**  41.1 (139) 35.9 (143) 37.6 (41) 22.4 (335) <0.001 
Poor Vitamin B12 (<260 pmol/L) 16.0 (52) 16.7 (65) 17.1 (18) 17.4 (344)   0.51 
Shortness of Breath While Walking 44.6 (154) 43.7 (178) 38.1 (43) 22.5 (344) <0.001 
Mental Health and Cognitive Function  
CES-D Score*** 8.2 ± 7.7 7.4 ± 7.0 7.6 ± 6.0 5.7 ± 5.8 <0.001 
3MSE Score**** 87.9 ± 8.9 89.0 ± 8.8 86.9 ± 9.6 91.6 ± 7.3 <0.001 
Digit Symbol Substitution Score 31.7 ± 14.4 34.7 ± 14.5 31.6 ± 15.2 28.6 ± 14.2 <0.001 
 
*Physical Activity: Kcals/kilogram body weight spent per week walking and stair climbing 
**Cystatin-C >1mg/dL 
***CES-D:  enter for Epidemiologic Studies Depression Scale [242] 
****3MSE:  Modified Mini-Mental State Examination [244]  
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Better peripheral nerve function was associated with being eligible for and having better 
performance on the LDCW (Table 7).  In particular, higher motor amplitude, lower vibration 
threshold, detection of both monofilaments, and no symptoms of peripheral neuropathy were 
associated with better LDCW performance (p<0.05 for each).  Motor nerve conduction velocity 
was not associated with LDCW eligibility or completion. 
 
Table 7:  Peripheral Nerve Function by LDCW Eligibility/Completion Group  
 
Peripheral Nerve Function 
Measure 
Ineligible 
for LDCW 
 
n=345 
Did Not 
Finish 
LDCW 
n=407 
Completed 
LDCW in >7 
Minutes 
n=113 
Completed 
LDCW in 
≤7 minutes 
n=1528 
P for 
trend 
Motor Nerve Function      
Motor amplitude, mV, Mean ± SD 3.0 ± 2.1 3.1 ± 2.0 3.1 ± 2.0 3.5 ± 2.0 <0.001 
Poor amplitude 19.9 (47) 13.8 (41) 15.0 (12) 8.8 (110) <0.001 
Sensory Nerve Function      
Conduction velocity, m/sec 43.2 ± 5.6 43.3 ± 5.2 44.8 ± 5.7 43.7 ± 5.4   0.33 
Poor conduction velocity 21.1 (52) 22.7 (63) 20.3 (15) 21.9 (262)   0.37 
Vibration threshold, microns 56.0 ± 39.5 52.5 ± 35.4 55.2 ± 35.8 50.1 ± 34.7   0.03 
Poor vibration threshold 9.9 (32) 4.8 (19) 9.2 (10) 5.0 (74)   0.008 
1.4 monofilament insensitivity 38.3 (127) 36.7 (35) 42.7 (84) 36.2 (23) <0.001 10-g monofilament insensitivity 13.0 (43) 10.3 (41) 14.6 (16) 7.1 (107) 
Symptoms of Peripheral Neuropathy     
One symptom 31.0 (105) 31.0 (125) 30.1 (34) 24.9 (379) <0.001 Two or More Symptoms 19.2 (65) 11.4 (46) 6.2 (7) 7.9 (120) 
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In the longitudinal analysis examining change in LDCW completion time over the 6 
years of follow-up (n=1178; age 76.2 ± 2.8 years; 52.1% male; 31.2% black), worse motor 
amplitude (per 1 SD lower), worse vibration threshold (per 1 SD higher) and poor vibration 
threshold (threshold >131 microns), 10g and 1.4gmonofilament insensitivity were associated 
with 3.9, 5.2, 19.6, 9.3, and 20.7 seconds  slower initial LDCW completion time, respectively, 
(Table 8) when adjusting for age, sex, race, site, height, and weight (p<0.05 for all).   In general, 
the relationships were slightly attenuated after further adjusting for health habits and health 
conditions, though the same significant relationships remained with the exception of lower motor 
amplitude (per SD poorer amplitude).   Poor vibration perception threshold (>130 microns) was 
associated with completing the LDCW 16.0 seconds slower, and an additional 4.3 seconds of 
slowing per year compared to those with vibration perception threshold ≤130 microns.  Standard 
10-g monofilament insensitivity was associated with completing the LDCW 14.1 seconds slower 
and an additional 4.3 seconds of slowing per year.  No associations between either motor nerve 
conduction velocity or presence of symptoms of peripheral neuropathy were found in any of the 
models.  In sensitivity analyses, no significant interaction was found between peripheral nerve 
function and diabetes, and all results remained consistent when excluding individuals with 
diabetes.    
Compared to those included in the mixed models, those not included in the longitudinal 
analyses were slightly older (mean age 76.9 ± 2.9 vs. 76.2 ± 2.8 years, p<0.001), more likely to 
be women (55.8% vs. 52.1%, p<0.001) and more likely to be black (44.9% vs. 32.2%, p<0.001).  
Those not included in the models also had worse motor nerve amplitude (3.1 ± 1.9 vs. 3.6 ± 2.0 
mV, p<0.001), higher vibration perception threshold (53.6 ± 36.4 vs. 49.5 ± 34.6 microns, 
p=0.005), were more likely to have 10-g (10.7% vs. 7.0%) or 1.4-g (37.6% vs. 36.1%) 
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monofilament insensitivity (p=0.004), and were more likely to report at least one symptom of 
peripheral neuropathy (42.3% vs. 31.8%, p<0.001).  No difference existed in motor nerve 
conduction velocity between those excluded and those included in the longitudinal analysis (43.5 
± 5.4 vs. 43.7 ± 5.8 m/sec, p=0.54).  The most common reasons for not being included in the 
mixed models were not finishing the initial LDCW (n=407) and meeting exclusion criteria at the 
initial LDCW assessment (n=345). 
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Table 8:  Peripheral nerve functioning and longitudinal performance in LDCW from 2000/01 to 2006/07 in the Health, Aging 
and Body Composition Study 
  Model 1 Model 2 Model 3:  Final Model 
Standardized Betas Standardized Betas Standardized Betas 
Main Effect  Time 
Interaction 
Main Effect  Time 
Interaction 
Main Effect Time 
Interaction 
Motor Nerve Function             
SD lower amplitude, mV 3.9*  0.5  3.7* 0.3 2.2 0.3 
Poor amplitude  5.8 4.8**  3.2 4.4** -0.9 4.7** 
SD Slower Conduction Velocity, m/sec -0.8 -0.1 -0.5 0.3 1.1 0.3 
Poor Conduction Velocity -2.1 -0.04 0.9 -0.3 -3.9 -0.5 
Sensory Nerve Function             
SD higher vibration perception threshold, μ  5.2** 1.6**   4.9** 1.7**  3.2* 1.7** 
Poor vibration perception threshold 19.6**  4.1* 20.1** 4.9** 16.0*  4.3* 
1.4 monofilament insensitivity  9.3**  -0.6 8.6** -0.6 6.7* -0.7 
10-g monofilament insensitivity 20.7** 4.4**  16.3** 4.5** 14.1** 4.3** 
 
*p<0.05, **p≤0.01.   Model 1:  Adjusted for age, sex, race and site.  Model 2:  Adjusted for Model 1 + health status, physical activity, current 
cigarette smoking, lean mass and fat mass 
Model 3:  Motor amplitude and conduction velocity:  Model 2 + PAD, cerebrovascular disease, diabetes, insufficient renal function, shortness of 
breath while walking, and DSST score.  Cigarette smoking and health status were removed from Model 3. 
Model 3:  Sensory nerves function: Model 2 + PAD, cerebrovascular disease, diabetes, insufficient renal function, DSST score, CES-D and 
hypertension.  Cigarette smoking and health status were removed from Model 3. 
Model 3:  Vibration perception threshold: Model 2 + PAD, cerebrovascular disease, diabetes, insufficient renal function, DSST score, CES-D and 
hypertension.   Health status was removed from Model 3.  
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3.4 DISCUSSION 
In this cohort of community-dwelling older adults, poorer motor and sensory peripheral 
nerve function was related to worse endurance walking performance and sensory nerve function 
was associated with greater slowing of endurance walking speed over time.  Additionally, 
peripheral nerve function and presence of symptoms of neuropathy were related to the inability 
to complete the LDCW.  Peripheral nerve dysfunction should be appreciated as a risk factor in 
the disablement pathway, and these findings add to the growing body of literature indicating that 
peripheral nerve dysfunction in older adults is related to adverse lower-extremity outcomes.  
Though peripheral nerve dysfunction is often thought to be primarily a concern for those with 
diabetes, these results support previous work indicating that peripheral nerve function is an 
important predictor of mobility related outcomes in older adults independent of diabetes 
[31,216].  
The sensory and motor nerves of the lower extremities play key roles in gait.   Sensory 
nerves detect touch, vibration, and other sensations regarding the external environment, and 
motor nerves that relay signals from the central nervous system that allow for voluntary 
movement.  Sensory peripheral nerve function in the lower extremities is crucial for perception 
of joint position, posture, and balance—all factors that play roles in walking quickly. Vibration 
perception threshold and standard monofilament insensitivity were strongly associated with the 
slowing of endurance walking over time.  Worse vibration perception threshold has been shown 
to be associated with worse balance and slower gait in older adults without diabetes or overt 
peripheral neuropathy [31,34,95,245].   
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Little work exists relating sensorimotor peripheral nerve function and endurance walking 
in older adults.  McDermott and colleagues found in the InCHIANTI study that motor nerve 
conduction velocity was associated with slower completion of a fast-paced 400m walking test for 
older adults [66], though this study did not include measures of motor nerve amplitude, sensory 
peripheral nerve function or the assessment of symptoms of peripheral neuropathy.  The 
association with conduction velocity is in contrast to our results where we found that sensory 
peripheral nerve function measures were associated with worse walking endurance and greater 
slowing over time, while there was no association with motor nerve conduction velocity.   Age 
and racial differences between the InCHIANTI and Health ABC cohorts may have contributed to 
the differences in findings.  Our null findings with nerve conduction velocity are consistent with 
prior work in this cohort.  Worse motor nerve amplitude (a sign of axonal degeneration) but not 
worse motor nerve conduction velocity (a sign of demyelination) has been shown to be 
associated with lower extremity physical performance [31] and incident lower extremity 
limitation [216] in the Health ABC cohort.   
The effect size of poor sensory peripheral nerve function was similar in magnitude to 
those of common risk factors associated with worse walking endurance.  For example, current 
smoking was independently associated with completing the initial LDCW 14.0 seconds slower, 
and those with cerebrovascular disease completed the initial LDCW 16.1 seconds slower than 
those without cerebrovascular disease, though neither of these factors were significantly 
associated with greater slowing over time.  This is similar to the effect of poor vibration 
perception threshold (16.0 seconds slower) and 10g monofilament insensitivity (14.1 seconds) on 
initial LDCW completion time, and these factors were each related to greater slowing over time 
(4.3 seconds slower for each).  This effect is also approximately equivalent to 5 years of aging.   
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Peripheral nerve impairments are common in older adults,[30] and improving functional 
outcomes in those with these impairments may be important on many levels.  Work in diabetic 
populations has shown that deficits in lower extremity peripheral nervous system function are 
associated with altered gait biomechanics [118-120].  Because of the associations between gait 
alterations and injuries and falls [117,122-124], these factors may also be in the pathway 
between peripheral nerve dysfunction and worse lower-extremity function for older adults.  
Sensory nerve impairments in particular may increase the risk of falling due to the inability to 
adequately sense the lower extremities.  Physical activity can help older adults improve physical 
function and delay persistent mobility limitations [246], however, whether physical activity 
interventions can be used to reduce physical functional impairments due to poor peripheral nerve 
function is currently unknown. 
A major strength of this study is that we incorporated several measures of both motor and 
sensory nerve function as well as symptoms associated with peripheral neuropathy.  Including 
objective and subjective measures is especially important because an absence of symptoms does 
not necessarily equate to an absence of disease [88], particularly in older adults where nerve 
function deficits may be asymptomatic [30].  In addition, the large sample size and longitudinal 
study design allowed an examination of several factors that could potentially influence peripheral 
nerve function and/or walking endurance over time.   
Though the use of mixed models allowed us to maximize our available data, only those 
who completed the LDCW at the 2000/01 clinic visit and at least one follow-up could be used in 
the longitudinal analysis.  Those who could not complete the LDCW at the 2000/01 clinic visit 
or at least one follow-up had worse peripheral nerve function compared to those who completed 
the LDCW, and it is possible that those without a 2000/01 clinic visit or at least one additional 
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follow-up had the worst peripheral nerve function of all.  Thus, we may have underestimated the 
true effect of peripheral nerve function on the worsening of walking endurance.  Unfortunately, 
the retention bias resulting from the fact that participants returning for clinic visits are healthier 
than those who did not is applicable to most cohort studies of older adults [247].  An additional 
limitation is that our physical activity assessment measure was restricted to only kilocalories per 
kilogram body weight spent per week in walking and stair climbing, as these were the only 
physical activities assessed consistently throughout the selected follow-up period.  Some limited 
evidence exists that adults with well controlled diabetes and  higher levels of physical activity 
are less likely to have peripheral neuropathy [158], though additional work is needed in 
determining the relationship between physical activity and peripheral nerve function.   
In conclusion, poorer sensory and motor peripheral nerve function in older adults is 
related to slower endurance walking and greater slowing over time.  Interventions to reduce the 
burden of sensorimotor peripheral nerve function impairments should be considered in order to 
help older adults to maintain walking endurance—which can be crucial for remaining 
independent in the community. 
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4.0  SENSORIMOTOR AND CARDIOVASCULAR AUTONOMIC PERIPHERAL 
NERVE FUNCTION IN OLDER ADULTS IN THE HEALTH, AGING AND BODY 
COMPOSITION STUDY 
ABSTRACT 
Age-related peripheral nervous system (PNS) impairments are prevalent, with sensorimotor 
impairments associated with poor mobility and cardiac autonomic impairments associated with 
adverse cardiac outcomes.  Although sensorimotor and cardiac autonomic impairments have 
been found associated in persons with diabetes, the nature of the relationship in general 
community-dwelling populations of older adults is unknown.  Health ABC Study participants 
(n=2393, age=76.5±2.9, 52% women, 38% black) underwent peripheral nerve testing at the 
2000/01 clinic visit.  Nerve conduction amplitude and velocity were measured at the peroneal 
motor nerve. Sensory nerve function was measured using vibration detection threshold and 
monofilament testing at the big toe.  Symptoms of lower-extremity peripheral neuropathy 
included numbness or tingling and sudden stabbing, burning, pain, or aches in the feet or legs.   
Cardiac autonomic function measures included resting HR (HR), orthostatic hypotension, as well 
as HR range and recovery to submaximal exercise testing.  Poor motor conduction velocity (<40 
m/sec) was associated with higher odds of orthostatic hypotension (OR=1.57, p=0.05), while 
poor motor amplitude (<1 mV) was associated with higher resting HR (β= 2.20, p=0.001).  
Insensitivity to the 1.4g monofilament was associated with worse HR range (increase in HR from 
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resting to the end of the submaximal test, adjusting for performance; β=-1.56, p=0.028).  Other 
PNS measures were not related.  Associations remained were independent of age, sex, race, 
diabetes, and health and lifestyle factors known to influence PNS function.  Sensorimotor and 
autonomic function are independently related, and future studies should investigate common 
underlying processes for the development of multiple PNS impairments in older adults. 
4.1 INTRODUCTION 
The peripheral nervous system (PNS) consists of two distinct divisions, the sensorimotor 
and the autonomic nervous systems.  Even though both play integral roles in providing 
information to the central nervous system to appropriately respond to stimuli and in controlling 
automatic functions of the body, typically they are examined as separate entities.  PNS aging is 
characterized by a phenomenon known as “selective vulnerability” in which locally specific 
structural and functional changes can occur which vastly affect some groups of neurons while 
leaving others relatively intact [248]. In particular, long, myelinated axons (like those 
innervating the lower limbs) and sympathetic neurons are vulnerable to damage.  PNS 
dysfunction is often considered in the context of diabetes or specific neurological conditions, 
though age-related impairments may occur in either division even in the absence of any 
pathologic conditions [28]. 
Sensorimotor peripheral nerve function impairments are common in older adults [29,30], 
with recent work from Health ABC showing that 55% of older adults (N=1,680; age 76.5 ± 2.9 
years) without mobility disability have evidence of lower extremity peripheral nerve 
impairments [216].  Sensorimotor nerve function impairments in the lower extremities are 
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associated with poorer lower extremity physical function [31-34], worse lower extremity muscle 
strength [36,215] and power [37], and an increased risk for falls [38-41]  and mobility limitations 
[216].  In contrast to lower extremity sensorimotor PNS impairments that impact sensory 
perception and motor control of the lower limbs, cardiac autonomic impairments inhibit the 
ability of the cardiovascular system to appropriately respond to internal and external stimuli and 
maintain homeostasis.  Autonomic nerve function impairments can affect other bodily systems, 
though cardiac autonomic nerve impairments are often seen as the most serious given their 
association with adverse cardiovascular outcomes and death [133,140,142,249,250].  Despite 
these risks, autonomic impairments are underappreciated as risk factors in epidemiologic studies 
of older adults.   Though under-studied, autonomic impairments are common in older adults.  In 
the Irish Longitudinal Study on Ageing (n=4475, age 50+ years), 6.9% of the study cohort and 
18.5% of participants age 80 and older had postural hypotension, an indicator of cardiac 
autonomic impairment [251].   
Although sensorimotor and autonomic nerve impairments seem very different, they may 
be related. Damage to sensorimotor and autonomic nerve fibers in diabetes has largely been 
attributed to damage related to hyperglycemia [132,252-254] and poor metabolic control; 
although advanced glycation end products [255,256], inflammation [257,258], dyslipidemia 
[259] and  other cardiovascular risk factors [73,260-262] appear to play roles as well.   Work in 
populations with diabetes (both Type 1 and Type 2) provides evidence that worse sensorimotor 
function is associated with an increased risk of cardiovascular events [263,264]. Additionally, 
cardiac autonomic neuropathy is associated with higher odds of developing diabetic somatic 
peripheral neuropathy [261], with the severity of cardiac autonomic neuropathy related to a 
higher prevalence of peripheral neuropathy [265].    
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Aside from the extensive studies of neuropathy in diabetic populations, the relationship 
between sensorimotor and cardiac autonomic function is largely unexamined in either diabetes or 
general populations of older adults.  Age-related PNS changes can occur independently of 
diabetes.  Associations between age-related sensorimotor and autonomic impairments have not 
been explored and may differ from impairments attributed to diabetes.  However, because of the 
common underlying risk factors associated with sensorimotor and autonomic peripheral nerve 
impairments (particularly cardiovascular risk factors), it is plausible that those with worse 
sensorimotor function may also have worse cardiac autonomic function.  The purpose of this 
study was to examine the independent association between lower-extremity sensorimotor 
peripheral nerve function and cardiac autonomic function in older adults.  
4.2 METHODS 
 Participants 4.2.1
Study participants were from the Health, Aging and Body Composition Study (Health 
ABC) who completed a clinic visit in 2000/01.  Briefly, Health ABC is a longitudinal cohort 
study of black and white, initially well-functioning, community dwelling older men and women 
from Pittsburgh, PA and Memphis, TN (n=3075; age 70-79; 48.4% male; 41.6% black at 
baseline).  The purpose of Health ABC was to investigate factors related to the development of 
functional limitations and disability [126].  Participants were recruited via mailings to a random 
sample of white Medicare beneficiaries and to all age-eligible black community residents.  
Eligibility criteria for this study included: having no self-reported difficulty in walking ¼ mile, 
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climbing 10 steps, or performing any basic activity of daily living; no life-threatening cancers; 
and plans to remain in the study area for at least the next three years.  Participants underwent 
baseline clinic visits between April 1997 and June 1998.   
Of the original cohort, 2404 participants completed the 2000/01 clinic visit (187 
participants were deceased, 74 had a home visit, 233 phone visit, 9 proxy visit, 9 withdrew from 
study, and 105 were missing for other reasons). A total of 2393 participants underwent 
sensorimotor peripheral nerve function testing and were considered for this analysis (1 refused 
nerve exam, 4 were missing nerve measures, 6 had other missing data).  All of the 2393 
participants included for this analysis had at least one measure of cardiac autonomic function.  
Figure 6 shows the participant flow chart of the analytic samples for this study.  All participants 
provided written informed consent before participating in the study. All study protocols were 
approved by institutional review boards at the University of Pittsburgh and University of 
Tennessee Health Science Center.   
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 Figure 6:  Participant Flow Chart for the 2000/01 Health ABC Clinic Visit 
 Sensorimotor Peripheral Nerve Function 4.2.2
Lower extremity sensory and motor nerve function testing was performed by a trained 
examiner.  Peroneal motor nerve conduction responses were obtained at the extensor digitorum 
brevis muscle, with recording of amplitude (in millivolts) and motor nerve conduction velocity 
(in meters per second), as previously described [89].  Peroneal nerve was stimulated at the 
popliteal fossa and ankle using the NeuroMax 8 (XLTEK, Oakville, Ontario, Canada).  Sensory 
nerve function was assessed via vibration threshold and light touch detection.  Vibration 
detection threshold (in microns) was measured at the bottom of the great toe with a VSA-3000 
Vibratory Sensory Analyzer (Medoc, Durham, NC).  Light touch sensitivity testing was 
performed using a standard 10-g monofilament and light touch 1.4-g monofilament (North Coast 
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Medical, Morgan Hill, CA).  Monofilament insensitivity was defined as the inability to detect at 
least 3 of 4 touches at the dorsum of the great toe.  If needed, feet were warmed to 30°C before 
nerve testing.  All measures were performed on the right side unless contraindicated due to knee 
replacement, amputation, trauma, ulcer, or recent surgery, in which case testing was performed 
on the left side.  Symptoms of peripheral neuropathy were collected via self-report using a 
modified version of the Michigan Neuropathy Screening Instrument questionnaire [108]. 
Presence of symptoms included reporting any of the following on either foot or leg in the past 12 
months: (1) numbness, "asleep feeling," prickly feeling or tingling (2) sudden stabbing, burning, 
or deep aches, or (3) an open persistent sore or gangrene.  Clinically meaningful cut-points of 
motor amplitude of <1 mV and motor nerve conduction velocity <40 m/sec were used to define 
poor function [240].  For vibration threshold, >130 microns was used to define impairment.  
These cut-points were previously used by Ward and colleagues, and have been shown to be 
associated with lower quadriceps strength [215] and worse endurance walking performance 
[266], as well as incident mobility limitation [216].  
 Cardiac Autonomic Function 4.2.3
Radial pulse was used for resting heart rate (HR).  Postural hypotension was assessed 
using the difference between blood pressure measurements taken while in a seated position, and 
one minute after transitioning to a standing position.  Diastolic postural hypotension measured in 
this manner predicted falls in diabetic participants in Health ABC [39].  Postural hypotension 
was defined as drop of >20 mmHg of systolic or >10mmHg diastolic blood pressure between 
seated and standing measurements [267].   
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Cardiac autonomic function was also assessed using the cardiovascular response to the 
long distance corridor walk (LDCW) [239].  Participants who were ineligible for the LDCW 
(n=345) or who did not complete the full 10 laps (n=407) were not included in analyses 
involving HR range or recovery.  Briefly, the LDCW is an over ground, submaximal walking test 
which has been validated to provide an estimate of aerobic fitness in older adults [214].  HR 
range was defined as the difference between resting HR and HR at the end of the LDCW, while 
HR recovery was defined as the difference between HR at the end of the LDCW and HR 2 
minutes post-test.  These methods have been used previously by Newman and colleagues in 
assessing the association between LDCW performance and incident cardiovascular disease, 
mortality, and mobility limitation and disability in Health ABC [268].  Because HR parameters 
measured during submaximal exercise are influenced by exertion, models for HR range and HR 
recovery were adjusted for LDCW completion time.  In Paper 2 we found that participants who 
had worse peripheral nerve function had slower LDCW completion times were more likely to 
complete the LDCW in greater than 7 minutes, an indicator of very low aerobic fitness [269].  
We tested for interactions between sensorimotor function and completion time on HR range and 
HR recovery and stratified analyses by completion time (completed in ≤7 minutes vs. >7 
minutes) if evidence of a significant interaction existed.  
 Covariates 4.2.4
Age, sex, race, and clinical site were included as demographic characteristics.  In 
addition, several factors which could potentially influence sensorimotor or cardiovascular 
function were considered as possible covariates.  All factors were measured at the 2000/01 clinic 
visit unless otherwise stated.  Lifestyle factors were assessed via self-report and included: 
112 
smoking history (never, former, current; reported in 1999/2000), current drinking frequency 
(drinks per week), and physical activity (kilocalories expended per week in walking and stair 
climbing) [203].  Body composition (fat mass and bone-free lean mass) was measured using 
dual-energy X-ray absorptiometry (DXA; 4500A, Hologic, Inc., Bedford, MA).  Body mass 
index (BMI) was calculated in weight in kilograms per squared height in meters using a standard 
physician’s balance scale and stadiometer, respectively.   
Diabetes was defined using self-reported physician’s diagnosis, hypoglycemic 
medication use, or by fasting glucose ≥126 mg/dL (8 hour fast) and impaired fasting glucose was 
defined as fasting glucose level of 100-125 mg/dL (8 hour fast).[226] Ankle brachial index 
values of <0.9 indicated peripheral arterial disease and >1.3 for arterial stiffening [227].  
Hypertension was defined by self-report, medication use, or systolic blood pressure ≥140mmHg 
or diastolic blood pressure ≥90mmHg measured at the clinic visit.  Poor vitamin B12 status was 
defined as <260 pmol/L [53] and insufficient renal function was defined as Cystatin-C >1mg/dL 
[241]. 
Other prevalent diseases or conditions assessed at baseline (1997/98) included 
cardiovascular disease (bypass/coronary artery bypass graft, carotid endarterectomy, myocardial 
infarction, angina, or congestive heart failure), Parkinson’s disease, cerebrovascular disease 
(transient ischemic attack or stroke), lung disease (asthma, chronic obstructive pulmonary 
disease, or emphysema), and osteoarthritis in knee or hip.   Self-reported pain in the lower 
extremities while walking was assessed via questionnaire.  Depressive symptoms were collected 
using the Center for Epidemiologic Studies Depression Scale (CES-D) [242]. Medications 
known to potentially influence HR, blood pressure, or cholesterol were included from the 
detailed medication inventory collected at the 1999/2000 visit.  These medications  included use 
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of beta blockers, anti-hypertensive medications (based on the Iowa Drug Information Service), 
calcium-channel blockers, tricyclic antidepressants [139] and statins. Levels of total cholesterol, 
interleukin-6 (IL-6), and C-reactive protein (CRP) were assessed from blood samples collected 
by venipuncture after an overnight fast.     
 Statistical Methods 4.2.5
Descriptive statistics and measures of sensorimotor and autonomic function were 
expressed using mean ± standard deviations and proportions for continuous and categorical 
variables, respectively.  Means and proportions were compared between men and women 
because of the potential sex-differences in PNS function [270,271].  T-tests and chi-squared 
tests, respectively, compared descriptive factors unless non-parametric versions of these tests 
were more appropriate.  We examined the correlations between sensorimotor and cardiac 
autonomic function using Pearson correlation coefficients for continuous measures, and 
Spearman correlation coefficients for correlations involving interval measures. 
We modeled the effect of sensorimotor function on continuous indicators of cardiac 
autonomic function (resting HR, HR range, and HR recovery) using linear regression.  We also 
split these continuous outcomes into quintiles, and modeled the effect using ordinal or 
multinomial logistic regression when appropriate to account for potential non-linear 
relationships.  The effect of sensorimotor peripheral nerve function and odds of postural 
hypotension were modeled using logistic regression.   
We began with minimally adjusted models, and progressively added covariates using 
manual stepwise regression techniques.   Covariates reaching a significance level of p<0.10 were 
considered for a multivariable model.  Only factors reaching a significance of p<0.05 in the 
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multivariable model were included in the final, parsimonious model, though age, sex, race, site, 
and diabetes were forced into final models regardless of significance.  Because measures of 
sensorimotor function are moderately correlated (r=0.32, p<0.001 between motor amplitude and 
conduction velocity), separate models were built for each. Models were sex stratified if 
interactions were observed between sex and sensorimotor function in predicting autonomic 
function.  We also ran sensitivity analyses using age tertiles rather than continuous age in order 
to determine whether associations between sensorimotor and autonomic function differed by age 
group or the effect of age was not linear.  Final sensitivity analyses were run removing 
participants taking any medication that could potentially influence heart rate (beta blockers 
tricyclic antidepressants, and calcium channel blockers).  
4.3 RESULTS 
Women and men in this study differed on many lifestyle and health factors (Table 9).  
The prevalence of select diseases and conditions varied by sex, with women being less likely to 
have diabetes or impaired fasting glucose, coronary heart disease, arterial stiffening, insufficient 
renal function, or poor vitamin B12 status, though women were more likely to have hypertension 
and osteoarthritis, and reported more depressive symptoms.  Women had higher levels of CRP 
and total fasting cholesterol, while men had slightly higher values of IL-6.  Women were more 
likely to take hypertensive, calcium channel blockers, and tricyclic antidepressants.   
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Table 9:  Health ABC 2000/01 Clinic Visit Participant Characteristics by Sex 
*Physical Activity:  Kilocalories/kilogram body weight spent per week in walking and stair 
climbing; **Cystatin-C >1mg/dL; ***CES-D:  Center for Epidemiologic Studies Depression 
Scale 
Participant Characteristics Men 
N= 1154 
Women 
N=1239 
P-Value 
 
Pittsburgh Site % (n) 51.2 (591) 50.7 (628)   0.80 
Age, Mean ± SD 76.7 ± 2.9 76.4 ± 2.9   0.01 
Black Race 33.5 (386) 42.6 (528) <0.001 
Health Fair or Poor 13.4 (154) 15.4 (190)   0.17 
Anthropomorphic Characteristics and Body Composition 
Body Mass Index 27.1 ± 4.0 27.4 ± 5.4   0.057 
Height, meters 1.7 ± 0.7 1.6 ± 0.6 <0.001 
Weight (kg) 81.0 ± 13.4 69.9 ± 14.6 <0.001 
Bone-Free Lean Mass (kg) 57.0 ± 7.3 41.5 ± 6.2 <0.001 
Fat Mass (kg) 23.9 ±  7.4 28.4 ± 9.2 <0.001 
Lifestyle Habits 
Current Smoker   8.9 (101)   8.3 (101) <0.001 
Drink >1 Drink/Week 39.0 (442) 21.9 (267) <0.001 
Physical Activity* (kcal/kg/week)   7.1 ± 18.2   4.7 ± 15.0 <0.001 
Prevalent Diseases and Conditions 
Diabetes 25.0 (289) 18.4 (228) <0.001 Impaired Fasting Glucose 20.0 (231) 12.4 (153) 
Hypertension 57.8 (658) 63.4 (774)   0.01 
Parkinson’s Disease   0.7 (8)   0.5 (6)   0.50 
Coronary Heart Disease 24.8 (269) 13.3 (155) <0.001 
Cerebrovascular Disease   6.4 (72)   7.1 (85)   0.54 
Lung Disease 16.2 (187) 19.6 (243)   0.03 
Osteoarthritis (Knee or Hip) 10.4 (120) 16.1 (200) <0.001 
Peripheral Arterial Disease 16.2 (180) 16.2 (192) <0.001 Arterial Stiffening   7.2 (80)   3.2 (38) 
Insufficient Renal Function**  33.1 (376) 23.5 (282) <0.001 
Poor Vitamin B12 (<260 pmol/L) 19.9 (221) 14.4 (169) <0.001 
Depressive Symptoms    5.6 ± 5.9   7.2 ± 6.8 <0.001 
Pain in Legs While Walking 23.0 (264) 24.9 (307)   0.48 
Laboratory Measures 
CRP, mg/L     4.4 ± 9.6     5.3 ± 7.3 0.014 
IL-6, pg/mL     3.8 ± 3.7     3.5 ± 3.8 0.048 
Total Fasting Cholesterol, mg/dL 180.6 ± 32.8 202.1 ± 38.4 <0.001 
Medication Use 
Statins 20.7 (232) 18.8 (228) 0.26 
Beta Blockers  17.5 (199) 16.9 (208) 0.71 
Calcium Channel Blockers 21.3 (242) 25.2 (310) 0.02 
Anti-hypertensive Medications 56.2 (640) 61.6 (758) 0.008 
Tricyclic Antidepressants    1.3 (15)   3.3 (40) 0.002 
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Several significant differences in sensorimotor and autonomic function were observed by 
sex (Table 10).  Women had better motor and sensory peripheral nerve function, but were more 
likely to report symptoms of peripheral neuropathy.  Women had slightly higher resting HR, but 
were less likely to have postural hypotension and also had a better HR range and recovery to the 
LDCW compared to men. 
  
Table 10:  Sensorimotor and Cardiac Autonomic Function by Sex  
  
*HR at End of LDCW – Resting HR, BPM, Mean ± SD 
**HR at End of LDCW – HR 2 Min Post Test, BPM, Mean ± SD  
Peripheral Nervous System Function 
Measure 
Men 
N=1154 
Women 
N=1239 
P-Value 
 
Motor Nerve Function 
Motor amplitude, mV, Mean ± SD   3.0 ± 1.9   3.6 ± 2.0 <0.001 
Poor amplitude, %(n) 15.7 (137)   7.4 (73) <0.001 
Conduction velocity, m/sec 41.7 ± 4.8 45.3 ± 5.3 <0.001 
Poor conduction velocity 33.2 (272) 12.9 (120) <0.001 
Sensory Nerve Function 
Vibration threshold, microns 59.8 ± 37.1 44.1 ± 32.5 <0.001 
Poor vibration threshold   8.7 (96)   3.2 (39) <0.001 
1.4 monofilament insensitivity 40.9 (463) 33.2 (404) <0.001 
 10-g monofilament insensitivity 12.3 (139)   5.6 (68) 
Symptoms of Peripheral Neuropathy 
One symptom 25.7 (296) 28.3 (347)   0.005 
Two or More Symptoms   8.2  (94) 11.8 (144) 
Autonomic Nervous System Function 
Resting HR, BPM,  Mean ± SD 62.3 ± 10.8 63.6 ± 10.0   0.002 
Postural Hypotension   7.2 (83)   6.1 (76)   0.30 
HR Range* 43.4 ± 14.3 44.6 ± 15.1   0.087 
HR Recovery 17.8 ± 10.5 18.9 ± 10.5   0.029 
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Despite the differences in participant characteristics and PNS function by sex, no 
significant interactions by sex existed, and thus the following results were not sex-stratified.  
Several of the motor and sensory nerve measures were significantly correlated with the 
indicators of cardiac autonomic function, although no associations were observed with symptoms 
of peripheral neuropathy (Table 11).   
 
Table 11:  Correlation* Matrix of Continuous Sensorimotor and Autonomic Function 
Measures 
 Resting HR Orthostatic Hypotension HR Range HR Recovery 
 
Motor Nerve 
Amplitude 
 
-0.052 
(0.026) 
0.014 
(0.547) 
0.037 
(0.179) 
0.019 
(0.481) 
Motor Nerve 
Conduction 
Velocity 
0.027 
(0.226) 
-0.090 
(<0.001) 
0.097 
(<0.001) 
0.057 
(0.044) 
Vibration 
Threshold 
0.005 
(0.830) 
0.046 
(0.029) 
-0.047 
(0.002) 
-0.022 
(0.378) 
 
Monofilament 
Insensitivity 
 
-0.010 
(0.650) 
-0.005 
(0.806) 
-0.051 
(0.041) 
0.008 
(0.738) 
Presence of 
Neuropathy 
Symptoms 
0.013 
(0.547) 
0.025 
(0.224) 
0.018 
(0.474) 
0.022 
(0.0372) 
 
*Pearson correlation coefficients shown for correlations of continuous measures, and Spearman 
correlation coefficients shown for correlations involving interval measures.  Partial correlation 
coefficients are shown for HR Range and HR Recovery to account for long distance corridor 
walk completion time. 
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Figure 7 displays the mean unadjusted resting heart rate by sensorimotor function.  After 
adjusting for age, study site, race, diabetes, beta blocker use, CRP and total fasting cholesterol, 
each standard deviation of lower motor nerve amplitude was associated with a resting HR of 1.03 
higher beats per minute, and having poor motor amplitude (< 1mV) was associated with higher 
resting HR of 2.20 beats per minute (p=0.005).  After removing participants taking medications 
that could influence heart rate (n=876), poor amplitude was associated with a higher resting heart 
rate of 2.48 beats per minute (p=0.011).  The relationship between amplitude and resting heart 
rate was attenuated when removing participants taking any medication that could influence 
resting heart rate, though results remained statistically significant. 
 
Figure 7:  Mean Unadjusted Resting Heart Rate by Sensorimotor Function 
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Unadjusted odds of orthostatic hypotension by sensorimotor function are displayed in 
Figure 8.  In adjusted models, only conduction velocity remained associated with odds of 
orthostatic hypotension.  Each standard deviation of slower motor nerve conduction velocity was 
associated with 1.37 higher odds of orthostatic hypotension (p=0.005) after adjusting for age, 
sex, race, site, diabetes, poor health, and IL-6.  Poor conduction velocity (< 40m/sec) was 
associated with 1.57 higher odds of orthostatic hypotension (p=0.05).  Finally, those with 1.4g 
monofilament insensitivity had an average HR range of 1.43 beats per minute lower compared to 
those who were able to detect the 1.4g monofilament (p=0.036).  No associations remained with 
HR recovery after adjusting for common covariates.   
 
Figure 8:  Unadjusted Odds of Orthostatic Hypotension by Sensorimotor Function 
 
  
Normal 
Function 
 
Poor Function/ 
Monofilament 
Insensitivity 
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HR range and recovery were negatively correlated with LDCW completion time     
(r = -0.309 and r = -0.328, respectively, p<0.001 for each.)  In adjusted models, associations 
between monofilament detection (1.4g and 10g insensitivity combined for statistical power) and 
HR range remained.  A significant interaction existed between completion time and 
monofilament detection on HR range, and thus models for monofilament detection and HR range 
were stratified by completion time (completed in ≤7 minutes vs. >7 minutes).  In separate fully 
adjusted models (adjusted for age, sex, race, site, diabetes, height, fat mass, lean mass, beta 
blocker use, and calcium channel blocker use), monofilament insensitivity was associated with a 
HR range of 1.8 beats per minute lower in participants who completed the LDCW in 7 minutes 
or less, while monofilament insensitivity was not significantly associated with HR range in those 
who competed the LDCW in greater than 7 minutes (Figure 9).  When removing participants 
taking any medication that could influence heart rate (n=534), monofilament insensitivity was 
associated with a heart rate range of 1.66 beats per minute lower (p=0.035) compared to those 
who detected the monofilaments. 
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 Adjusted for age, sex, race, site, diabetes, fat mass, lean body mass, height, beta blocker use, 
and calcium channel blocker use.
 Figure 9:  Adjusted Heart Rate Range During the LDCW By Monofilament Detection
4.4 DISCUSSION 
Some indicators of worse sensorimotor peripheral function were independently 
associated with worse cardiac autonomic function for some, but not all measures.  Motor nerve 
function was associated with cardiac autonomic function measures of resting heart rate and 
orthostatic hypotension.  Monofilament insensitivity was associated with lower HR range in 
participants who completed the LDCW in seven minutes or less, while monofilament 
insensitivity was associated with higher HR range in those who took greater than 7 minutes 
complete the LDCW.  To our knowledge, this is the first study examining the association 
between these PNS divisions in a population of community dwelling older adults.  Generally, the 
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sensorimotor and autonomic divisions of the PNS are not examined simultaneously.  Though 
PNS function is often considered in the context of diabetes, age-related PNS changes are not as 
well understood.   
The PNS is comprised of large and small fibers, each responsible for distinct aspects of 
neurotransmission. Within the sensorimotor division, large myelinated fibers (Aα, Aβ) mediate 
motor control as well as touch, vibration, and position perception.  Small, thinly myelinated (Aδ) 
or unmyelinated (C fibers) of the sensorimotor division provide information about pain in 
addition to cold and warm perception, respectively.  The autonomic division is made up of thinly 
myelinated and unmyelinated fibers, and mediates HR, blood pressure, sweating, gastrointestinal 
and genitourinary function.  The most consistent significant associations observed in this 
analysis were between motor nerve function and HR and orthostatic hypotension, which are 
highly influenced by vagal nerve function.  Though these relationships were between different 
fiber types, this observation is consistent with the notion of selective vulnerability, where the 
long nerve fibers (like the vagus and peroneal nerves) are particularly prone to damage.   
Damage to the peripheral nervous system in the context of diabetes is often attributed to 
long-term metabolic disturbances and hyperglycemia, [88,110,260] though our observed 
associations were not explained by factors largely thought of as influencing nerve function.  In 
particular, these associations were independent of age, sex, race, diabetes, and prevalent diseases.  
In the model building process, very few covariates were significantly associated with 
sensorimotor and indicators of cardiac autonomic function, and multivariable models included 
few parameters beyond age, sex, race, study site and diabetes—which were included in all 
models regardless of significance, suggesting a primary association between the PNS 
components.  However, the effect sizes of the observed relationships were small.  For example, 
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poor motor amplitude was associated with a resting heart rate of 2.20 beats per minute higher 
compared to those with normal amplitude.  In a longitudinal study by Jensen and colleagues 
examining the risk of mortality by resting heart rate in middle aged men, the risk of mortality 
increased by about 16% per every 10 beats per minute higher.  The heart rate differences 
observed in our study were much smaller, and may not be as clinically relevant. Additionally, 
even though some measures of sensorimotor peripheral nerve function were independently 
associated with the indicators of cardiac autonomic function, the overall R2 values for these 
models were low (results not shown).  This may indicate potential underlying mechanisms 
common to the pathogenesis of sensorimotor and autonomic dysfunction that were not captured 
by the included covariates, or it may simply indicate small associations.   
We expected age to explain a large portion of the association between sensorimotor and 
cardiac autonomic function.  Sensorimotor impairments are highly prevalent in this cohort of 
older adults; however, age was weakly associated with orthostatic hypotension and HR recovery, 
and was not associated with resting HR or HR range (results not shown).  Age did not 
significantly attenuate any of the observed associations between sensorimotor and autonomic 
function. This supports an independent relationship between sensorimotor and autonomic 
function, and that the relationships we observed were not simply due to simultaneous age related 
declines in sensorimotor and autonomic function, but rather a direct relationship between the 
two.       
Monofilament insensitivity was differentially associated with HR range in this cohort, 
with the relationship differing between those who completed the LDCW in ≤7 compared to those 
who completed in >7 minutes.  In those who completed the LDCW in ≤7, monofilament 
insensitivity was associated with lower HR range when adjusting for continuous completion 
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time, indicating worse cardiac autonomic function.  However, in those who completed in >7 
minutes, monofilament insensitivity was not significantly associated with larger HR range.  
Work validating the LDCW against maximal treadmill testing indicated that requiring >7 
minutes (420 seconds) to complete the LDCW is approximately equivalent to an aerobic capacity 
level of <12 mL O2 per kilogram of body weight per minute [269], which is a critical threshold 
of fitness where independence and community living may be severely compromised [272]. 
A major strength of this study is the inclusion of many diverse factors known to influence 
sensorimotor or autonomic function. In addition, sensorimotor peripheral nerve function was 
assessed through the use of objective and subjective measures in addition to self-reported 
symptoms—an important consideration since impairments in older adults are commonly 
asymptomatic [30].  Examining motor and sensory nerve function separately allowed us to 
investigate specific pathways in which sensorimotor and autonomic function may be related.  
The measures of autonomic function are clinically relevant and could feasibly be administered in 
a variety of settings.  A limitation is that we could only assess heart rate range and heart rate 
recovery in participants who completed the full LDCW.  In Paper 2 we demonstrated that 
participants with sensorimotor impairments are less likely to complete the full LDCW compared 
to those with better sensorimotor function. Thus, the participants who were included in the heart 
rate range and heart rate recovery portion of the analysis had better sensorimotor function overall 
compared the full analytic sample, potentially biasing these results towards the null.    
Though we were able to include a variety of measures of cardiac autonomic function, 
other measures often utilized in clinical settings—for example, expiratory-inspiratory ratio, HR 
variability, and tilt-table testing—were not assessed in Health ABC.  These measures are rarely 
included in epidemiologic studies, and HR variability in particular can be computationally 
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challenging to analyze and also difficult to interpret.  The measures we used are surrogates of 
autonomic function, and could be influenced by current acute physiologic and health status, 
potentially resulting in residual confounding.  This is a first step in an area which needs much 
more investigation, including detailed assessments of cardiac autonomic function.  Future work 
should include comprehensive examinations of each aspect of sensorimotor and autonomic 
function.  Including HR variability and other sensitive measures of autonomic function may aid 
in clarifying this association.  Though it has limitations, HR variability analyzed using frequency 
domain methods may be useful for separating the effects of sympathetic and parasympathetic 
modulation.  Consideration of other organ systems controlled largely by the autonomic nervous 
system (gastrointestinal, genitourinary) may also be useful.  A final limitation is that though we 
had access to a detailed medication inventory, these medications were assessed in the 1999/2000 
clinic visit and thus may not reflect the participants’ medication regimen one year later when 
PNS function was measured.   
This study demonstrated that some aspects of worse sensorimotor peripheral nerve 
function are independently associated with worse indicators of cardiovascular autonomic 
function in community-dwelling older adults.  Both play roles in the ability of older adults to be 
physically active and remain independent. Given the poor outcomes associated with PNS 
impairments, future epidemiologic studies should consider assessing these often 
underappreciated risk factors in order to gain insight into the contribution of PNS function to 
health in old age.   
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5.0  DISSERTATION DISCUSSION 
5.1 SUMMARY OF FINDINGS 
The overall objective of this dissertation was to examine age-related peripheral nerve 
function impairments in the context of PA, fitness, and autonomic function in older adults.  Prior 
work has indicated the association between poor sensorimotor peripheral nerve function 
impairments and mobility-related outcomes in older adults.  PA, fitness, endurance, and 
autonomic function may be in the pathway between sensorimotor impairments and geriatric 
outcomes. This work is critical as it provides potential mechanisms with ay underlie the 
relationships between poor peripheral nerve impairment and lower extremity outcomes in old 
age.   
One factor which may account for the relationships of poor peripheral nerve impairment 
and lower extremity outcomes of older age is reduced PA.  Lower extremity sensorimotor 
impairments were found to be cross-sectionally associated with lower levels of PA in older men 
from the MrOS study.  In particular, worse distal motor latency and the presence of neuropathic 
symptoms were associated with lower self-reported PA, while worse motor and sensory 
amplitude were associated with fewer minutes per day of objectively measured PA. Crude 
associations between worse motor and sensory amplitude with light and moderate activity were 
attenuated by age, BMI, diabetes, self-reported health, peripheral arterial disease and arterial 
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stiffening, though significant relationships existed with vigorous activity.  Because of the cross-
sectional nature of this study, it is unclear whether higher levels of activity (particular vigorous 
activity) are protective against age-related peripheral nerve function impairments, or whether 
those with intact peripheral nerve function are able to maintain high activity levels because of 
their better nerve function.  However, this was the first study to examine the relationship 
between peripheral nerve impairments and PA in older adults and supports the need for 
longitudinal studies for clarifying the direction of these relationships and the intensity of PA that 
is most beneficial.   
Declines in physical fitness and endurance in old age can lead to mobility 
impairments/disability [15,273] and even death [16,274].  PA can influence physical fitness and 
endurance in older adults [5,19,20], though declines in physical fitness and endurance may be 
fundamental aspects of the aging process [4,2,8,275].  Maintaining fitness and endurance above 
critical thresholds is pertinent for preventing mobility disability.  In addition to reduced PA, 
declines in fitness and endurance could also be in the pathway between sensorimotor 
impairments and adverse mobility outcomes.  Poor sensorimotor function was associated with 
worse walking endurance performance, with sensory impairments being associated with a greater 
rate of slowing over time in older black and white men and women in Health ABC.  Those with 
sensory peripheral nerve impairments completed the long distance corridor walk approximately 
15 seconds slower and experienced an additional slowing of four seconds per year compared to 
those without these impairments.  Interestingly, motor impairments were not related to 
longitudinal decline.  These findings were independent of diabetes and other health and 
behavioral factors known to influence sensorimotor function.  Sensory nerve impairments (poor 
vibration perception threshold and 1.4/10g monofilament insensitivity) had the largest effect on 
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endurance walking performance over time, indicating the major impact that reduced sensation 
has on mobility.  Maintaining walking endurance is critical for remaining independent in the 
community.  Interventions aimed at reducing the burden of sensory impairments, or maintaining 
endurance in spite of impairments should be considered. 
An additional component of the PNS, the autonomic division, supports the ability to be 
physically active, particularly via cardiovascular response to exercise.   The capacity of the 
cardiovascular system to adequately respond to and recover from activity is a major focus in 
exercise physiology, and is largely controlled by the autonomic nervous system.  Poor cardiac 
autonomic function is associated with exercise intolerance and can ultimately lead to cardiac 
outcomes, disability, and death.  Work in populations with diabetes has suggested an association 
between cardiac autonomic neuropathy and the development of sensorimotor peripheral 
neuropathy [261]. Greater severity of cardiac autonomic neuropathy has also been associated 
with a higher prevalence of peripheral neuropathy [276].   
Despite being components of the same system, sensorimotor function and autonomic 
function are rarely examined together, and the association has not been previously examined or 
defined for older adults.  Cardiac autonomic impairments could potentially also be within the 
pathway between sensorimotor impairments and geriatric outcomes. In Health ABC, we found 
that poor conduction velocity was associated with higher odds of orthostatic hypotension, 
suggesting an association between demyelination and the inability for the cardiac autonomic 
system to adequately respond to postural changes.   Additionally, poor motor amplitude was 
associated with higher resting HR.  Insensitivity to the 1.4g monofilament was associated with a 
lower heart rate range during the submaximal exercise test, after adjusting for performance on 
the test.   Sensorimotor and autonomic function remained independently related after adjusting 
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for age, sex, race, diabetes, and health and lifestyle factors known to influence PNS function, and 
these factors did not attenuate findings substantially.  Therefore, this work suggests a primary 
association between function in the two divisions of the PNS.  Future studies should investigate 
common underlying processes for the development of multiple PNS impairments. 
5.2 PUBLIC HEALTH SIGNIFICANCE 
Traditionally, studies examining PNS function were concentrated in the area of diabetes 
or other disease-related dysfunction and impairment.  Despite the important work from 
populations with diabetes, age-related peripheral nerve impairments may differ from those in 
diabetes and should be examined for their impact on geriatric conditions and outcomes.  Though 
diabetes-related peripheral nerve impairments can give insight and drive hypotheses regarding 
age-related changes, is important to study these impairments in broader populations of older 
adults—particularly given the tremendous expected increase in number and proportion of this 
population in the coming years. Gaining a better understanding of the peripheral nervous system 
in older adults can ultimately help drive prevention efforts including the development of 
interventions to help reduce the poor outcomes associated with age-related impairments.   Work 
from this dissertation suggests PA interventions which focus on PNS impairments may be 
beneficial for older adults.  Alternative PA recommendations for those with reduced sensation in 
the lower extremities may be warranted, though further work is needed in this area. 
Ultimately, PA is likely in the pathway between PNS impairments and major geriatric 
outcomes like falls, disability, and death.  Older adults tend to become less active over time 
[277], and PNS impairments may be a contributing factor to these declines in activity.  No 
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longitudinal studies have examined changes in physical activity by peripheral nerve impairments.  
However, peripheral nerve impairments are associated with a higher risk of mobility disability 
[216], an indicator that physical activity is likely decreasing as well.    
My prior work in Health ABC has indicated that higher levels of PA are associated with 
better long distance corridor walk performance [275].  Additionally, higher levels of PA are 
associated with better cardiac autonomic function in older adults [278], and PA interventions can 
also improve cardiac autonomic function [171,174].  It is unclear whether PA interventions lead 
to improvements in sensorimotor peripheral nerve function in older adults; though improving 
outcomes for those with sensorimotor impairments via PA is a worthy of study, particularly 
given the high prevalence of these impairments in community-dwelling older adults [29,30,216]. 
PA can play a key role in improving health, reducing chronic conditions, and promoting 
independence throughout the aging process [279]. Given the drastic demographic shift occurring 
in the U.S. as the “baby boomer” generation ages, keeping older adults healthy and independent 
for as long as possible is a major public health priority.  By the year 2030, it is expected that the 
population of U.S. adults age 65+ will double, with this age group making up 20% of the 
population [280].  Because many older adults have at least one chronic health condition, nearly 
66% of national health care expenditures are for this age group [280].   
Per Olaf Astrand, a notable exercise physiologist may have best stated the major cost of 
physical inactivity and reduced aerobic fitness in older adults: “As a consequence of diminished 
exercise tolerance, a large and increasing number of elderly people will be living below, at, or 
just above "thresholds" of physical ability, needing only a minor intercurrent illness to render 
them completely dependent” [19].  Unfortunately little has changed regarding the PA status of 
older adults since he made this comment nearly 20 years ago.   
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Sensorimotor and autonomic peripheral nerve function impairments have been 
underappreciated as risk factors for disability in older adults, despite their potential to 
significantly impact lower extremity and cardiovascular function.  Although national PA 
guidelines acknowledge that older adults may have difficulty achieving the recommended levels 
of PA due to chronic conditions, these recommendations are generally not tailored to these 
specific chronic conditions.  For example, reduced sensation in the lower extremities due to PNS 
impairments may make walking difficult, whereas other forms of physical activity may be more 
appropriate.  Acknowledging specific conditions like PNS impairments and providing PA 
recommendations based upon those conditions may make PA more feasible for older adults.   
5.3 FUTURE DIRECTIONS 
Both sensorimotor and cardiac autonomic peripheral nerve function play roles in the 
ability for older adults to be physically active.  Peripheral nerve impairments should be 
integrated into future work examining the impact of PA on functional outcomes in older adults.   
Worse sensorimotor peripheral nerve function was found to be associated with lower 
levels of PA in a primarily white, community-dwelling population of older men.  An obvious 
future direction of this work is to examine this association in women and in ethnically diverse 
populations.  The field of PA epidemiology has advanced significantly with the development of 
activity monitors, though the use of traditional summary measures of activity (i.e. total minutes 
spent in various intensities of activity) has its limitations.  More recently, novel techniques for 
analyzing raw PA signals has allowed for researchers to examine patterns of activity 
accumulation [191], duration of activity bouts, and even the identification of specific activities 
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[192,193].  Though some of these methods need further validation in free-living environments, 
they bring exciting possibilities for future work.  Examining whether sensorimotor peripheral 
nerve function impairments are not only associated with lower levels but also different activity 
patterns could help drive the development of successful PA interventions.  Considering the high 
prevalence of sedentary behaviors in older adults, work examining patterns of sedentary time and 
breaks in sedentary behaviors are warranted.  Simply avoiding sedentary behavior confers its 
own health benefits [185], which are important even for those who are active [186]. 
Currently, many traditional algorithms used for analyzing objectively measured physical 
activity data do not distinguish between aerobic and resistance training activities.  However, 
novel analysis techniques are constantly being developed which may allow for even more 
detailed analyses of activity than are currently available.  Given the association between 
sensorimotor impairments with worse lower extremity strength [36,215] and power [230], 
resistance training activities are of particular interest in examining the association between PA 
and sensorimotor impairments and for developing future interventions to reduce mobility 
limitations.  Though overground walking may be difficult for those with reduced lower extremity 
sensation, weight bearing activities for the purpose of developing muscle strength and power 
may be beneficial for improving functional outcomes. 
Aspects of cardiac autonomic function are often assessed in exercise physiology studies, 
including heart rate range and heart rate recovery to exercise testing.  Autonomic function can 
impact the ability to be active, and is a potential mechanism in which PNS impairments lead to 
geriatric outcomes and conditions. The association between sensorimotor and cardiac autonomic 
function is a particularly novel finding, and provides valuable insight into PNS aging.  This work 
suggests a primary association between cardiac autonomic and lower extremity sensorimotor 
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function.    Traditionally, effects of aging on specific bodily systems have been examined 
separately, though aging does not affect single system components in isolation.  Work is needed 
to further investigate the development of multiple PNS impairments during the aging process.  
The inclusion of comprehensive sensorimotor and cardiac autonomic assessment methods (i.e. 
nerve conduction and heart rate variability, among others) into one single study could help 
further clarify this relationship. Using a holistic approach to study PNS impairments may also be 
more efficient for developing interventions for improving overall PNS function and related 
lower-extremity outcomes for older adults.   
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